Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 305
Encontrada(s) 4 página(s)

BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

Sarcopenic Obesity and Longitudinal Trajectories on Cognitive Performance and Subtle Cognitive Impairment Over 6 Years in Older Adults

  • Vázquez Lorente, Héctor
  • Paz Graniel, Indira
  • Margara Escudero, Hernando J.
  • Martínez González, Miguel Ángel
  • Romaguera, Dora
  • Martínez Urbistondo, Diego
  • Estruch, Ramón
  • Martín Sánchez, Vicente
  • Vidal, Josep
  • Fitó, Montserrat
  • Goñi, Nuria
  • Chaplin, Alice
  • Zulet, María Ángeles
  • Sacanella, Emilio
  • Paz Fernández, José Antonio de
  • Altés, Andreu
  • García Gavilán, Jesús Francisco
  • Konieczna, Jadwiga
  • Martínez, J. Alfredo
  • Salas Salvadó, Jordi
[EN] Background: Sarcopenic obesity has been suggested as a potential risk factor for cognitive decline; however, few prospective studies have been conducted to test this hypothesis. We aimed to assess the relationship between baseline sarcopenic obesity and 6-year trajectories of cognitive performance and subtle cognitive impairment in older adults. Methods: This longitudinal study comprised 1097 older adults aged 55–75 years (mean [SD] age, 65.3 [4.9] years; 506 females [46.1%] and 591 males [53.9%]) exhibiting baseline overweight/obesity and metabolic syndrome. Baseline lower-limb muscle strength was determined by the validated 30-s Chair Stand Test. Baseline total body weight, fat mass percentage and appendicular lean mass were obtained through dual-energy x-ray absorptiometry scans. Baseline sarcopenic obesity (n = 364 [33.2%]) was subsequently defined based on the new European Society for Clinical Nutrition and Metabolism and the European Association for the Study of Obesity consensus criteria. Cognitive performance was assessed at baseline, 2, 4 and 6 years of follow-up through five composite scores derived from a comprehensive battery of eight validated neuropsychological tests, encompassing global cognitive function, general cognitive function, executive function, attention and language. Subtle cognitive impairment was defined for those z-scores 0.5 standard deviations below the mean for each cognitive performance composite score at baseline. Linear and logistic two-level mixed models including lost to follow-up participants were fitted as main analyses. Complete case analyses were additionally performed. Results: After adjusting for multiple covariates, main analyses showed that, compared to older adults without sarcopenic obesity, those with sarcopenic obesity showed a higher decline in global cognitive function (between-group difference, −1.0 [95% CI, −2.2 to 0.2] after 6 years; overall p = 0.048) and general cognitive function (between-group difference, −2.5 [95% CI, −4.4 to 0.5] after 6 years; overall p = 0.028) and had a higher risk of subtle global cognitive function impairment (between-group difference, 2.3 [95% CI, 0.9 to 5.6] after 6 years; overall p = 0.038) over 6 years of follow-up. Associations remained consistent in the complete case analysis and attenuated when comparing those participants with baseline sarcopenic obesity with those only presenting sarcopenia, obesity or overweight. Of note, participants with baseline sarcopenia or obesity, compared to the absence of these conditions, showed no relationship with cognitive performance and subtle cognitive impairment over 6 years of follow-up. Conclusions: Sarcopenic obesity may be considered a potential independent risk factor for cognitive decline over the long term that warrants further evaluation in clinical settings, SI, This study was supported by the official Spanish Institutions for FundingScientific Biomedical Research, CIBER Fisiopatología de la Obesidad yNutrición (CIBEROBN) and Instituto de Salud Carlos III (ISCIII), throughthe Fondo de Investigación para la Salud (FIS), which is co-funded bythe European Regional Development Fund (six coordinated FIS proj-ects led by J.S.-S. and J.V., including the following projects: PI13/00673,PI13/00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184,PI13/00728, PI13/01090, PI13/01056, PI14/01722, PI14/00636, PI14/00618,PI14/00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI14/00972,PI14/00728, PI14/01471, PI16/00473, PI16/00662, PI16/01873, PI16/01094,PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120,PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827,PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926,PI19/00957, PI19/00386, PI19/00309, PI19/01032, PI19/00576, PI19/00017,PI19/01226, PI19/00781, PI19/01560, PI19/01332, PI20/01802, PI20/00138,PI20/01532, PI20/00456, PI20/00339, PI20/00557, PI20/00886, PI20/01158and PI23/00220); the Especial Action Project entitled: Implementación yevaluación de una intervención intensiva sobre la actividad física CohortePREDIMED-Plus grant to J.S.-S.; the European Research Council(Advanced Research Grant 2014–2019; agreement #340918) grantedto M.A.M.-G.; the Agencia Catalana de Recerca i Universitats, AGAUR(2021SGR00336 to J.S.-S; the Recercaixa (number 2013ACUP00194) grantto J.S.-S.; grants from the Consejería de Salud de la Junta de Andalucía(PI0458/2013, PS0358/2016 and PI0137/2018); the PROMETEO/21/2021and the AICO/2021/347 grants from the Generalitat Valenciana; theMINECO (CNS2022–135862) grant to D.R. and the Horizon 2020 PRIMEstudy (Prevention and Remediation of Insulin Multimorbidity in Europe;grant agreement #847879). J.K. received funding from ISCIII, throughthe Miguel Servet Project (CP24/00089), co-funded by the EuropeanUnion. H.V.-L. was funded by a research grant from the Agència de Gestiód‘Ajuts Universitaris de Recerca via Unión Europea, Next Generation EU(AGAUR, record number: 2023POST-INV- 01).H.J.M.-E holds a ContratoPre-doctoral de Formacion en Investigacion en Salud (PFIS FI24/00038)funded by the ISCIII. None of the funding sources took part in the design,collection, analysis, interpretation of the data or writing of the report orin the decision to submit the manuscript for publication. J.S.-S., senior au-thor, gratefully acknowledges the financial support by ICREA under theICREA Academia program.Ethics StatementThe study protocol was approved by the Research Ethics Committees ofall recruiting centres. In addition, all participants signed an informedconsent form upon entry into the study.Conflicts of InterestThe authors declare no conflicts of interest.Data Availability StatementData described in the manuscript, codebook and analytic code will bemade available upon request pending application and approval of thePREDIMED-Plus Steering Committee. There are restrictions on theavailability of data for the PREDIMED-Plus trial, due to the signed con-sent agreements around data sharing, which only allow access to exter-nal researchers for studies following the project purposes. Requestorswishing to access the PREDIMED-Plus trial data used in this study canmake a request to the PREDIMED-Plus trial Steering Committee chair:jordi.salas@urv.cat. The request will then be passed to members of thePREDIMED-Plus Steering Committee for deliberation
Docta Complutense
Publicación Artículo científico (JournalArticle)

Understanding suicidal behavior and gender-specific pathways in an adolescent community sample: A structural model approach.

  • García Ramos, Adriana
  • Doval Moreno, Sandra
  • O'Connor, Rory
  • Innamorati, Marco
  • Pemau Gurumeta, Andrés
  • Sanchez, Alberto
  • Ayad Ahmed, Wala
  • Suárez Soto, Elizabeth
  • Ayuso Mateos, Jose Luis
  • De La-Torre Luque, Alejandro Francisco
Suicide remains a leading cause of death among adolescents, highlighting the need for more effective risk models to aid in prevention strategies. This study examined motivational and volitional factors contributing to suicidal ideation and attempts among adolescents aged 12-16 in a community-based sample., We investigated the roles of emotional abuse, non-suicidal self-injury, impulsivity, and emotional symptoms in predicting suicidal ideation intensity and likelihood of suicide attempt. We also investigated whether these associations differed by sex assigned at birth. Data were collected from 1,526 adolescents (M = 13.8; SD = 1.27) in Madrid, Spain, and analyzed under a Multiple Indicators and Multiple Causes (MIMIC) structural equation model. This Structural Equation Model (SEM) showed good fit (CFI = .96, TLI = .97, RMSEA = .078, SRMR = .061). Emotional symptoms and emotional abuse were significant predictors of ideation, while non-suicidal self-injury and ideation intensity were strongly associated with suicide attempt probability. A multigroup analysis showed that gender assigned at birth did not significantly moderate the relationship between risk factors and suicidal outcomes. However, females were more impacted by emotional abuse and emotional symptoms. These findings highlight the importance of inclusive, comprehensive prevention strategies that address universal and gender-specific risk factors in adolescent suicide prevention. Longitudinal studies are recommended to further explore the temporal dynamics of these associations.
Docta Complutense
Publicación Artículo científico (JournalArticle)

An immuno-fragile profile is associated with mortality risk in patients with chronic kidney disease

  • Ceprián, Noemí
  • Martínez De Toda Cabeza, Irene
  • Jara Caro, Paula
  • Yuste, Claudia
  • Valera Arévalo, Gemma
  • González de Pablos, Ignacio
  • Figuer, Andrea
  • Alique, Matilde
  • Ramírez, Rafael
  • Morales Ruiz, Enrique
  • Carracedo, Julia
Background/Objectives: Patients with chronic kidney disease (CKD) face higher risks of infections, poor vaccine responses, and cardiovascular diseases, leading to increased morbidity and mortality due to immune dysfunction and frailty. This study aims to evaluate immune status and frailty in CKD patients across different treatments, examine the influence of frailty on immune status, and link these factors to mortality. Methods: A total of 174 participants were included (end-stage renal disease, ESRD n = 40; hemodialysis, HD n = 40; peritoneal dialysis, n = 36; kidney transplant patients, n = 40; healthy subjects n = 18). Immunophenotyping of lymphocyte and monocyte subpopulations was performed, and frailty was assessed using the Edmonton Frail Scale. Principal component analysis (PCA) integrated immune and frailty variables to define an “immuno-fragile profile,” and survival was monitored for up to six years. Results: CKD patients, especially those on HD, showed decreased lymphocyte counts and proinflammatory monocyte subpopulations with increased expression of costimulatory molecules B7.2/CD86 and ICAM-1/CD54). Frailty was most prevalent in HD patients (53%), with notable sex differences. PCA identified three components—lymphocyte counts, monocyte co-stimulatory expression, and frailty—that together explained 70% of the variance. Survival analysis revealed that patients with lower lymphocyte counts and higher frailty scores had increased mortality risk, especially in the HD and ESRD groups. Cox regression confirmed that the immuno-fragile profile independently predictedmortality. Conclusions: The integration of immune alterations and frailty defines an immuno-fragile profile strongly associated with mortality in CKD patients, which may serve as a robust prognostic tool to improve risk stratification and guide personalized interventions in clinical practice.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Pharmacological Strategies for Cataract Management: From Molecular Targets to Clinical Translation

  • De Diego García, Laura
  • Rejas González, Raquel
  • Cereza Latre, Ignacio
  • Guzmán Aránguez, Ana Isabel
Cataracts, characterized by the opacification of the eye lens, remain a leading cause of reversible blindness globally. Age and diabetes are key risk factors, and with the increasing aging and diabetic population, the global burden of cataracts is projected to rise significantly. Current treatment is predominantly surgical; however, pharmacological strategies could offer a non-invasive alternative with the potential to delay, prevent, or even reverse cataract progression. Recent research has enhanced our understanding of cataractogenesis, emphasizing oxidative stress as a key underlying mechanism, but also including other processes such as calcium dysregulation and altered lens homeostasis or specific events induced by hyperglycemia in diabetic cataracts. New therapeutic approaches have emerged considering the molecular mechanisms involved in cataracts, most of which focus on pharmacological agents with antioxidant properties. Additionally, small-molecule chaperones, aldose reductase inhibitors, and protein aggregation inhibitors have also demonstrated potential in stabilizing or restoring lens protein structure and transparency. While experimental results have shown encouraging results, further research is needed to optimize drug delivery systems to the lens, assess long-term safety, and confirm the clinical efficacy of these treatments. This article reviews current progress in pharmacological treatments for cataracts, outlining challenges and prospects for future integration into clinical practice.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of Epicardial Adipose Tissue on Infarct Size and Left Ventricular Systolic Function in Patients with Anterior ST-Segment Elevation Myocardial Infarction

  • Gavara Doñate, Jose|||0000-0002-3483-7066
  • Merenciano, Héctor|||0000-0002-1734-0381
  • Llopis-Lorente, Jordi|||0000-0002-3958-8062
  • Molina-Garcia, Tamara
  • Perez-Solé, Nerea|||0000-0003-3527-0337
  • de Dios, Elena
  • Marcos-Garces, Víctor
  • Monmeneu, José V.
  • Lopez-Lereu, María P.
  • Canoves, Joaquim
  • Bonanad, Clara
  • Moratal, David|||0000-0002-2825-3646
  • Núñez, Julio|||0000-0003-1672-7119
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Sanchis, Juan|||0000-0003-0797-8709
  • Chorro, Francisco J.
  • Rios-Navarro, Cesar|||0000-0002-6405-6279
  • Bodi, Vicente|||0000-0001-6425-5828
We aimed to assess the correlation of cardiovascular magnetic resonance (CMR)-derived epicardial adipose tissue (EAT) with infarct size (IS) and residual systolic function in ST-segment elevation myocardial infarction (STEMI). We enrolled patients discharged for a first anterior reperfused STEMI submitted to undergo CMR. EAT, left ventricular (LV) ejection fraction (LVEF), and IS were quantified at the 1-week (n = 221) and at 6-month CMR (n = 167). At 1-week CMR, mean EAT was 31 ± 13 mL/m. Patients with high EAT volume (n = 72) showed larger 1-week IS. After adjustment, EAT extent was independently related to 1-week IS. In patients with large IS at 1 week (>30% of LV mass, n = 88), those with high EAT showed more preserved 6-month LVEF. This association persisted after adjustment and in a 1:1 propensity score-matched patient subset. Overall, EAT decreased at 6 months. In patients with large IS, a greater reduction of EAT was associated with more preserved 6-month LVEF. In STEMI, a higher presence of EAT was associated with a larger IS. Nevertheless, in patients with large infarctions, high EAT and greater subsequent EAT reduction were linked to more preserved LVEF in the chronic phase. This dual and paradoxical effect of EAT fuels the need for further research in this field.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Enhancing linkage to care for hepatitis B, D, and C patients, A retrospective-prospective study

  • Vargas-Accarino, Elena|||0000-0002-2521-0368
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Palom, Adriana|||0000-0002-0130-1302
  • Feliu-Prius, Anna|||0000-0002-6835-1718
  • Martínez-Campreciós, Joan|||0000-0002-8899-8447
  • Barreira-Diaz, Ana|||0000-0002-4368-8939
  • Romero-Vico, Judith
  • Ruiz Cobo, Juan Carlos|||0000-0003-2239-4939
  • Llaneras Artigues, Jordi|||0000-0001-9011-3954
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Esteban, Rafael|||0000-0001-5280-392X
  • Buti, Maria|||0000-0002-0732-3078
Background: The WHO has set a goal to decrease viral hepatitis-related fatalities by 65% by 2030. Aims: To locate and retrieve to care all individuals diagnosed with hepatitis B, D or C, and investigate why they were not linked to appropriate medical management. Methods: We conducted a retrospective-prospective search for patients with hepatitis B, D or C virus (HBV, HDV and HCV) infection in the central laboratory database of the Barcelona northern health area (catchment population, 450,000). We reviewed records and contacted candidates for retrieval who were offered a specialist medical visit. Results: We reviewed records of 3731 patients with viral hepatitis (January 2019-December 2022): 1763 HBsAg+, 69 anti-HDV+ and 1899 HCV-RNA+. Among these, 644 (37%) HBV, 20 (29%) HDV and 1116 (56%) HCV patients were not currently linked to care. The proportion of patients receiving appropriate care was higher in HBV and HDV (p < 0.0001), and a higher percentage of unlinked hepatitis C patients had low life expectancy/comorbidities (39%; p < 0.0001). After implementing the linkage strategy, 254 HBV, 16 HDV and 54 HCV patients were successfully reintegrated into care. Among 1780 patients requiring linkage, 638 (35.8%) had moved to another health area or were missing essential contact data. Conclusions: Among patients with viral hepatitis who required appropriate specialist care and were eligible for contact, 64% with HBV, 100% with HDV and 27% with HCV were successfully reintegrated into care. Overall, 324 (47.2%) eligible patients were linked to care, indicating the success of this strategy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Blood DNA Methylation Analysis Reveals a Distinctive Epigenetic Signature of Vasospasm in Aneurysmal Subarachnoid Hemorrhage

  • Fernandez-Perez, Isabel|||0000-0002-9949-1393
  • Jiménez-Balado, Joan|||0000-0003-4125-9134
  • Macias Gómez, Adrià|||0000-0003-0926-681X
  • Suárez-Pérez, Antoni|||0000-0002-0832-7580
  • Vallverdú-Prats, Marta|||0000-0002-5262-817X
  • Pérez-Giraldo, Alberto
  • Viles-García, Marc
  • Peris-Subiza, Julia
  • Vidal-Notari, Sergio
  • Giralt Steinhauer, Eva|||0000-0002-7463-0983
  • Guisado-Alonso, Daniel|||0000-0002-5799-3184
  • Esteller, M.|||0000-0003-4490-6093
  • Rodriguez Campello, Ana Maria|||0000-0001-8621-1420
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
  • Ois, Angel|||0000-0002-1375-5950
  • Cuadrado Godia, Elisa|||0000-0002-9147-875X
Vasospasm is a potentially preventable cause of poor prognosis in patients with aneurysmal subarachnoid hemorrhage (aSAH). Epigenetics might provide insight on its molecular mechanisms. We aimed to analyze the association between differential DNA methylation (DNAm) and development of vasospasm. We conducted an epigenome-wide association study in 282 patients with aSAH admitted to our hospital. DNAm was assessed with the EPIC Illumina chip (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The study protocol of a double-blind randomized controlled trial of EMDR and multifocal transcranial current stimulation (MtCS) as augmentation strategy in patients with fibromyalgia

  • Gardoki-Souto, Itxaso|||0000-0002-0775-1275
  • Martín de la Torre, Ona
  • Hogg, Bridget|||0000-0002-2405-0593
  • Redolar-Ripoll, Diego
  • Martínez Sadurní, Laura|||0000-0001-8693-8902
  • Fontana-McNally, Marta|||0000-0001-6523-6688
  • Blanch i Ribas, Josep Maria|||0000-0001-7298-457X
  • Lupo, Walter
  • Pérez, Victor
  • Radua, Joaquim|||0000-0003-1240-5438
  • Amann, Benedikt L|||0000-0002-4407-1519
  • Valiente-Gómez, Alicia|||0000-0003-0220-2397
  • Moreno Alcázar, Ana|||0000-0002-3392-5590
Fibromyalgia (FM) is a generalized, widespread chronic pain disorder affecting 2.7% of the general population. In recent years, different studies have observed a strong association between FM and psychological trauma. Therefore, a trauma-focused psychotherapy, such as Eye Movement Desensitization and Reprocessing (EMDR), combined with a non-invasive brain stimulation technique, such as multifocal transcranial current stimulation (MtCS), could be an innovative adjunctive treatment option. This double-blind randomized controlled trial (RCT) analyzes if EMDR therapy is effective in the reduction of pain symptoms in FM patients, and if its potential is boosted with the addition of MtCS. Ninety-six patients with FM and a history of traumatic events will be randomly allocated to the treatment as usual (TAU) condition, EMDR + active-MtCS condition, or EMDR + sham-MtCS condition. Therapists and patients will be kept blind to MtCS conditions, and raters will be kept blind to both EMDR and MtCS. All patients will be evaluated at baseline, post-treatment, and follow-up at 6 months after post-treatment. Evaluations will assess the following variables: sociodemographic data, pain, psychological trauma, sleep disturbance, anxiety and affective symptoms, wellbeing, self-care, emotional regulation, self-esteem, and cognitive functioning. This study will provide evidence of whether EMDR therapy is effective in reducing pain symptoms in FM patients, and whether the effect of EMDR can be enhanced by MtCS. This trial was registered at ClinicalTrials.gov on 2 August 2019, identifier: NCT04084795. The online version contains supplementary material available at 10.1186/s13063-024-08708-3.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Mild Presentation of X-Linked Hypophosphatemia Caused by a Non-Canonical Splice Site Variant in the PHEX Gene

  • Fraga Rodriguez, Gloria Maria|||0000-0002-7682-1396
  • Herreros García, Alba|||0009-0003-0451-7568
  • Pybus, Marc|||0000-0002-6195-5738
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Pilco-Teran, Melissa|||0000-0002-1311-0896
  • Furlano, Monica|||0000-0003-1025-3901
  • Garcia Borau, Maria José|||0000-0002-8223-8033
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Ars, Elisabet|||0000-0002-4118-4358
X-linked hypophosphatemia (XLH) is a rare inherited disorder of renal phosphate wasting with a highly variable phenotype caused by loss-of-function variants in the PHEX gene. The diagnosis of individuals with mild phenotypes can be challenging and often delayed. Here, we describe a three-generation family with a very mild clinical presentation of XLH. The diagnosis was unexpectedly found in a 39-year-old woman who was referred for genetic testing due to an unclear childhood diagnosis of a tubulopathy. Genetic testing performed by next-generation sequencing using a kidney disease gene panel identified a novel non-canonical splice site variant in the PHEX gene. Segregation analysis detected that the consultand's father, who presented with hypophosphatemia and decreased tubular phosphate reabsorption, and the consultand's son also carried this variant. RNA studies demonstrated that the non-canonical splice site variant partially altered the splicing of the PHEX gene, as both wild-type and aberrant splicing transcripts were detected in the two male members with only one copy of the PHEX gene. In conclusion, this case contributes to the understanding of the relationship between splicing variants and the variable expressivity of XLH disease. The mild phenotype of this family can be explained by the coexistence of PHEX transcripts with aberrant and wild-type splicing.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dissecting the polygenic contribution of attention-deficit/hyperactivity disorder and autism spectrum disorder on school performance by their relationship with educational attainment

  • Cabana-Domínguez, Judit|||0000-0002-4732-7284
  • Bosch, Rosa|||0000-0002-7596-183X
  • Soler Artigas, María|||0000-0002-3213-1107
  • Alemany Sierra, Silvia|||0000-0002-7925-6767
  • Llonga, Natalia|||0000-0003-4325-6201
  • Vilar-Ribó, L.|||0000-0001-8758-523X
  • Carabí-Gassol, Pau
  • Arribas, Lorena|||0000-0002-9683-9999
  • Macias-Chimborazo, Valeria
  • Español-Martín, Gemma|||0000-0002-2362-8189
  • del Castillo, Clara
  • Martínez, Laura
  • Pagerols, Mireia|||0000-0003-0856-6247
  • Pagespetit, Èlia
  • Prat, Raquel|||0000-0001-8097-6617
  • Puigbó, Julia
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Ribasés Haro, Marta|||0000-0003-1039-1116
Attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorders (ASD) are strongly associated with educational attainment (EA), but little is known about their genetic relationship with school performance and whether these links are explained, in part, by the genetic liability of EA. Here, we aim to dissect the polygenic contribution of ADHD and ASD to school performance, early manifestation of psychopathology and other psychiatric disorders and related traits by their relationship with EA. To do so, we tested the association of polygenic scores for EA, ADHD and ASD with school performance, assessed whether the contribution of the genetic liability of ADHD and ASD to school performance is influenced by the genetic liability of EA, and evaluated the role of EA in the genetic overlap between ADHD and ASD with early manifestation of psychopathology and other psychiatric disorders and related traits in a sample of 4,278 school-age children. The genetic liability for ADHD and ASD dissected by their relationship with EA show differences in their association with school performance and early manifestation of psychopathology, partly mediated by ADHD and ASD symptoms. Genetic variation with concordant effects in ASD and EA contributes to better school performance, while the genetic variation with discordant effects in ADHD or ASD and EA is associated with poor school performance and higher rates of emotional and behavioral problems. Our results strongly support the usage of the genetic load for EA to dissect the genetic and phenotypic heterogeneity of ADHD and ASD, which could help to fill the gap of knowledge of mechanisms underlying educational outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma p-tau212 as a biomarker of sporadic and Down Syndrome Alzheimer's disease

  • Kac, Przemysław R.|||0000-0001-5083-0924
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Fernández, Susana|||0000-0002-9777-1156
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • González-Ortiz, Fernando
  • Benejam, Bessy|||0000-0002-6789-8615
  • Turton, Michael
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Harrison, Peter
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Lleó, Alberto|||0000-0002-2568-5478
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Karikari, Thomas K.|||0000-0003-1422-4358
  • Fortea, Juan|||0000-0002-1340-638X
  • Blennow, Kaj|||0000-0002-1890-4193
All individuals with Down Syndrome (DS) will develop full-blown Alzheimeŕs disease (AD) pathology by age 40, decades before the occurrence of sporadic late-onset AD. Understanding this strong biological relation between age and AD pathology risk in DS is important to accelerate diagnostics, disease monitoring, and treatment. Several genes encoded in chromosome 21 including dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) have been proven to contribute to the pathology. A recently validated plasma immunoassay to measure tau phosphorylation at threonine-212 (p-tau212) has very high diagnostic accuracy in detecting AD. P-tau212 is also very sensitive to DYRK1A phosphorylation and is increased in DSAD brain lysates. Here, we assessed the potential of this biomarker in DSAD and sporadic AD. Using Simoa technology, we tested p-tau212 and p-tau181 (n=245 for plasma, n=114 matching cerebrospinal fluid (CSF) samples). We used AUC-ROC to examine diagnostic performance and the DeLong test to compare the AUC-ROC differences between methods. Spearman correlation is used to examine correlations. Fold changes relative to median levels were calculated for their respective asymptomatic groups. ANCOVA followed by Tukey posthoc test was used to calculate differences across groups. LOESS was used to determine the temporality of plasma biomarker changes. We have confirmed that p-tau212 has extremely high accuracy in detecting AD-related changes in euploid controls. For the DS population, we observed a strong correlation between plasma and CSF p-tau212 (r=0.867; p<0.001). In prodromal DS (pDS) and dementia DS (dDS), we observed significantly elevated levels of p-tau212 in reference to asymptomatic DS (aDS). The diagnostic accuracy to differentiate between aDS and dDS was AUC=0.91 and AUC = 0.86 in discriminating between DS amyloid positive and amyloid negative participants. Plasma p-tau212 started increasing approximately when people became amyloid PET-positive. We have confirmed that the levels of plasma p-tau212 are increased in the DS population and sporadic AD cases including prodromal and MCI states. Plasma p-tau212 might have utility for theragnostic, monitoring therapy efficacy, and as a target engagement biomarker in clinical trials both in sporadic and DSAD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

SpadaHC, a database to improve the classification of variants in hereditary cancer genes in the Spanish population

  • Moreno-Cabrera, José Marcos|||0000-0001-8570-0345
  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Pineda, Marta|||0000-0002-5403-5845
  • Prada Dacasa, Patricia|||0000-0003-0689-9072
  • Ramos-Muntada, Mireia|||0000-0002-5531-1442
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Brunet, Joan|||0000-0003-1945-3512
  • Gel, Bernat|||0000-0001-8878-349X
  • Currás-Freixes, M.
  • Calsina Pla Giribert, Bruna|||0000-0002-6922-9415
  • Salazar-Hidalgo, Milton E.
  • Rodríguez-Balada, M.
  • Roig, Bàrbara
  • Fernández-Castillejo, Sara|||0000-0002-8109-9713
  • Durán, Mercedes|||0000-0002-6301-9732
  • Arranz Ledo, Mónica
  • Infante, Mar
  • Castillejo Castillo, Adela|||0000-0002-9581-6285
  • Dámaso, Estela|||0000-0002-9650-7791
  • Soto, José Luis
  • de Miguel, Montserrat
  • Hidalgo Calero, Beatriz
  • Sánchez-Zapardiel, José M.
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Lasa, Adriana|||0000-0001-9957-9646
  • Gisbert-Beamud, Alexandra|||0000-0001-6515-3081
  • López Novo, Anael
  • Ruiz-Ponte, C.
  • Potrony, Miriam|||0000-0003-2766-0765
  • Álvarez Mora, María Isabel|||0000-0003-3788-8915
  • Osorio, Ana|||0000-0001-8124-3984
  • Lorda Sánchez, Isabel
  • Robledo, Mercedes|||0000-0001-6256-5902
  • Cascón, Alberto|||0000-0003-2119-891X
  • Ruiz, Anna|||0000-0001-7314-5962
  • Spataro, Nino|||0000-0002-2127-2238
  • Hernán Sendra, Imma
  • Borràs, Emma
  • Moles-Fernández, Alejandro|||0000-0003-0252-6084
  • Earl, Julie
  • Cadiñanos, J.
  • Sánchez-Heras, Ana Beatriz|||0000-0003-1742-5374
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Capella, Gabriel|||0000-0002-4669-7320
  • Lázaro, C.
Accurate classification of genetic variants is crucial for clinical decision-making in hereditary cancer. In Spain, genetic diagnostic laboratories have traditionally approached this task independently due to the lack of a dedicated resource. Here we present SpadaHC, a web-based database for sharing variants in hereditary cancer genes in the Spanish population. SpadaHC is implemented using a three-tier architecture consisting of a relational database, a web tool and a bioinformatics pipeline. Contributing laboratories can share variant classifications and variants from individuals in Variant Calling Format (VCF) format. The platform supports open and restricted access, flexible dataset submissions, automatic pseudo-anonymization, VCF quality control, variant normalization and liftover between genome builds. Users can flexibly explore and search data, receive automatic discrepancy notifications and access SpadaHC population frequencies based on many criteria. In February 2024, SpadaHC included 18 laboratory members, storing 1.17 million variants from 4306 patients and 16 343 laboratory classifications. In the first analysis of the shared data, we identified 84 genetic variants with clinically relevant discrepancies in their classifications and addressed them through a three-phase resolution strategy. This work highlights the importance of data sharing to promote consistency in variant classifications among laboratories, so patients and family members can benefit from more accurate clinical management.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Surpassing protein specificity in biomimetics of bacterial amyloids

  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Parladé, Eloi|||0000-0001-5750-550X
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
In nature, nontoxic protein amyloids serve as dynamic, protein-specific depots, exemplified by both bacterial inclusion bodies and secretory granules from the endocrine system. Inspired by these systems, chemically defined and regulatory-compliant artificial protein microgranules have been developed for clinical applications as endocrine-like protein repositories. This has been achieved by exploiting the reversible coordination between histidine residues and divalent cations such as Zn, that promotes protein-protein interactions. While stereospecificity is a main architectonic feature of natural amyloids, the potential for synthetic approaches to create hybrid protein materials remains unexplored. Such materials could enable the occurrence and synchronized local application of diverse proteins in predefined molar ratios, for coupled enzymatic reactions or delivery of synergistically acting polypeptides. Here, we report on the fabrication of artificial protein granules with amyloidal architecture formed by combining two structurally distinct polypeptides. Specifically, we tested co-aggregation of the pairs GFP/IRFP and GFP/β-galactosidase. The formation of hybrid microparticles was confirmed through FRET and complementary methodologies, demonstrating that the His-Zn clustering technology does not require sequential or structural homologies between aggregating polypeptides. This approach opens new avenues for the development of functional depots that capitalize on synergistic protein functionalities, paving the way for next-generation functional materials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer's disease and Down syndrome

  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • O'Connor, A.
  • Llibre-Guerra, J.
  • Lao, P.|||0000-0003-2243-3547
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Fortea, Juan|||0000-0002-1340-638X
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
Autosomal dominant Alzheimer's disease (ADAD) and Down syndrome (DS) constitute genetic forms of Alzheimer's disease (AD). The study of these forms has been crucial in understanding the biomarker changes and disease progression, notably in advancing our knowledge of the natural history of AD. However, some specific characteristics of biomarkers in genetically determined forms and, most importantly, the near full penetrance and predictability of disease onset lead to a very different context of use for biomarkers in these populations. This article delves into the similarities and differences in biomarker profiles between genetically determined AD and sporadic cases, discussing the implications for research and clinical practice. It also emphasizes the need to account for factors that may affect biomarker reliability differently in genetically determined AD. Enhancing our understanding of the disease will pave the way for more personalized therapeutic approaches for affected individuals.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Citrate-Assisted Regulation of Protein Stability and Secretability from Synthetic Amyloids

  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Chellou-Bakkali, Sara|||0009-0007-1643-4558
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Parladé, Eloi|||0000-0001-5750-550X
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
The mammalian endocrine system uses functional amyloids as dynamic depots to store and release protein hormones into the bloodstream. Such depots, acting as secretory granules within the microscale, are formed in specialized cells by the coordination between the ionic, divalent form of zinc (Zn2+) and the imidazole ring from accessible His residues. The reversibility of such cross-linking events allows for the release of monomeric or oligomeric forms of the functional protein for biological activity. In vitro, and mimicking such a natural coordination process, synthetic amyloidal granules with secretory properties can be fabricated using selected therapeutic proteins as building blocks. Then, these microparticles act as delivery systems for endocrine-like, sustained protein release, with proven applicability in vaccinology, cancer therapy, regenerative medicine, and as antimicrobial agents. While the temporal profile in which the protein is leaked from the material might be highly relevant to clinically oriented applications, the fine control of such parameters remains unclear. We have explored here how the kinetics of protein release can be regulated by intervening in the storage formulation of the granules, through the concentration of citrate not only as a buffer component and protein stabilizer but also as a chelating agent. The citrate-assisted, time-prolonged regulatable release of proteins, in their functional form, opens a spectrum of possibilities to adjust the preparation of synthetic secretory granules to specific clinical needs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Screening Strategies to Improve Early Diagnosis in Endometrial Cancer

  • Cabrera, S.
  • de la Calle, Irene|||0000-0002-2227-1640
  • Baulies Caballero, Sonia|||0000-0001-7670-5603
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Colás Ortega, Eva|||0000-0003-0302-4828
Endometrial cancer is the most common gynecological malignancy in high-income countries and the sixth most common cancer in women. Overall incidence has risen in the last few decades as a consequence of the increase in the prevalence of its risk factors, mainly obesity and the aging of the population, and although diagnoses have increased across all age groups, the incidence rates have doubled in women under the age of 40 years. The survival rates of endometrial cancer are highly dependent on its stage at diagnosis, bringing to the fore the importance of early diagnosis. The aim of a screening strategy in this type of tumor should be to detect the disease in the pre-invasive or early stage (before developing myometrial invasion), which would improve cure rates, reduce the morbidity associated with aggressive treatment and offer uterus-sparing management options for younger women. The ideal screening tool in this scenario would be a minimally invasive, inexpensive and easy-to-perform test or auto-test, which could be implemented in a routine gynecologic checkup of patients at-risk or in the general adult population. In this comprehensive review, we aim to define the populations at higher risk of developing endometrial cancer, to assess the performance of current diagnostic tools when used in a screening setting and to discuss the accuracy of new molecular screening strategies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Insights into the use of biomarkers in clinical trials in Alzheimer's disease

  • Pascoal, Tharick|||0000-0001-9057-8014
  • Aguzzoli, C.S.
  • Lussier, F.Z.
  • Crivelli, L.
  • Suemoto, C.K.|||0000-0002-5942-4778
  • Fortea, Juan|||0000-0002-1340-638X
  • Rosa-Neto, P.
  • Zimmer, E.R.
  • Ferreira, P.C.L.
  • Bellaver, B.|||0000-0002-2212-3373
Biomarkers have been instrumental in population selection and disease monitoring in clinical trials of recently FDA-approved drugs targeting amyloid-β to slow the progression of Alzheimer's disease (AD). As new therapeutic strategies and biomarker techniques emerge, the importance of biomarkers in drug development is growing exponentially. In this emerging landscape, biomarkers are expected to serve a wide range of contexts of use in clinical trials focusing on AD and related dementias. The joint FDA-NIH BEST (Biomarkers, EndpointS, and other Tools) framework provides standardised terminology to facilitate communication among stakeholders in this increasingly complex field. This review explores various applications of biomarkers relevant to AD clinical trials, using the BEST resource as a reference. For simplicity, we predominantly provide contextual characterizations of biomarkers use from the perspective of drugs targeting amyloid-β and tau proteins. However, general definitions and concepts can be extrapolated to other targets.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Trans-Mediated, Cis-Inhibited Paradoxal Activity of Clostridium perfringens Enterotoxin (c-CPE) in Modulating Epithelial Permeability

  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Parladé, Eloi|||0000-0001-5750-550X
  • Di Somma, Angela|||0000-0003-4916-7875
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Villaverde, Antonio|||0000-0002-2615-4521
In the context of transdermal delivery, favoring the drug permeability of epithelia through convenient formulations would open new opportunities for local versus systemic drug delivery, envisaging higher patient comfort and an enhanced therapeutic effect. Ligands of tight junctions are interesting agents that enhance epithelial permeability by relaxing the protein complexes that form them. The C-terminal domain of Clostridium perfringens enterotoxin (c-CPE), which binds claudins, one of the tight junction (TJ) components, has been explored here as a functional domain in modular recombinant proteins, to evaluate its ability to self-promote its paracellular epithelial passage in a Caco-2 cell monolayer model. c-CPE-containing fusion proteins bind cells in the absence of internalization and cytotoxicity and support the passage, in trans, of other fusion proteins devoid of c-CPE. However, c-CPE-carrying proteins fail to cross the epithelia by themselves, probably because their affinity for TJs immobilizes them in the intercellular space. Therefore, while recombinant c-CPE versions have been here confirmed as convenient epithelial-permeabilizing agents, a paradoxical behavior has been observed where this effect is only successful when applied in trans, specifically on entities that lack c-CPE. Then, c-CPE itself inhibits the paracellular mobility of carrier molecules, not being suited as a self-driver (in c-CPE-drug complexes) for drug delivery through epithelia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Testicular large B-cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL

  • Rivas Delgado, Alfredo|||0000-0003-0385-3415
  • López, Cristina
  • Clot, Guillem|||0000-0003-2588-7413
  • Nadeu, Ferran|||0000-0003-2910-9440
  • Grau Vorster, Marta|||0000-0003-3779-0387
  • Frigola, Gerard|||0000-0001-6794-6456
  • Bosch-Schips, Jan
  • Radke, Josefine
  • Ishaque, Naveed|||0000-0002-8426-901X
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Luizaga Velasco, Luis|||0000-0001-9314-5783
  • Barcena, Carmen
  • Kelleher, Nicholas|||0000-0003-4610-2718
  • Villamor, Neus|||0000-0001-6538-4111
  • Baumann, Tycho|||0000-0003-4421-0088
  • Muntañola, Ana|||0000-0001-7839-6648
  • Sancho-Cia, Juan M.
  • Martín García-Sancho, Alejandro|||0000-0001-6330-1028
  • González Barca, Eva|||0000-0002-1323-1508
  • Matutes, Estella|||0000-0001-6745-7046
  • Brito, Jordi A.
  • Karube, Kennosuke
  • Salaverria Frigola, Itziar|||0000-0002-2427-9822
  • Enjuanes, Anna|||0000-0002-4679-6687
  • Wiemann, Stefan|||0000-0003-4683-3174
  • Heppner, Frank L.
  • Siebert, Reiner
  • Climent, Fina|||0000-0002-4360-8388
  • Campo, Elias|||0000-0001-9850-9793
  • Giné, Eva|||0000-0002-0532-1204
  • López Guillermo, Armando|||0000-0002-8588-8381
  • Bea, Sílvia|||0000-0001-7192-2385
Testicular large B-cell lymphoma (TLBCL) is an infrequent and aggressive lymphoma arising in an immune-privileged site and has recently been recognized as a distinct entity from diffuse large B-cell lymphoma (DLBCL). We describe the genetic features of TLBCL and compare them with published series of nodal DLBCL and primary large B-cell lymphomas of the CNS (PCNSL). We collected 61 patients with TLBCL. We performed targeted next-generation sequencing, copy number arrays, and fluorescent in situ hybridization to assess chromosomal rearrangements in 40 cases with available material. Seventy percent of the cases showed localized stages. BCL6 rearrangements were detected in 36% of cases, and no concomitant BCL2 and MYC rearrangements were found. TLBCL had fewer copy number alterations (p < 0.04) but more somatic variants (p < 0.02) than nodal DLBCL and had more frequent 18q21.32-q23 (BCL2) gains and 6q and 9p21.3 (CDKN2A/B) deletions. PIM1, MYD88, CD79B, TBL1XR1, MEF2B, CIITA, EP300, and ETV6 mutations were more frequent in TLBCL, and BCL10 mutations in nodal DLBCL. There were no major genetic differences between TLBCL and PCNSL. Localized or disseminated TLBCL displayed similar genomic profiles. Using LymphGen, the majority of cases were classified as MCD. However, we observed a subgroup of patients classified as BN2, both in localized and disseminated TLBCL, suggesting a degree of genetic heterogeneity in the TLBCL genetic profile. TLBCL has a distinctive genetic profile similar to PCNSL, supporting its recognition as a separate entity from DLBCL and might provide information to devise targeted therapeutic approaches.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Altered tubulin detyrosination due to SVBP malfunction induces cytokinesis failure and senescence, underlying a complex hereditary spastic paraplegia

  • Launay, Nathalie|||0000-0002-7498-217X
  • Espinosa-Alcantud, María Dolores|||0000-0002-1126-2458
  • Verdura, Edgard|||0000-0003-3856-2060
  • Fernández-Eulate, Gorka|||0000-0003-1112-7464
  • Ondaro, Jon|||0000-0002-2879-9497
  • Iruzubieta, Pablo
  • Marsal, Maria|||0000-0001-9678-8717
  • Schlüter, Agatha|||0000-0001-6732-1528
  • Ruiz, Montserrat|||0000-0003-0466-2653
  • Fourcade, Stéphane|||0000-0002-8031-5007
  • Rodríguez-Palmero, Agustí|||0000-0002-4141-5515
  • Zulaica, Miren
  • Sistiaga, Andone|||0000-0003-2511-0911
  • Labayru, Garazi
  • Loza-Alvarez, Pablo|||0000-0002-3129-1213
  • Vaquero, Alejandro|||0000-0002-8735-4156
  • Lopez de Munain, Adolfo|||0000-0002-9509-4032
  • Pujol, Aurora|||0000-0002-9606-0600
Senescence, marked by permanent cell cycle arrest may contribute to the decline in regenerative potential and neuronal function, thereby promoting neurodegenerative disorders. In this study, we employed whole exome sequencing to identify a previously unreported biallelic missense variant in SVBP (p.Leu49Pro) in six patients from three unrelated families. These affected individuals present with a complex hereditary spastic paraplegia (HSP), peripheral neuropathy, verbal apraxia, and intellectual disability, exhibiting a milder phenotype compared to patients with nonsense SVBP mutations described previously. Consistent with SVBP's primary role as a chaperone necessary for VASH-mediated tubulin detyrosination, both patient fibroblasts with the p.Leu49Pro mutation, and HeLa cells harboring an SVBP knockdown exhibit microtubule dynamic instability and alterations in pericentriolar material (PCM) component trafficking and centrosome cohesion. In patient fibroblasts, structural abnormalities in the centrosome trigger mitotic errors and cellular senescence. Notably, premature senescence characterized by elevated levels of p16INK4, was also observed in patient peripheral blood mononuclear cells (PBMCs). Taken together, our findings underscore the critical role of SVBP in the development and maintenance of the central nervous system, providing novel insights associating cytokinesis failure with cortical motor neuron disease and intellectual disability.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment

  • Cabrero-de las Heras, Sara|||0000-0002-9364-5371
  • Hernández-Yagüe, Xavier|||0000-0002-3742-1218
  • González Valencia, Andrea|||0009-0005-4236-0199
  • Losa, Ferran|||0000-0003-0111-8708
  • Soler, Gemma
  • Bugés, Cristina|||0000-0003-2013-1510
  • Baraibar, Iosune|||0000-0002-3500-9641
  • Esteve, Anna|||0000-0002-1962-971X
  • Pardo-Cea, Miguel Ángel|||0000-0003-4823-6613
  • Ree, Anne Hansen
  • Martínez Bosch, Neus|||0000-0003-3596-0039
  • Nieva, Maria
  • Musulén, Eva|||0000-0002-9667-6464
  • Meltzer, Sebastian
  • Lobato, Tania
  • Vendrell-Ayats, Carla|||0009-0000-2740-0918
  • Queralt, C|||0000-0001-9875-0173
  • Navarro, Pilar|||0000-0003-4314-4584
  • Montagut Viladot, Clara|||0000-0003-1438-2903
  • Grau-Leal, Ferran|||0000-0003-3072-2250
  • Camacho Martín, David
  • Legido, Raquel
  • Mulet-Margalef, Nuria|||0000-0002-2385-6448
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
Metastatic colorectal cancer (mCRC) currently lacks reliable biomarkers for precision medicine, particularly for chemotherapy-based treatments. This study examines the behavior of 11 CXC chemokines in the blood of 104 mCRC patients undergoing first-line oxaliplatin-based treatment to pinpoint predictive and prognostic markers. Serum samples were collected before treatment, at response evaluation (EVAR), and at disease progression or last follow-up. Chemokines were assessed in all samples using a Luminex® custom panel. CXCL13 levels increased at EVAR in responders, while in non-responders it decreased. Increasing levels of CXCL13 at EVAR, independently correlated with improved progression-free survival (PFS) and overall survival (OS). Nanostring® analysis in primary tumor samples showed CXCL13 gene expression's positive correlation not only with gene profiles related to an immunogenic tumor microenvironment, increased B cells and T cells (mainly CD8+) but also with extended OS. In silico analysis using RNAseq data from liver metastases treated or not with neoadjuvant oxaliplatin-based combinations, and deconvolution analysis using the MCP-counter algorithm, confirmed CXCL13 gene expression's association with increased immune infiltration, improved OS, and Tertiary Lymphoid Structures (TLSs) gene signatures, especially in neoadjuvant-treated patients. CXCL13 analysis in serum from 36 oxaliplatin-treated patients from the METIMMOX study control arm, reported similar findings. In conclusion, the increase of CXCL13 levels in peripheral blood and its association with the formation of TLSs within the metastatic lesions, emerges as a potential biomarker indicative of the therapeutic efficacy in mCRC patients undergoing oxaliplatin-based treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Undiscovered bird extinctions obscure the true magnitude of human-driven extinction waves

  • Cooke, Rob|||0000-0003-0601-8888
  • Sayol Altarriba, Ferran|||0000-0003-3540-7487
  • Andermann, Tobias|||0000-0002-0932-1623
  • Blackburn, Tim|||0000-0003-0152-2663
  • Steinbauer, Manuel J.|||0000-0002-7142-9272
  • Antonelli, Alexandre|||0000-0003-1842-9297
  • Faurby, Søren|||0000-0002-2974-2628
Birds are among the best-studied animal groups, but their prehistoric diversity is poorly known due to low fossilization potential. Hence, while many human-driven bird extinctions (i.e., extinctions caused directly by human activities such as hunting, as well as indirectly through human-associated impacts such as land use change, fire, and the introduction of invasive species) have been recorded, the true number is likely much larger. Here, by combining recorded extinctions with model estimates based on the completeness of the fossil record, we suggest that at least ~1300-1500 bird species (~12% of the total) have gone extinct since the Late Pleistocene, with 55% of these extinctions undiscovered (not yet discovered or left no trace). We estimate that the Pacific accounts for 61% of total bird extinctions. Bird extinction rate varied through time with an intense episode ~1300 CE, which likely represents the largest human-driven vertebrate extinction wave ever, and a rate 80 (60-95) times the background extinction rate. Thus, humans have already driven more than one in nine bird species to extinction, with likely severe, and potentially irreversible, ecological and evolutionary consequences. The true number of human-driven bird extinctions is likely larger than we think. Here, the authors combine recorded extinctions with estimates from the fossil record to suggest that ~1400 bird species have gone extinct since the Late Pleistocene.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Detection of germline CNVs from gene panel data, benchmarking the state of the art

  • Munté, Elisabet|||0000-0001-8396-8284
  • Roca, Carla|||0000-0003-1171-0588
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Pineda, Marta|||0000-0002-5403-5845
  • Gel, Bernat|||0000-0001-8878-349X
  • Castellanos, Elisabeth|||0000-0002-8133-5325
  • Rivera, Bárbara
  • Cordero, David
  • Lázaro, Contxi
  • Moreno-Cabrera, José Marcos|||0000-0001-8570-0345
Germline copy number variants (CNVs) play a significant role in hereditary diseases. However, the accurate detection of CNVs from targeted next-generation sequencing (NGS) gene panel data remains a challenging task. Several tools for calling CNVs within this context have been published to date, but the available benchmarks suffer from limitations, including testing on simulated data, testing on small datasets, and testing a small subset of published tools. In this work, we conducted a comprehensive benchmarking of 12 tools (Atlas-CNV, ClearCNV, ClinCNV, CNVkit, Cobalt, CODEX2, CoNVaDING, DECoN, ExomeDepth, GATK-gCNV, panelcn.MOPS, VisCap) on four validated gene panel datasets using their default parameters. We also assessed the impact of modifying 107 tool parameters and identified 13 parameter values that we suggest using to improve the tool F1 score. A total of 66 tool pair combinations were also evaluated to produce better meta-callers. Furthermore, we developed CNVbenchmarker2, a framework to help users perform their own evaluations. Our results indicated that in terms of F1 score, ClinCNV and GATK-gCNV were the best CNV callers. Regarding sensitivity, GATK-gCNV also exhibited particularly high performance. The results presented here provide an evaluation of the current state of the art in germline CNV detection from gene panel data and can be used as a reference resource when using any of the tools.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Network analysis of influential risk factors in adolescent suicide attempters

  • Fernandez-Fernandez, Jennifer
  • Jiménez-Treviño, Luis|||0000-0002-9551-8587
  • Andreo Jover, Jorge|||0000-0002-6703-8017
  • Ayad-Ahmed, Wala|||0000-0002-0786-0076
  • Bobes-Bascarán, Maria T.|||0000-0002-5279-504X
  • Canal-Rivero, Manuel|||0000-0002-5818-5103
  • Cebrià, Ana Isabel|||0000-0002-2632-8130
  • Crespo-Facorro, Benedicto|||0000-0003-0033-7132
  • Torre-Luque, Alejandro de la|||0000-0003-0595-6127
  • Díaz-Marsá, Marina|||0000-0003-1364-3163
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Gómez Vallejo, Sandra|||0000-0003-0963-6585
  • Grande, Iria|||0000-0002-0137-0666
  • Iglesias, Noelia
  • Ortin, Francisco
  • March, Katya B.
  • Palao Tarrero, Ángela|||0000-0003-2717-5807
  • Pérez-Díez, Iván|||0000-0002-9972-2825
  • Pérez-Guerra, Carla
  • Ruiz-Veguilla, Miguel|||0000-0002-5790-7346
  • Vieta, Eduard|||0000-0002-0548-0053
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Sáiz, Pilar A.|||0000-0002-5705-4523
Objective: This study aims to investigate the interrelationship of risk factors for suicidal behaviour and their influence on attempt severity in a sample of adolescents who have recently attempted suicide. For it a network analyse was performed. Method: Data from a sample of adolescents from 12 to 17 years of age with documented suicide attempts were collected and analysed in the context of a larger study conducted in Spain called SURVIVE. Several factors were examined including age, sex, depression, trauma, impulsivity, and substance abuse. Graph analysis was performed to identify relationships and centrality measures among these factors. Results: A total of 267 participants were enrolled: 233 females and 34 males with a mean age of 15.00 years (SD = 1.52). The results indicate that age and sex do not have a notable relationship with attempt severity in adolescents. Emotional and behavioural difficulties, measured by the Strengths and Difficulties Questionnaire (SDQ), have the greatest influence on other variables. Depression and childhood trauma show varying degrees of association with suicidal behaviour, as does motor impulsivity. Substance use does not appear to be strongly related to suicide attempt severity. The number of suicide attempts is strongly correlated with emotional and behavioural difficulties, depression, and childhood trauma. Lethality of suicide attempts and intensity of suicidal ideation do not show significant associations with the other variables. Conclusion: This study identifies significant risk factors for adolescent suicide. Emotional and behavioural symptoms, depression, and childhood trauma are strongly linked to suicidal behaviour. However, age, sex, and substance abuse show minimal correlation. Assessing emotional difficulties and depressive symptoms using specific questionnaires could be crucial in evaluating suicidal behaviour in adolescents.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Internal structure, reliability and cross-cultural validity of the Warwick-Edinburgh Mental Wellbeing Scale in three European populations

  • Yadav, Prateek
  • Arias de la Torre, Jorge|||0000-0001-6908-9611
  • Bakolis, Ioannis|||0000-0002-4800-1630
  • Bartoll, Xavier|||0000-0001-6865-8034
  • Casajuana Kogel, Cristina
  • Colom, Joan
  • Dregan, Alex
  • Garcia Forero, Carlos
  • Botella-Juan, Lorena
  • Martín, Vicente|||0000-0003-0552-2804
  • Molina de la Torre, Antonio José
  • Mortier, Philippe|||0000-0003-2113-6241
  • Nielsen, Line
  • Pérez, Catherine|||0000-0001-5892-2807
  • Puertolas, Beatriz
  • Ronaldson, Amy|||0000-0001-8369-9168
  • Santini, Ziggi
  • Schiaffino, Anna|||0000-0001-8787-2634
  • Serrano-Blanco, Antoni|||0000-0001-6123-0633
  • Stewart-Brown, Sarah
  • Valderas, Jose M.|||0000-0002-9299-1555
  • Alonso, Jordi|||0000-0001-8627-9636
  • Vilagut, Gemma|||0000-0002-3714-226X
The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS), a questionnaire designed for the assessment of mental well-being, is widely used in different countries and cultures worldwide. However, there is a lack of studies examining its metric performance and measurement invariance across countries. This study aims to examine the internal structure, reliability and cross-country validity of the WEMWBS in three European populations. WEMWBS data collected in 2016 from three representative population health surveys from an autonomous region in Spain (Catalonia) and two countries (Denmark and the UK) were used (n=13 940). The mean WEMWBS Scores were compared between populations. The internal consistency (ω coefficients), internal structure (confirmatory factor analyses (CFA) and bifactor exploratory structural equation models), reliability (item response theory models, item and test information functions), and cross-cultural comparability (multigroup CFA) of the WEMWBS were assessed. Differences in mean scores observed between regions merit further study. The WEMWBS showed high internal consistency across countries (ω=0.942). The unidimensionality of the scale was confirmed overall and for each population. Evidence of reliability and of measurement invariance at the configural, scalar and metric levels was found. The results support the use of the WEMWBS in different cultures to inform the understanding of population well-being in public health and its possible use as an outcome measure in clinical studies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Beyond myeloid neoplasms germline guidelines, Validation of the thresholds criteria in the search of germline predisposition variants

  • Mestre, Julia|||0000-0002-4809-3897
  • Chaparro, Lorea|||0009-0008-6806-9342
  • Manzanares Mileo, Ana|||0000-0003-4125-4675
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Sole, F|||0000-0002-3251-2161
  • Calvete, Oriol|||0000-0002-2623-2876
Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency (VAF) higher than 30% for point mutations in specific genes. To investigate the VAF thresholds' accuracy we have explored the prevalence of germline variants below the 30% VAF threshold. A total of 40 variants with VAF lower than 30% in bone marrow samples of myeloid neoplasm patients were selected and studied in CD3 + cells. All the selected variants were not found in CD3 + cells except one variant in the SF3B1 gene. However, the whole series was found somatic. Selected variants were also evaluated with our previously studied series of 52 variants with VAF higher than 30%. Our study suggests that variants with VAF below 30% are strong somatic candidates but the variants with VAF higher than 30% cannot be considered of germline origin.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Benefits of Living Over Deceased Donor Kidney Transplantation in Elderly Recipients. A Propensity Score Matched Analysis of a Large European Registry Cohort

  • Toapanta, Néstor|||0000-0001-5983-6863
  • Comas, Jordi|||0000-0001-5257-7029
  • Revuelta, Ignacio|||0000-0002-3584-4516
  • Manonelles, Anna|||0000-0003-2456-388X
  • Facundo, Carme|||0000-0003-1254-5553
  • Pérez-Sáez, María José|||0000-0002-8601-2699
  • Vila, Anna
  • Arcos, Emma
  • Tort, Jaume
  • Giral, Magali|||0000-0001-7641-1592
  • Naesens, Maarten|||0000-0002-5625-0792
  • Kuypers, Dirk RJ.|||0000-0001-5546-9680
  • Åsberg, Anders|||0000-0002-0628-1769
  • Moreso, Francesc|||0000-0002-7267-3963
  • Bestard Matamoros, Oriol|||0000-0001-9468-7920
Although kidney transplantation from living donors (LD) offers better long-term results than from deceased donors (DD), elderly recipients are less likely to receive LD transplants than younger ones. We analyzed renal transplant outcomes from LD versus DD in elderly recipients with a propensity-matched score. This retrospective, observational study included the first single kidney transplants in recipients aged ≥65 years from two European registry cohorts (2013-2020, n = 4,257). Recipients of LD (n = 408), brain death donors (BDD, n = 3,072), and controlled cardiocirculatory death donors (cDCD, n = 777) were matched for donor and recipient age, sex, dialysis time and recipient diabetes. Major graft and patient outcomes were investigated. Unmatched analyses showed that LD recipients were more likely to be transplanted preemptively and had shorter dialysis times than any DD type. The propensity score matched Cox's regression analysis between LD and BDD (387-pairs) and LD and cDCD (259-pairs) revealing a higher hazard ratio for graft failure with BDD (2.19 [95% CI: 1.16-4.15], p = 0.016) and cDCD (3.38 [95% CI: 1.79-6.39], p < 0.001). One-year eGFR was higher in LD transplants than in BDD and cDCD recipients. In elderly recipients, LD transplantation offers superior graft survival and renal function compared to BDD or cDCD. This strategy should be further promoted to improve transplant outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Targeted Nanotoxin Inhibits Colorectal Cancer Growth Through Local Tumor Pyroptosis and Eosinophil Infiltration and Degranulation

  • Carrasco-Díaz, Luis Miguel|||0000-0003-0567-2802
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Virgili Manrique, Anna Cristina|||0000-0001-9733-6034
  • Paez, David|||0000-0002-5596-6588
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Álamo, Patricia|||0000-0003-0510-5701
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ranib
  • Alba Castellón, Lorena|||0000-0003-3449-7820
Background: Colorectal cancer (CRC) has traditionally been treated with genotoxic chemotherapy to activate pro-apoptotic proteins to induce anticancer effects. However, cancer cells develop resistance to apoptosis, which leads to recurrence and poor prognosis. Moreover, this kind of therapy has been shown to be highly toxic to healthy tissues and, therefore, to patients. To overcome this issue, we developed a self-assembly tumor-targeted nanoparticle, T22-DITOX-H6, that incorporates the T22 peptide (a CXCR4 ligand) to selectively target cells overexpressing CXCR4, fused to the catalytic domain of diphtheria toxin, that exhibits a potent cytotoxic effect on these CXCR4+ cancer cells that exhibits potent cytotoxic effects on CXCR4-overexpressing cancer cells through the activation of pyroptosis, an immunogenic type of cell death. Methods: Colorectal CXCR4-expressing tumor cells (CT26-CXCR4+) were implanted subcutaneously into immunocompetent mice to study the effects of T22-DITOX-H6 treatment on tumor growth, cell death and innate immune cell recruitment to the tumor. Results: Here, we demonstrated that the T22-DITOX-H6 nanoparticle selectively activated pyroptosis, an immunogenic cell death that differs from apoptosis, leading to cell death in CXCR4-expressing cells, without affecting the viability of CXCR4-lacking cells. In addition, the nanoparticle administered to tumor-bearing mice induced a local antitumor effect due to the selective activation of pyroptosis in CXCR4+ targeted cancer cells. Biochemical analysis of plasma and histological analysis of non-tumor tissues revealed no differences between the groups. Remarkably, pyroptosis activation stimulates eosinophil infiltration into the tumor microenvironment, an effect recently reported to have an anti-tumorigenic function. Conclusion: These results highlight the dual role of CXCR4-targeted cytotoxic nanoparticle in eliminating cancer cells and boosting the self-immune response without compromising healthy organs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Targeting the chemokine receptor CXCR4 for cancer therapies

  • Rueda, Ariana|||0000-0001-7588-9279
  • Serna, Naroa|||0000-0001-5682-8198
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
The C-X-C chemokine receptor type 4 (CXCR4) has emerged as a key molecular biomarker for cancer therapies due to its critical role in tumor progression and metastases by displaying a stem cells phenotype. Its overexpression has been observed in more than 20 types of cancers, including solid tumors and hematological malignancies, and it is often associated with tumor aggressiveness and poor prognosis. Being initially recognized as a co-receptor involved in HIV infection, numerous CXCR4-targeting ligands and antagonists, including small molecules, peptides and biologics have been identified over the past decades. While only few of them have been used in the context of cancer therapies, recent biotechnological advancements using CXCR4 as a molecular target are showing significant potential to revolutionize future cancer therapies. Therefore, this review highlights the biotechnological innovations developed for cancer therapy and diagnosis by targeting the chemokine receptor CXCR4. It also discusses future perspectives on emerging therapeutic strategies, ranging from the use of small molecule inhibitors that block receptor signaling to cutting-edge nanocarriers designed for the targeted delivery of innovative drugs and proteins into cancer stem cells, aiming at cell-selective precision nanomedicines.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

De Novo or inherited, gonosomal mosaicism in hereditary angioedema due to C1 inhibitor deficiency

  • Batlle-Masó, Laura|||0000-0002-4209-176X
  • Perurena Prieto, Janire|||0000-0002-3048-1058
  • Viñas-Giménez, Laura|||0000-0003-2913-1154
  • Aguiló-Cucurull, Aina|||0000-0001-5622-778X
  • Fernández-Álvarez, Paula|||0000-0003-2695-3531
  • Gil-Serrano, Johana|||0000-0002-0673-7391
  • Guilarte, Mar|||0000-0001-7242-9584
  • Colobrán Oriol, Roger|||0000-0002-5964-536X
Hereditary angioedema (HAE) is a rare genetic disease, characterized by transient and self-limiting episodes of subcutaneous or submucosal swelling that spontaneously resolve within two to five days. The most common form of HAE, HAE-C1-INH, is caused by deleterious mutations in the SERPING1 gene, encoding the C1-Inhibitor protein, and its diagnosis is confirmed by decreased C1-INH function. Distinctively from other genetic forms of HAE, up to 15-20% of HAE-C1-INH cases are sporadic caused by de novo mutations. Here, we report a patient with apparently sporadic HAE-C1-INH. The patient had compatible clinical symptoms and a markedly low C1-INH function, and the parents showed normal values of C4 and normal C1-INH function. In the patient, we identified a novel splice site mutation in SERPING1 (c.890-1G.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension, a randomized, single-blind clinical trial

  • Pérez Campuzano, Valeria|||0000-0002-5997-9511
  • Olivas, Pol|||0000-0002-1919-0284
  • Ferrusquía-Acosta, José|||0000-0001-8034-1291
  • Torres, Sonia
  • Borràs, Roger|||0000-0002-8585-2522
  • Baiges, Anna|||0000-0002-6963-9203
  • Orts, Lara|||0000-0002-3070-0310
  • Vizcarra, Pamela
  • Falgà Tirado, Angeles
  • Codina, Joana|||0000-0002-1768-9460
  • Shalaby, Sarah|||0000-0002-8700-6282
  • Ojeda, Asunción
  • Turon, Fanny|||0000-0001-5940-2838
  • Hernández-Gea, Virginia|||0000-0001-7937-984X
  • Cárdenas, Andrés|||0000-0002-0764-7873
  • García-Pagán, JC.|||0000-0001-9032-4954
Background & Aims: Continuous infusion of terlipressin may result in a more sustained reduction in portal pressure with fewer adverse effects than administered as a bolus. This study aimed to compare the hepatic and cardiopulmonary hemodynamic effects and safety profiles of bolus vs. terlipressin continuous infusion. Methods: This is a single-center, single-blinded, double-dummy, parallel-group, clinical trial in which 38 patients with cirrhosis and portal hypertension were randomized to receive the following: 1 mg bolus of terlipressin + continuous infusion of placebo (TERLBOL, n = 12), a bolus of placebo + continuous infusion of terlipressin (2 or 4 mg/day if <10% reduction in hepatic venous pressure gradient [HVPG] at 30 min of infusion) (TERLINF, n = 14), or a bolus of octreotide (50 μg) + continuous infusion of octreotide (50 μg/h) (OCTR, n = 12) as an additional control group. HVPG, cardiopulmonary pressures, and cardiac output were measured at baseline and after 30, 60, and 120 min. Results: Sixty-eight percent of patients were male, with a median age of 59 years. There were no significant differences in baseline characteristics. In the TERLBOL group, there was a nonsignificant reduction in HVPG (at 120 min, -4.9%; p = 0.14). However, cardiopulmonary and mean arterial pressures significantly increased, whereas cardiac output and heart rate significantly decreased. In the TERLINF group, there were nonsignificant changes in cardiopulmonary hemodynamics or HVPG (NS) despite doubling the infusion dose after 30 min in 13/14 patients. In the OCTR group, there was a nonsignificant reduction in HVPG (at 120 min, -4.9%; p = 0.08), and pulmonary capillary pressure significantly decreased. All treatments were well tolerated, and no adverse events were observed. Conclusions: There were nonsignificant reductions in HVPG with the three therapeutic strategies. Further investigations are warranted to determine the optimal dosing strategy for continuous infusion of terlipressin in patients with cirrhosis and portal hypertension. Impact and implications: The results of our study do not show a significant reduction in portal pressure, at least in the first 2 h after the selected dose. Although the study was not performed in the setting of acute variceal bleeding and terlipressin was used as a standard therapy, these results do not support the treatment strategy of terlipressin infusion alone at the doses studied for the management of acute variceal bleeding, where a quick reduction in portal pressure is thought to play a major role controlling variceal bleeding. It is important to highlight that the continuously infused terlipressin regimen is better tolerated and appears to have a better cardiopulmonary safety profile. Other treatment strategies of continuous terlipressin infusion, such as initial bolus administration or higher infusion doses, should be evaluated to support its use in managing variceal bleeding. Clinical trial identifier: EudraCT No. 2019-004328-39.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Deep Sequencing Reveals Dual Evolution of SARS-CoV-2, Insights Into Defective Genomes From Wuhan-Hu-1 Variants to Omicron Subvariants

  • Campos, Carolina|||0000-0002-0132-7027
  • Ibañez Lligoña, Marta|||0000-0003-3428-2168
  • Colomer Castell, Sergi|||0000-0002-0307-7455
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Andrés, Cristina|||0000-0002-3200-0895
  • Piñana, Maria|||0000-0002-4766-2613
  • González Sánchez, Alejandra|||0000-0002-1809-3415
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Saubi, Narcis|||0000-0001-5493-1044
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Tabernero, David|||0000-0002-1146-4084
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Ferrer Costa, Roser|||0000-0002-8925-3172
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Kakze-van der Honing, Renate W.
  • Kampfraath, Andries A.
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • van der Poel, Wim H. M.
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Quer, Josep|||0000-0003-0014-084X
SARS-CoV-2 has evolved from early variants dominating the first (B.1.5, B.1.1) and second (B.1.177) pandemic waves, which exhibited a higher frequency of minority mutants with deletions leading to Defective Viral Genomes (DVGs) in the spike region near the S1/S2 cleavage site than the Alpha, Beta, and Delta variants. The emergence of Omicron has significantly altered the dominant variant profile, with Omicron subvariants now representing 100% of circulating viruses. To monitor the evolution and adaptation of Omicron in the human population, a deep-sequencing study was performed in RNA samples of BA.1, BA.1.1, BA.2, BA.5, BQ.1.1, XBB.1.5 and BA.2.86 Omicron subvariants. The findings reveal two occurrences of similar evolutionary patterns within SARS-CoV-2 characterized by a shift from a significant to a very low production of DVGs. This event suggests that DVGs might play a role in the virus's spread and adaptation for persistence in infected humans.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic determinants of testicular sperm extraction outcomes, insights from a large multicentre study of men with non-obstructive azoospermia

  • Riera-Escamilla, Antoni|||0000-0002-4485-3094
  • Arafa, Mohamed M.
  • Farnetani, Ginevra
  • Xavier, Miguel|||0000-0003-0709-7223
  • Oud, Manon S.|||0000-0001-9513-3030
  • Majzoub, Ahmad A.
  • Ramos, Liliana|||0000-0002-4269-013X
  • Abrardo, Chiara|||0000-0002-9577-6025
  • Spinelli, Matilde|||0009-0009-4820-4620
  • Moreno-Mendoza, Daniel
  • Defazio, Giuseppe|||0000-0002-9356-5224
  • Ars, Elisabet|||0000-0002-4118-4358
  • Pybus, Marc|||0000-0002-6195-5738
  • Sánchez-Curbelo, Josvany|||0000-0002-6489-3309
  • Elbardisi, Haitham|||0000-0003-3902-7924
  • Nawaz, Shoaib
  • Syed, Najeeb
  • Ruiz-Castañé, Eduardo|||0000-0002-7469-4610
  • van der Heijden, Godfried W.
  • Fakhro, Khalid A.
  • Veltman, Joris A.|||0000-0002-3218-8250
  • Krausz, Csilla|||0000-0001-6748-8918
What is the diagnostic yield and the pre-testicular sperm extraction (TESE) prognostic value of a non-obstructive azoospermia (NOA)-specific virtual gene panel? The diagnostic yield in our cohort was 6.1%, and by combining our data with published literature, we identified 11 genes compatible with testicular sperm production and 19 genes associated with no sperm retrieval in carriers of pathogenic (P) or likely pathogenic (LP) mutations. Azoospermia, the most severe form of male infertility, affects ∼1% of the male population, with TESE being the primary treatment option. However, in NOA, TESE fails in nearly 50% of cases and existing clinical parameters are unable to predict TESE failure. Over the past decade, next-generation sequencing (NGS) has identified several candidate NOA genes, but their diagnostic utility and impact on TESE outcomes have not been fully explored. A literature search was addressed to identify well-established NOA genes for designing a specific virtual gene panel for NOA. Our retrospective study analysed the diagnostic yield of the NGS-based virtual gene panel, comprising 145 genes, in 571 men affected by idiopathic NOA with known TESE outcomes. Subsequently, a second literature search was performed to identify carriers of LP/P variants in the genes where we identified mutations, focusing on individuals with known TESE outcomes. This approach allowed us to integrate the published data with our findings and predict a genotype-phenotype correlation between the affected genes and TESE success. 571 NOA patients with known TESE outcomes were recruited in two European and one Middle East centres. Variants were obtained from a whole-exome sequencing dataset and crossed with the 145 genes of the virtual gene panel. After a filtering process, variants were manually assessed and classified according to ACMG guidelines by using two methods: (i) In order to compare our data with previously published studies, we applied ACMG-AMP guidelines along with ClinGen recommendations used by other similar studies. (ii) A new approach was used to optimize ACMG-AMP guidelines with all ClinGen recommendations and incorporated NOA-specific rules addressing phenotypic, locus, and allelic heterogeneity. LP and P variants were confirmed by Sanger sequencing. By using the new variant classification approach adapted for NOA, we identified LP/P variants in 6.1% of patients, with a higher yield (9.4%) in cases with negative TESE outcomes and maturation arrest (11.7%). By integrating our findings with the literature, we highlight 19 genes recurrently associated with negative TESE outcomes and 11 genes associated with positive sperm retrieval either in the testis or in semen. TESE is recommended for patients with LP or P variants in the 11 specific genes. Notably, six of these genes are located on the X chromosome, therefore, these variants will be obligatorily transmitted to daughters, and potentially increase the risk of NOA-related infertility in male offspring. We observed that nine genes, in which we identified LP/P variants, have been previously described in individuals with premature ovarian insufficiency (POI). Of these, eight were associated with negative TESE outcomes in men. Furthermore, we propose seven additional genes mutated in our cohort of NOA patients as novel POI candidates. These genes have not yet been considered as POI candidates, but they result in female infertility when knocked out in mouse models. LP/P variants have been submitted to ClinVar (). NOA is genetically heterogeneous, and our panel excludes those genes which were reported only in a single subject or single family. Although this can limit the diagnostic yield in our study, it ensures that only genes with clear relationship with NOA have been analysed. While in our cohort TESE outcomes are known for all patients, this information is often not available for mutation carriers in the published studies. Consequently, the total number of patients with P variants in the same gene remains relatively low, limiting our final conclusions. However, even if the number of carriers of genes associated with positive sperm retrieval is relatively low, it does not constrain our conclusions regarding TESE prediction. On the other hand, caution is warranted for genes linked to negative TESE outcomes, except for TEX11, SYCE1, and MSH4, each of which have 10 or more reported TESE-negative cases. Our study was performed on the largest available NOA cohort with known TESE outcomes. It not only provides an estimate on the diagnostic potential of a NOA-specific virtual gene panel, but it also advances the understanding of genetic factors influencing TESE outcomes. Half of the genes mutated in our study and presenting TESE-positive outcomes are already informative for clinical decision-making. The observed genotype-phenotype correlations may help in personalized decision-making prior to TESE, in order to undergo the procedure or to avoid unnecessary invasive treatment. It provides valuable insights that can inform clinical management strategies and potentially offer personalized treatments based on genetic profiles. The use of two different variant classification methods highlights that previous studies may have over-estimated the diagnostic yield, underscoring the need for a standardized variant classification approach addressed specifically to male infertility. Our study also emphasizes the overlap between NOA- and POI-associated genes, which has important clinical implications for genetic counselling of female siblings of affected individuals. This work was funded by the Spanish Ministry of Health Instituto Carlos III-FIS FONDOS FEDER (grant numbers PI20/01562 and PI23/00425) and the Fanconi Research Fund awarded to C.K. and A.R.-E. This article is based upon work from COST Action CA20119 (ANDRONET), supported by COST (European Cooperation in Science and Technology) (). C.K., A.R.-E., G.F., M.J.X., M.S.O., C.A., M.S., and E.R.-C. are members of the Action. This research was also supported by the Qatar National Research Fund (QNRF) under grant NPRP12S-0318-190394, and by an Investigator Award in Science from the Wellcome Trust (209451 to J.A.V.). The authors declare no competing interests.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cerebrospinal fluid lipoprotein-mediated cholesterol delivery to neurons is impaired in Alzheimer's disease and involves APOE4

  • Borràs, Carla|||0000-0002-0998-7855
  • Canyelles, Marina|||0000-0002-0278-5337
  • Santos, David|||0000-0003-1157-4969
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Nuñez, Estefania|||0000-0002-0876-1264
  • Vázquez, Jesús|||0000-0003-1461-5092
  • Maspoch, Daniel|||0000-0003-1325-9161
  • Cano-Sarabia, Mary|||0000-0003-4254-8157
  • Zhao, Qi
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
In the central nervous system, apolipoprotein (APO)E-containing lipoprotein particles mediate the transport of glial-derived cholesterol to neurons, which is essential for neuronal membrane remodeling and maintenance of the myelin sheath. We aimed to examine cholesterol transport via lipoprotein particles in cerebrospinal fluid (CSF) of Alzheimer's disease (AD) patients compared to control individuals. Additionally, we explored the ability of reconstituted HDL containing different APOE isoforms to regulate cholesterol transport. We evaluated the capacity of CSF lipoprotein particles to facilitate radiolabeled unesterified cholesterol efflux from A172 human glioblastoma astrocytes and to deliver cholesterol to SH-SY5Y human neuronal cells. The CSF lipoprotein proteome was analyzed by LC-MS/MS. Reconstituted HDL nanoparticles were prepared by combining phospholipids and cholesterol with human APOE3 or APOE4, followed by radiolabeling with unesterified cholesterol. Our results showed that cholesterol efflux from astrocytes to CSF were similar between AD patients and controls, both under baseline conditions and after activation of ABCA1 and ABCG1. However, CSF lipoprotein-mediated neuronal cholesterol uptake was significantly reduced in the AD group. LC-MS/MS analysis identified 239 proteins associated with CSF lipoproteins in both groups, with no major alterations in proteins linked to cholesterol metabolism. However, 27 proteins involved in noncholesterol-related processes were differentially expressed. Notably, synthetic reconstituted HDL particles containing APOE4 exhibited reduced capacity to deliver cholesterol to neurons compared to those with APOE3. These findings indicate that CSF lipoproteins from patients with AD demonstrate impaired cholesterol delivery to neurons. Our study highlights APOE4 as a critical contributor to abnormal neuronal cholesterol uptake in AD pathophysiology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Alpha-synuclein co-pathology in Down syndrome-associated Alzheimer's disease

  • Bernhardt, Alexander Maximilian
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Longen, Sebastian
  • Trossbach, Svenja Verena
  • Giese, Armin
  • Matthias, Torsten
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Sanjuan, Aída
  • Fernández, Susana|||0000-0002-9777-1156
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Aranha, Mateus|||0000-0001-9594-292X
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Nübling, Georg|||0000-0003-4492-7302
  • Wagemann, Olivia
  • Stockbauer, Anna
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Fortea, Juan|||0000-0002-1340-638X
  • Levin, Johannes|||0000-0001-5092-4306
Alpha-synuclein (αSyn) seed amplification assay (SAA) enables in vivo study of αSyn but remains underexplored in Down syndrome-associated Alzheimer's disease (DSAD). We analyzed αSyn-SAA in cerebrospinal fluid (CSF) from 270 adults with Down syndrome, from the Down Alzheimer Barcelona Neuroimaging Initiative and from the AD21 cohort from the Department of Neurology at the University Hospital, Ludwig Maximilian University of Munich, Germany. Neuropathological examinations were conducted in 19 brain donors (five with ante mortem CSF). Participants were classified as asymptomatic or symptomatic (prodromal/dementia) Alzheimer's disease (AD). CSF Aβ1-42/1-40, CSF and plasma p-Tau181, and neurofilament light chain (NfL) levels were measured. Neuropathological evaluations assessed AD neuropathological changes and Lewy body pathology (LBP). ΑSyn-SAA was positive in 9.2% of cases, independent of age or cognitive status. Symptomatic αSyn-positive cases exhibited higher plasma NfL levels than αSyn-negative cases (31 vs 21 pg/mL, p = 0.027). LBP was observed in 47% of necropsies. The individual with severe neocortical LBP was αSyn-SAA-positive. These findings highlight LBP prevalence in DSAD but suggest current SAA may fail to detect limited αSyn deposition.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Single-cell RNA sequencing highlights the role of distinct natural killer subsets in sporadic amyotrophic lateral sclerosis

  • Álvarez-Sánchez, Esther|||0009-0002-8760-2153
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Muñoz, Laia|||0000-0003-0578-3094
  • Aumatell Escabias, Joaquim
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Lleó, Alberto|||0000-0002-2568-5478
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Fortea, Juan|||0000-0002-1340-638X
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Dols Icardo, Oriol|||0000-0003-2656-8748
Neuroinflammation plays a major role in amyotrophic lateral sclerosis (ALS), and cumulative evidence suggests that systemic inflammation and the infiltration of immune cells into the brain contribute to this process. However, no study has investigated the role of peripheral blood immune cells in ALS pathophysiology using single-cell RNA sequencing (scRNAseq). We aimed to characterize immune cells from blood and identify ALS-related immune alterations at single-cell resolution. For this purpose, peripheral blood mononuclear cells (PBMC) were isolated from 14 ALS patients and 14 cognitively unimpaired healthy individuals (HC), matched by age and gender, and cryopreserved until library preparation and scRNAseq. We analyzed differences in the proportions of PBMC, gene expression, and cell-cell communication patterns between ALS patients and HC, as well as their association with plasma neurofilament light (NfL) concentrations, a surrogate biomarker for neurodegeneration. Flow cytometry was used to validate alterations in cell type proportions. We identified the expansion of CD56 dim natural killer (NK) cells in ALS (fold change = 2; adj. p -value = 0.0051), mainly driven by a specific subpopulation, NK_2 cells (fold change = 3.12; adj. p -value = 0.0001), which represent a mature and cytotoxic CD56 dim NK subset. Our results revealed extensive gene expression alterations in NK_2 cells, pointing towards the activation of immune response (adj. p -value = 9.2 × 10 - 11) and the regulation of lymphocyte proliferation (adj. p -value = 6.46 × 10 - 6). We also identified gene expression changes in other immune cells, such as classical monocytes, and distinct CD8 + effector memory T cells which suggested enhanced antigen presentation via major histocompatibility class-II (adj. p -value = 1.23 × 10 - 8) in ALS. The inference of cell-cell communication patterns demonstrated that the interaction between HLA-E and CD94:NKG2C from different lymphocytes to NK_2 cells is unique to ALS blood compared to HC. Finally, regression analysis revealed that the proportion of CD56 bright NK cells along with the ALSFRS-r, disease duration, and gender, explained up to 76.4% of the variance in plasma NfL levels. Our results reveal a signature of relevant changes occurring in peripheral blood immune cells in ALS and underscore alterations in the proportion, gene expression, and signaling patterns of a cytotoxic and terminally differentiated CD56 dim NK subpopulation (NK_2), as well as a possible role of CD56 bright NK cells in neurodegeneration. The online version contains supplementary material available at 10.1186/s12974-025-03347-0.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fecal Short-Chain Fatty Acids to Predict Prediabetes and Type 2 Diabetes Risk: An Exploratory Cross-Sectional Study

  • Puig, Rocío
  • Rojo López, Marina Idalia|||0000-0001-6748-3156
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Ponomarenko, Julia|||0000-0002-1477-9444
  • Amézqueta, Susana
  • Vendrell, Joan|||0000-0002-6994-6115
  • Franch-Nadal, Josep|||0000-0002-5175-1555
  • Torres, Josep Lluís|||0000-0002-5072-8265
  • Mauricio, Didac|||0000-0002-2868-0250
  • Ramos-Romero, Sara|||0000-0002-9293-4454
Background/Objectives: Gut microbiota is profoundly influenced by dysglycemic states, including prediabetes (preDM) and type 2 diabetes (T2D). Although short-chain fatty acids (SCFAs) may serve as proxies reflecting these microbial changes, their predictive role remains elusive. This study aimed to evaluate the association between fecal SCFA concentrations and glycemic status (preDM and T2D), using individuals with normoglycemia (NonDM) as the reference group in a Mediterranean adult population. Methods: This study included a total of 88 participants from the Di@bet.es study who were classified into three groups according to the American Diabetes Association criteria: NonDM (45%), preDM (27%), and T2D (28%), respectively. We evaluated gut microbiota populations through massive sequencing and determined SCFAs concentration using gas chromatography-mass spectrometry. Adjusted multiple logistic regression models were used to estimate associations between SCFAs and metabolic status. Results: The mean age of subjects with preDM and T2D was approximately 68 years, older than that of NonDM participants (about 60 years). About 50% of the subjects in the NonDM and preDM groups were female, whereas in the T2D group, females represented about 25%. The analysis revealed that only fecal acetic acid was significantly reduced in T2D compared to NonDM (p = 0.036) and preDM (p = 0.018) groups. Remarkably, fecal acetic acid was negatively associated with T2D risk when taking preDM as the reference state (OR = 0.561 [95% CI: 0.371-0.846], p = 0.009). Intriguingly, fecal acetic acid was identified as a significant positive predictor of preDM risk, taking the NonDM group as reference (OR = 1.422; p = 0.028), while propionic acid was inversely associated with preDM (OR = 0.714; p = 0.028). Conclusions: Our analysis showed that fecal acetic acid levels were associated with a reduced risk of T2D but also with an increased risk of preDM; however, the biological relevance of these findings remains uncertain.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Novel Splicing Variant in Atypical Presentation of Familial Frontotemporal Lobar Degeneration

  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Bernal, Sara|||0000-0003-4427-0574
  • Almenta Gallego, David|||0000-0001-9069-8948
  • Perez Blanco, Josefina|||0000-0002-6489-8871
  • Camacho, Valle|||0000-0003-0748-0847
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
C-truncating variants in the charged multivesicular body protein 2B (CHMP2B) gene are a rare cause of frontotemporal lobar degeneration (FTLD), previously identified only in Denmark, Belgium, and China. We report a novel CHMP2B splice-site variant (c.35-1G>A) associated with familial FTLD in Spain. The cases were two monozygotic male twins who presented at ages 62 and 66 years with a slowly progressive behavioral variant of frontotemporal dementia and a syndrome mimicking dementia with Lewy bodies, respectively. Functional and in silico analyses supported the pathogenicity of this variant. Our findings contribute new insights into the genetic landscape and clinical heterogeneity of FTLD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Beyond Risk Factors, Rethinking Hepatitis B and Hepatitis C Screening in Primary Care

  • Vargas-Accarino, Elena|||0000-0002-2521-0368
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Úbeda, María Asunción
  • Valls, Imma
  • Ventosa, Carla
  • García, Núria
  • Arcusa, Ingrid
  • Monserrate, Elena
  • de Diego, Eva
  • Selvi, Marta
  • Palom, Adriana|||0000-0002-0130-1302
  • Llorens, Marina
  • Santos, Maria
  • Romero-Vico, Judit
  • Dalfó Pibernat, Artur|||0000-0002-2539-3715
  • Ruiz Cobo, Juan Carlos|||0000-0003-2239-4939
  • Pallares, Ester
  • Buti, Maria|||0000-0002-0732-3078
Most international guidelines recommend screening for hepatitis B virus (HBV) and hepatitis C virus (HCV) only for individuals with risk factors or elevated ALT levels. However, this approach may not suffice to eradicate viral hepatitis. This study evaluates the application of EASL HBV and HCV screening guidelines in primary care centres (PCCs). The study included two components: (1) A retrospective review (January 2021-March 2023) of microbiology data to determine testing rates, analyse clinical characteristics, and assess management; and (2) A prospective intervention (March-April 2024) involving HBV and HCV screening and risk factor surveys for all adults attending two PCCs for blood collection. In the retrospective analysis of 90 170 patients, HBV and HCV screening rates were 16% and 10%, respectively. Among HBsAg-positive patients (n = 84 (0.5%)), 67% lacked risk factors or elevated ALT. Among anti-HCV-positive (n = 277 (3%)) and HCV RNA-positive (n = 45 (0.5%)) patients, 54% and 46% respectively lacked these indicators. In the prospective study of 1030 patients (mean age 55, 39.6% men, 73% Spanish), anti-HCV was detected in 1.16% of cases (HCV RNA in 0.19%). Of these, 67% lacked risk factors or elevated ALT. No HBsAg-positive cases were identified, and hepatitis B vaccination status was uncertain for 50% of patients. Risk factor-based screening for HBV and HCV in primary care is a suboptimal approach. More than half of the patients testing positive lacked identifiable risk factors or elevated ALT levels. Universal one-time screening for all adults could address these limitations and significantly advance viral hepatitis elimination efforts.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparison of the amyloid plaque proteome in Down syndrome, early-onset Alzheimer's disease, and late-onset Alzheimer's disease

  • Martá-Ariza, M.
  • Leitner, D.F.
  • Kanshin, E.
  • Suazo, J.
  • Giusti Pedrosa, A.
  • Thierry, M.
  • Lee, E.B.
  • Devinsky, O.
  • Drummond, E.
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Ueberheide, B.
  • Wisniewski, Thomas M.
Down syndrome (DS) is strongly associated with Alzheimer's disease (AD) due to APP overexpression, exhibiting Amyloid-β (Aβ) and Tau pathology similar to early-onset (EOAD) and late-onset AD (LOAD). We evaluated the Aβ plaque proteome of DS, EOAD, and LOAD using unbiased localized proteomics on post-mortem paraffin-embedded tissues from four cohorts (n = 20/group): DS (59.8 ± 4.99 y/o), EOAD (63 ± 4.07 y/o), LOAD (82.1 ± 6.37 y/o), and controls (66.4 ± 13.04). We identified differentially abundant proteins when comparing Aβ plaques and neighboring non-plaque tissue (FDR < 5%, fold-change.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Efficacy of a brief psychological intervention for adolescents with recent suicide attempt, A randomized clinical trial

  • García-Fernández, Ainoa|||0000-0002-4874-0353
  • Couce-Sánchez, Manuel|||0000-0002-2183-3824
  • Andreo Jover, Jorge|||0000-0002-6703-8017
  • Ayad-Ahmed, Wala|||0000-0002-0786-0076
  • Bobes-Bascarán, Maria T.|||0000-0002-5279-504X
  • Botí, M.|||0000-0003-2963-6929
  • Canal-Rivero, Manuel|||0000-0002-5818-5103
  • Cebrià, Ana Isabel|||0000-0002-2632-8130
  • Crespo-Facorro, Benedicto|||0000-0003-0033-7132
  • Díaz-Marsá, Marina|||0000-0003-1364-3163
  • Fernández-Rodrigues, Verónica|||0000-0003-0397-513X
  • Gómez Vallejo, Sandra|||0000-0003-0963-6585
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Grande, Iria|||0000-0002-0137-0666
  • Iglesias Gutiérrez, Noelia|||0000-0002-8684-8082
  • Jiménez-Treviño, Luis|||0000-0002-9551-8587
  • López-Pena, Purificación
  • Palao, Diego|||0000-0002-3323-6568
  • Palao Tarrero, Ángela|||0000-0003-2717-5807
  • Pedrola-Pons, Anna|||0009-0007-1641-5541
  • Ruiz-Veguilla, Miguel|||0000-0002-5790-7346
  • Suárez-Soto, Elizabeth|||0000-0001-7599-0078
  • Torre-Luque, Alejandro de la|||0000-0003-0595-6127
  • Zorrilla, Iñaki|||0000-0001-6444-8208
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Sáiz, Pilar A.|||0000-0002-5705-4523
Adolescents are at a heightened risk of suicide reattempts following hospital discharge, but few evidence-based interventions exist. This study evaluated the efficacy of the self-awareness of mental health (SAM) program combined with treatment as usual (TAU) versus TAU alone in reducing reattempts among high-risk adolescents. A randomized clinical trial was conducted across nine Spanish hospitals (January 2021-March 2024) with 261 adolescents (12-17 years) who had attempted suicide within the last 15 days. Participants were assigned to SAM + TAU (n=128) or TAU (n=133), with 12-month follow-up. The primary outcome was suicide reattempts within 12 months; secondary analyses examined time to reattempt and associated risk factors. After 12-months, no significant differences were found in reattempt rates [22.6% (SAM) versus 27.8% (TAU); OR=0.610, 95%CI (0.321-1.151), p=0.127] or time to reattempt [HR=0.606, 95%CI (0.390-1.021), p=0.060]. In SAM, attentional impulsivity emerged as a significant risk factor [HR=1.126, 95% CI (1.004-1.263), p=0.043], while nonplanning impulsivity was protective [HR=0.878, 95%CI (0.814-0.948), p<0.001]. In TAU, increased suicide risk was linked to suicidal intentionality [HR=1.341, 95%CI (1.009-1.782), p=0.044] and more prior attempts [HR=1.230, 95%CI (1.039-1.457), p=0.016]. Conversely, fewer psychiatric diagnoses emerged as a protective factor [HR=0.821, 95%CI (0.677-0.996), p=0.045]. While no significant differences were found between groups, SAM identified important psychological factors influencing suicide risk. These findings provide a foundation for targeted interventions to prevent reattempts in adolescents.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Self-disintegrating protein-leaking microparticles for topical protein delivery

  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Martínez-Cuentra, Genís Josep
  • Contreras, Estefanía|||0000-0002-8645-2790
  • Di Somma, Angela|||0000-0003-4916-7875
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Advanced drug delivery systems, if engineered to enhance drug stability and extend its kinetic bioavailability, are expected to expand the spectrum of local therapeutic approaches for dermatological conditions. In this context, the objective of this study was to explore whether artificial secretory granules, namely nontoxic, microscale granular Zn-assisted protein depots that leak the forming protein in a time-prolonged way, could be suited as functional agents in topical delivery. A model, recombinant form of the human fibroblast growth factor 2 (FGF-2), formulated as secretory granules, promoted efficient tissue repair and wound healing in a rat skin injury model faster than the natural repair process. The kinetic and histological analysis of FGF-2-treated wounds revealed that the package of the protein as secretory granules improves skin regeneration over the soluble version, and that it conduces to a more ordered construction of the extracellular matrix with limited risk of fibrosis. On the other hand, the addition of a claudin-binding peptide (c-CPE) as a fused protein segment slightly delays wound healing but offers functional and histological particularities that modulate the skin regeneration process. Altogether, the data presented here validates this endocrine-like protein drug delivery from synthetic disintegrating protein depots as a powerful and versatile platform for topical application in dermatological disorders.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Validation of the CAMCOG-DS-II, a neuropsychological test battery for Alzheimer's disease in people with Down syndrome, A Horizon 21 European Down syndrome Consortium study

  • Ivain, P.|||0000-0001-5302-1639
  • Baksh, A.
  • Saini, F.
  • Idris, M.
  • Tamayo-Elizalde, M.
  • Wells, J.
  • Benejam, Bessy|||0000-0002-6789-8615
  • Loosli, S.V.
  • Sandkühler, Katja|||0009-0000-7117-2270
  • Wlasich, E.
  • Wagemann, O.
  • Levin, J.
  • Martet, D.
  • Sacco, Simona|||0000-0003-0651-1939
  • Falquero, S.
  • Clert, M.
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Khoo, W.M.
  • Smith, M.A.
  • Beresford-Webb, J.
  • Zaman, Shahid
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Fortea, Juan|||0000-0002-1340-638X
  • Langballe, E.M.
  • Medbøen, I.T.
  • Larsen, F.K.
  • Baldimtsi, E.
  • Paradisi, R.
  • Ntailakis, P.
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Papantoniou, G.
  • McGlinchey, E.
  • McCarron, M.
  • Kennelly, S.
  • Strydom, A.
INTRODUCTION: The Cambridge Cognitive Examination modified for use in people with Down syndrome (CAMCOG-DS) is a sensitive cognitive test for Alzheimer's disease (AD)-related decline in people with DS, but needs updates for sensitivity, cultural adaptability, and additional memory/executive function items. This study aimed to develop and validate the CAMCOG-DS-II. METHODS: In this multi-language, multi-site study, the psychometric properties of the CAMCOG-DS-II were evaluated against previously validated measures in 223 participants (mean age: 40.18 years) with DS across seven countries. RESULTS: The CAMCOG-DS-II had a high completion rate, minimal floor/ceiling effects (compared to the modified Cued Recall Test, the CANTAB Paired Associates Learning, and the Purdue Pegboard), strong validity and reliability, and performance was unaffected by language across sites. It differentiated between those with/without AD and distinguished clinically rated cognitively stable and prodromal individuals. CONCLUSION: The CAMCOG-DS-II is a sensitive measure of cognitive performance in people with DS at risk of AD. Its cross-language and site reliability support its potential use in AD-DS clinical trials. Highlights: Developed and validated the Cambridge Cognitive Examination modified for use in people with Down syndrome (CAMCOG-DS-II) for Alzheimer's disease in Down syndrome. CAMCOG-DS-II shows increased sensitivity to Alzheimer's disease-related decline in Down syndrome. Improved applicability across an international and culturally diverse population. Differentiates Alzheimer's disease status: cognitively stable, prodromal, and clinical.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exploratory analysis of the proteomic profile in plasma in adults with Down syndrome in the context of Alzheimer's disease

  • Wagemann, O.
  • Nübling, G.
  • Martínez-Murcia, F.J.
  • Wlasich, E.
  • Loosli, S.V.
  • Sandkühler, Katja|||0009-0000-7117-2270
  • Stockbauer, A.
  • Prix, C.
  • Katzdobler, S.
  • Petrera, A.
  • Hauck, S.M.
  • Fortea, Juan|||0000-0002-1340-638X
  • Romero-Zaliz, R.
  • Jiménez-Mesa, C.
  • Górriz Sáez, J.M.
  • Höglinger, G.
  • Levin, J.
INTRODUCTION: Adults with Down syndrome (DS) show increased risk for Alzheimer's disease (AD) due to the triplication of chromosome 21 encoding the amyloid precursor protein gene. Further, this triplication possibly contributes to dysregulation of the immune system, furthering AD pathophysiology. METHODS: Using Olink Explore 3072, we measured ∼3000 proteins in plasma from 73 adults with DS and 15 euploid, healthy controls (HC). Analyses for differentially expressed proteins (DEP) were carried out, and pathway and protein network enrichment using Gene Ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG), and STRING database was investigated. Within DS, the LASSO (least absolute shrinkage and selection operator) feature selection was applied. RESULTS: We identified 253 DEP between DS and HC and 142 DEP between symptomatic and asymptomatic DS. Several pathways regarding inflammatory and neurodevelopmental processes were dysregulated in both analyses. LASSO feature selection within DS returned 15 proteins as potential blood markers. DISCUSSION: This exploratory proteomic analysis found potential new blood biomarkers for diagnosing DS-AD in need of further investigation. Highlights: Inflammatory pathways are dysregulated in symptomatic versus asymptomatic DS. NFL and GFAP are confirmed as powerful biomarkers in DS with clinical and/or cognitive decline. Further circulating proteins were identified as potential blood biomarkers for symptomatic DS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Generational effects in Down syndrome, Enriched environment enhances functionality without reducing Alzheimer's disease risk

  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernández, Susana|||0000-0002-9777-1156
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Sanjuan, Aída
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Arenaza-Urquijo, Eider|||0000-0001-7016-7576
  • Lleó, Alberto|||0000-0002-2568-5478
  • Bartrés-Faz, David|||0000-0001-6020-4118
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
Down syndrome (DS) is the leading cause of intellectual disability (ID) and a genetic form of Alzheimer's disease (AD). We wanted to assess whether generational changes have induced (1) milder ID with greater independence and (2) delayed AD diagnosis. We analyzed 681 asymptomatic DS to test generational effects on ID, functionality, and cognition. In 353 DS individuals with AD, we compared clinical diagnosis age by ID using analysis of variance. In addition, dementia diagnosis age was examined through a published meta-analysis. Our results indicate a generational shift toward a higher proportion of individuals with mild/moderate ID, greater intelligence, and autonomy. However, it was not paralleled by an ID-related delay in the age at AD onset in our cohort, or by generational delays reported over the past 35 years. The findings highlight notable generational improvements in DS, but no effects on the age at AD dementia diagnosis. OrderedDict([(u'list', OrderedDict([(u'@list-type', u'bullet'), (u'@id', u'alz70447-list-0001'), (u'list-item', [OrderedDict([(u'p', u'A generational effect has reduced the severity of intellectual disability in Down syndrome (DS).')]), OrderedDict([(u'p', u'Individuals with DS have increased autonomy and improved intellectual milestones.')]), OrderedDict([(u'p', u"The enriched environment has not delayed the age at Alzheimer's disease (AD) dementia in DS.")]), OrderedDict([(u'p', u'Further studies should confirm if cognitive reserve might delay AD in DS.'.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HTGAnalyzer, An accessible R package with a web interface for enhanced transcriptomic analysis in precision medicine

  • Díez-Ahijado, Laia
  • del Rincón, Aarón Marcén
  • Marimón, Lorena|||0000-0002-2943-3550
  • Saco, Adela
  • del Pino, Marta|||0000-0003-2178-2403
  • Torne, Aureli|||0000-0003-4700-9507
  • Darecka, Katarzyna
  • Sisuashvili, Lia
  • Peñuelas, Núria|||0000-0001-6443-9790
  • Pascual-Mas, Pau|||0000-0002-6873-6538
  • Carreras-Dieguez, Núria|||0000-0002-4809-8102
  • Ordi, Oriol
  • Rakislova, Natalia|||0000-0001-5030-3526
  • Albero Gallego, Robert|||0000-0001-5527-0997
Transcriptomics generates promising data for personalized medicine, but its clinical utility is hindered by technical barriers associated with formalin-fixed, paraffin-embedded samples. Advances in automation and simplified workflows are key for integrating these technologies into routine care. We have developed HTGAnalyzer, an R package that enables bulk transcriptomics analysis from multiple data sources, such as HTG EdgeSeq and RNA-seq. Designed with clinical and molecular diagnostics in mind, HTGAnalyzer includes a fully automatic pipeline that performs sample quality control, data normalization, and a set of transcriptomic and clinical analyses. Importantly, HTGAnalyzer provides quality control and analysis tailored for HTG data, filling the gap left by HTG closure with no alternative solutions. Designed for ease of use without knowledge of bioinformatics, it features a user-friendly Shiny app, standardized functions for easy Docker setup, and enhanced connectivity to clinical data management systems. It delivers a complete analytical workflow in less than 20 min on a standard PC (Intel i7-7500U, 16 GB RAM). We applied HTGAnalyzer to diverse datasets, including a new vulvar cancer cohort, and generated interpretable reports with rich visual outputs. In summary, HTGAnalyzer offers robust quality control and advanced analytics in a single, unified tool, supporting the clinical use of transcriptomics in precision medicine.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Validation of the Spanish Childhood Trauma Questionnaire-Short Form in adolescents with suicide attempts

  • García-Fernández, Ainoa|||0000-0002-4874-0353
  • Martínez-Cao, Clara|||0000-0002-3803-9301
  • Sánchez-Fernández-Quejo, Alberto
  • Bobes-Bascarán, Maria T.|||0000-0002-5279-504X
  • Andreo Jover, Jorge|||0000-0002-6703-8017
  • Ayad-Ahmed, Wala|||0000-0002-0786-0076
  • Cebrià, Ana Isabel|||0000-0002-2632-8130
  • Díaz-Marsá, Marina|||0000-0003-1364-3163
  • Garrido-Torres, Nathalia|||0000-0003-1810-947X
  • Gómez, Sandra
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Grande, Iria|||0000-0002-0137-0666
  • Iglesias Gutiérrez, Noelia|||0000-0002-8684-8082
  • March, Katya B.
  • Palao, Diego|||0000-0002-3323-6568
  • Pérez-Díez, Iván|||0000-0002-9972-2825
  • Roberto Herrero, Natalia|||0000-0002-5391-2711
  • Ruiz-Veguilla, Miguel|||0000-0002-5790-7346
  • Torre-Luque, Alejandro de la|||0000-0003-0595-6127
  • Zorrilla, Iñaki|||0000-0001-6444-8208
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Sáiz, Pilar A.|||0000-0002-5705-4523
  • García-Portilla, María Paz|||0000-0003-3643-1622
Child maltreatment is associated with a higher probability of mental disorders and suicidal behavior in adolescence. Therefore, accurate psychometric instruments are essential to assess this. To validate the Spanish version of the Childhood Trauma Questionnaire-Short Form (CTQ-SF) in adolescents with suicide attempts. Multisite cohort study of 208 adolescents with suicide attempts using data from the following scales: Mini International Neuropsychiatric Interview (MINI), Columbia Suicide Severity Rating Scale (C-SSRS), Patient Health Questionnaire (PHQ-9), and CTQ-SF. Statistical analysis: CTQ-SF scores analyzed by descriptive statistics. Internal consistency: McDonald's omega and Cronbach's alpha. Concurrent validity with PHQ-9 and C-SSRS scores: Spearman correlation coefficient. Structural validity: Confirmatory factor analysis. Floor and ceiling effects: Physical abuse and neglect as well as sexual abuse demonstrated high floor effects (50.0, 35.1, and 61.1% of adolescents, respectively). No ceiling effects were found. The CTQ-SF had excellent internal consistency (McDonald's omega = 0.94), as did the majority of its subscales (Cronbach's alpha 0.925-0.831) except for physical neglect (0.624). Its concurrent validity was modest, and the emotional neglect subscale had the lowest Spearman correlation coefficients (0.067-0.244). Confirmatory factor analysis: Compared with alternative factor structures, the original CTQ-SF model (correlated 5-factor) exhibited a better fit [S-B χ 2 = 676.653, p < 0; RMSEA (90% CI = 0.076-0.097) = 0.087; SRMR = 0.078; CFI = 0.980; TLI = 0.978]. The Spanish CTQ-SF is a reliable, valid instrument for assessing traumatic experiences in adolescents at high risk of suicide. It appears appropriate for use in routine clinical practice to monitor maltreatment in this group.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Nerve growth factor precursor alterations in neuron-derived extracellular vesicles from individuals with Down syndrome along the Alzheimer's disease continuum

  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Aranha, Mateus|||0000-0001-9594-292X
  • Pérez-González, R.
  • Serrano-Requena, S.
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Benejam, Bessy|||0000-0002-6789-8615
  • Chiva-Blanch, Gemma|||0000-0001-6093-0160
  • Jiménez Pineda, Amanda|||0000-0003-4967-1174
  • Busciglio, J.
  • Wisniewski, Thomas M.
  • Carmo, S.D.
  • Álvarez-Sánchez, Esther|||0009-0002-8760-2153
  • Muñoz, L.
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Belbin, Olivia|||0000-0002-6109-6371
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Lleó, Alberto|||0000-0002-2568-5478
  • Cuello, AC.|||0000-0003-2143-2745
  • Fortea, Juan|||0000-0002-1340-638X
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Iulita, M. Florencia|||0000-0002-3360-4498
BACKGROUND: In Down syndrome (DS) and Alzheimer's disease (AD), nerve growth factor precursor protein (proNGF) accumulates in the brain. However, its non-invasive detection using neuron-derived extracellular vesicles (NDEVs) from plasma remains unexplored. METHODS: We included 139 adults with DS (45 asymptomatic [aDS], 94 symptomatic for AD [sDS]) and 37 healthy controls. NDEVs were isolated from plasma. ProNGF and tetraspanin (CD81) were quantified by enzyme-linked immunosorbent assay. We assessed proNGF/CD81 changes with age, along the AD continuum (aDS and sDS), and associations with cerebrospinal fluid (CSF), plasma biomarkers, episodic memory, and basal forebrain volume. RESULTS: In DS, proNGF/CD81 levels increased with age and were higher in NDEVs from asymptomatic and symptomatic individuals compared to controls, with the highest levels in the symptomatic group. ProNGF correlated with CSF phosphorylated tau (p-tau)181, plasma p-tau217, neurofilament light chain, and episodic memory. DISCUSSION: ProNGF/CD81 levels in NDEVs increase along the AD continuum in DS and parallel tau pathology, indicating the potential as a promising biomarker for monitoring disease progression in plasma. Highlights: Nerve growth factor precursor protein (ProNGF)/tetraspanin (CD81) ratio increased in the third decade of life, 20 years before Alzheimer's disease (AD) symptom onset in Down syndrome (DS). proNGF/CD81 concentrations were significantly higher in individuals with DS compared to controls and were notably elevated in individuals with DS and symptomatic AD compared to asymptomatic AD. proNGF/CD81 concentrations were associated with tau pathology and neuronal injury.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sex differences in the executive and behavioral reserve of autosomal dominant frontotemporal dementia

  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Casaletto, Kaitlin B.
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Memel, M.|||0000-0001-6827-6335
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Belbin, Olivia|||0000-0002-6109-6371
  • Fortea, Juan|||0000-0002-1340-638X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Heuer, H.W.
  • Forsberg, L.K.
  • Kantarci, K.
  • Staffaroni, Adam M.
  • Tartaglia, C.
  • Rankin, K.P.
  • Boeve, Bradley
  • Boxer, A.
  • Rosen, H.J.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
INTRODUCTION: Self-reported sex influences brain resilience, but its role in genetic frontotemporal dementia (FTD) remains unclear. METHODS: We analyzed 394 genetic-FTD patients and 279 controls from the ALLFTD consortium, assessing annual neuropsychological performance and MRI-based cortical thickness. Clinical characteristics and cortical thickness were compared between sexes. We used the residuals of linear regression models, which predict each participant's cognitive and behavioral performance levels relative to cortical thickness, as a proxy for reserve. We then modeled sex differences in longitudinal trajectories with linear mixed-effects models. RESULTS: Symptomatic females with genetic FTD had lower frontal cortical thickness than males, and the C9orf72 subgroup showed lower-than-expected frontal cortical thickness for a given level of executive functioning. Differences in cognitive reserve between sexes peaked near symptom onset but diminished thereafter. DISCUSSION: Females with genetic FTD showed higher cognitive reserve than males, suggesting that self-reported sex modulates resilience to frontotemporal neurodegeneration. Highlights: Females with genetic FTD showed higher cognitive reserve than males. Those differences were particularly pronounced in the C9orf72 and GRN subgroups. The higher cognitive reserve in females declined as the disease progressed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

When should the nephrologist think about genetics in patients with glomerular diseases?

  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Barros, Xoana|||0000-0001-9690-9769
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Fayos de Arizón, Leonor|||0000-0002-9277-645X
  • Furlano, Monica|||0000-0003-1025-3901
  • Pilco-Teran, Melissa|||0000-0002-1311-0896
  • Pybus, Marc|||0000-0002-6195-5738
  • Shabaka, Amir|||0000-0001-7039-4701
  • Viera, Elizabeth|||0000-0002-3548-7061
  • Ars, Elisabet|||0000-0002-4118-4358
This review discusses the significance of genetics in diagnosing glomerular diseases. Advances in genetic testing, particularly next-generation sequencing, have improved the accessibility and accuracy of diagnosing monogenic diseases, allowing for targeted gene panels and whole-exome/genome sequencing to identify genetic variants associated with glomerular diseases. Key indicators for considering a genetic cause include the age of onset, extrarenal features, family history, and inconclusive kidney biopsy results. Early-onset diseases, for instance, have a higher likelihood of being genetically caused, while extrarenal manifestations can also suggest an underlying genetic condition. A thorough family history can reveal patterns of inheritance that point to monogenic causes, although complexities like incomplete penetrance, skewed X inactivation and mosaicism can complicate the assessment. Also, autosomal recessive conditions imply asymptomatic parents, making genetic suspicion less likely, while de novo mutations can occur without any family history, further obscuring genetic assessment. Focal segmental glomerulosclerosis (FSGS) is characterized by podocyte injury and depletion, presenting in various forms, including primary, genetic, and secondary FSGS. Accurate classification of FSGS patients based on clinical and histological features is essential for guiding treatment decisions, optimizing therapeutic plans, avoiding unnecessary immunosuppression, and predicting relapse risk after kidney transplantation. Overall, a clinicopathological approach, enriched by genetic testing, offers a precise framework for diagnosis and management in glomerular diseases. Future directions for research and clinical practice include potential advancements in genetic testing and personalized medicine, which could further improve diagnostic precision and individualized treatment strategies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of Alzheimer's disease on sleep in adults with Down syndrome

  • Giménez, Sandra|||0000-0001-8031-2319
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Zhu, Nuole|||0000-0002-0015-9455
  • Benejam, Bessy|||0000-0002-6789-8615
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Bueno-López, Ana|||0000-0003-2390-219X
  • Fernández, Susana|||0000-0002-9777-1156
  • Ribas, Laia
  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lisgaras, Christos Panagiotis
  • Blessing, Esther
  • Osorio, Ricardo S.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
INTRODUCTION: Down syndrome (DS) is a genetic form of Alzheimer's disease (AD), with a high prevalence of sleep disorders, but data in adults with DS and dementia are lacking. We aim to assess sleep in adults with DS across the AD continuum. METHODS: We studied 78 healthy controls and 229 adults with DS (154 asymptomatic, 25 with prodromal AD, and 75 with AD) with subjective sleep measures and objective nocturnal polysomnography. RESULTS: Adults with DS presented worse sleep quality and higher prevalence of unnoticed obstructive sleep apnea (OSA) than controls. Sleep disruption and OSA severity increased across the AD continuum. Age-related decreases in slow-wave sleep and rapid eye movement sleep were more pronounced in the DS group. Subjective sleep measures did not capture sleep disorders. CONCLUSIONS: In DS, AD is linked to worse sleep disturbances and altered architecture. However, longitudinal studies are needed to clarify directionality and disease progression. Highlights: Down syndrome (DS) is associated with increased slow-wave sleep (SWS) and reduced rapid eye movement (REM) sleep. Obstructive sleep apnea prevalence increases along the Alzheimer's disease continuum in DS. Age-related decreases in SWS and REM sleep are accelerated in DS. Subjective sleep measures do not detect sleep disturbances in adults with DS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Insulin resistance modulates gut microbiota and incretin response remodeling after bariatric surgery in severe obesity

  • Puig, Rocío
  • Rodríguez-Peña, M-Mar
  • Hernández-Montoliu, Laura
  • Astiarraga, Brenno|||0000-0003-2216-8974
  • Martínez, Eva
  • Balibrea Del Castillo, José María|||0000-0002-0764-7179
  • Llauradó, Gemma|||0000-0002-3237-6366
  • Tarascó, Jordi
  • Caballero, Albert
  • Joaquín, Clara|||0000-0002-9063-4853
  • Puig Domingo, Manuel|||0000-0002-6744-7195
  • Vilarrasa, Nuria|||0000-0003-3188-1990
  • Fernández-Veledo, Sonia|||0000-0003-2906-3788
  • Vendrell, Joan|||0000-0002-6994-6115
  • Pellitero, Silvia|||0000-0002-9510-7251
This study aims to assess the impact of insulin resistance (IR) on gut microbiota (GM) composition, incretin responses, and metabolic outcomes following sleeve gastrectomy (SG) in people with severe obesity who do not have diabetes. Methods: A prospective single-center study encompassed patients with severe obesity and normal glucose tolerance who underwent SG. Participants were stratified into two cohorts based on the magnitude of their insulin resistance state, as determined by the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) index: high-IR (Hi-IR; HOMA-IR 95th percentile) and low-IR (Lo-IR; HOMA-IR < 25th percentile). Body composition measurements, biochemical analyses, and microbiota assessments were performed before and six months post-surgery. Additionally, the responses to a standardized meal tolerance test (MTT) of glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) were evaluated. Results: The study cohort consisted of 18 patients (9 with Hi-IR and 9 with Lo-IR), with a mean age of 48.8 ± 9.2 years and a mean body mass index (BMI) of 45.03 ± 4.82 kg/m². Six months post-surgery, the mean percentage of total weight loss (WL) was 26.5 ± 6%, with both groups exhibiting enhanced secretion of GLP-1 and GLP-2 following MTT. At baseline, participants exhibited distinct microbiota profiles; the Hi-IR group showed a higher relative abundance of Prevotella species, which are previously associated with adverse metabolic and inflammatory profiles. Post-surgery, both groups exhibited positive incretin responses and significant modifications in GM composition. Notably Hi-IR people experienced more 146 pronounced changes in microbial diversity, including increases in Akkermansia and Veillonella species and decreases in Prevotella species. Enhanced GLP-1 and GLP-2 responses were correlated with WL and metabòlic improvement, particularly in the Lo-IR population. Conclusions: These findings underscore the role of GM in metabolic changes and surgical outcomes after SG. Targeting gut microbiota may offer a promising avenue for improving obesity treatment strategies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

From Genetics to Psychosocial Functioning, Unraveling the Mediating Roles of Cognitive Reserve, Cognition, and Negative Symptoms in First-Episode Psychosis

  • Forte, Maria Florencia|||0000-0001-5930-5501
  • Clougher, Derek|||0000-0001-7631-3845
  • González-Segura, Àlex|||0000-0002-9398-2183
  • Mezquida, Gisela|||0000-0002-6080-2203
  • Sánchez Torres, Ana Maria|||0000-0002-9505-2406
  • Vieta, Eduard|||0000-0002-0548-0053
  • Garriga, Marina|||0000-0001-7312-4969
  • Lobo, Antonio|||0000-0002-9098-655X
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Diaz-Caneja, C.M.
  • Roldan-Bejarano, Alexandra|||0000-0001-9905-3943
  • Martínez-Àran, Anabel|||0000-0002-0623-6263
  • de la Serna, Elena|||0000-0002-7869-9881
  • Mané, Anna|||0000-0003-2127-349X
  • Mas, Sergi|||0000-0003-3336-6298
  • Torrent, Carla|||0000-0003-0335-582X
  • Allot, K.|||0000-0002-0640-4634
  • Bernardo, Miquel|||0000-0001-8748-6717
  • Amoretti, Silvia|||0000-0001-6017-2734
  • Pérez, Antonio|||0000-0001-5528-1143
  • Meseguer, A.
  • Cámara, Concepción de la|||0000-0003-2284-7862
  • Ruiz-Lazaro, P.M.
  • Calvo, L.
  • Estébanez, M.J.
  • Ferrer, Marta
  • Echevarría, A.
  • Escarti, M.J.
  • Rivero, O.
  • Trabsa, Amira|||0000-0002-8669-0676
  • Legido, Teresa|||0000-0002-1175-2641
  • Serra, M.
  • Baeza, Inmaculada|||0000-0003-2611-5781
  • Castro Gutiérrez, Jorge
  • Parra, S.M.
  • Santo, F.D.
  • García-Portilla, María Paz
  • Echevarría, R.S.
  • Rabadán, A.Z.
  • Martínez-Gras, I.
  • Rodriguez-Jimenez, Roberto|||0000-0003-2251-7249
  • Usall, J.
  • Butjosa Molines, Anna|||0000-0001-5317-9508
  • Clotet, E.P.
  • Salvador, R.
  • Ibañez, Angela|||0000-0003-2751-0150
  • Cuesta, M.J.
  • Balanzá-Martínez, Vicent|||0000-0001-7772-7396
Background: Studies have shown associations between polygenic risk scores for educational attainment (PRS), cognitive reserve (CR), cognition, negative symptoms (NS), and psychosocial functioning in first-episode psychosis (FEP). However, their specific interactions remain unclear. This study aimed to investigate the mediating roles of CR, cognition, and NS in the relationship between PRS and psychosocial functioning one year after a FEP. Additionally, we sought to explore the impact of two NS subtypes on this relationship: diminished Expression (EXP-NS) and Motivation and Pleasure (MAP-NS). Methods: A total of 138 FEP participants, predominantly male (70%), with a mean age of 24.77 years (SD = 5.29), underwent genetic, clinical, and cognitive assessments two months after study enrollment. Functioning evaluation followed at one-year follow-up. To investigate the mediating role of CR, cognition, and NS in the relationship between PRS and functioning, a serial mediation model was employed. Two further mediation models were tested to explore the differential impact of EXP-NS and MAP-NS. Mediation analysis was performed using the PROCESS macro version 4.1 within SPSS version 26. Results: The serial mediation model revealed a causal chain for PRS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma p-tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease

  • Kac, Przemysław R.|||0000-0001-5083-0924
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Fernández, S.
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • González-Ortiz, F.
  • Benejam, Bessy|||0000-0002-6789-8615
  • Turton, M.
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Harrison, P.
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Lleó, Alberto|||0000-0002-2568-5478
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Karikari, Thomas K.|||0000-0003-1422-4358
  • Fortea, Juan|||0000-0002-1340-638X
  • Blennow, Kaj|||0000-0002-1890-4193
BACKGROUND: All individuals with Down syndrome (DS) will develop full-blown Alzheimer's disease (AD) pathology by age 40. Several genes encoded in chromosome 21, including dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), have been proven to contribute to the pathology. Phosphorylation of tau at threonine-212 (p-tau212) is very sensitive to DYRK1A phosphorylation and is increased in DSAD brain lysates. Here, we assessed the potential of this biomarker in DSAD and sporadic AD. METHODS: Using single molecule array (Simoa) technology, we tested p-tau212 and p-tau181 (n = 245 for plasma, n = 114 matching cerebrospinal fluid [CSF] samples). RESULTS: We have confirmed that the levels of plasma p-tau212 are increased in the DS population and sporadic AD cases, including prodromal and mild cognitive impairment states. Plasma p-tau212 started increasing approximately when people became amyloid positron emission tomography positive. DISCUSSION: Plasma p-tau212 might have utility for theragnostics, monitoring therapy efficacy, and as a target engagement biomarker in clinical trials both in sporadic and DSAD. Highlights: Plasma p-tau212 is increased in the Down syndrome (DS) population. Plasma p-tau212 increases ≈15 years before the disease onset in DSAD. Plasma p-tau212 accurately differentiates between control and disease groups. Plasma p-tau212 accurately differentiates amyloid beta (Aβ)+ and Aβ- participants.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Bridging perspectives, The value of collaboration between Traditional Healing Practitioners and Medical Doctors in dementia research and care in South Africa

  • McGlinchey, E.
  • Ranchod, K.
  • Stroebel, R.
  • Lusizi, B.
  • Galvin, M.
  • Kleinhans, A.V.
  • Fortea, Juan|||0000-0002-1340-638X
  • Hoffman, J.
  • Makanya, S.
INTRODUCTION: Traditional Healing Practitioners (THPs) provide care to the majority of the population in South Africa. Despite their widespread presence, they remain largely excluded from dementia research and policy. This reinforces healthcare inequities and overlooks the realities of communities where THPs provide care. METHODS: This paper explores the role of THPs in dementia care by examining literature in South Africa. It identifies key barriers to collaboration between THPs and medical doctors and discusses pathways for integration. RESULTS: Barriers include epistemological historical marginalization, mutual distrust, fragmented care pathways, and language barriers. These challenges hinder knowledge exchange and joint dementia care strategies. DISCUSSION: Strengthening relationships through structured engagement, bidirectional knowledge exchange, and ethical collaboration could bridge the gap between THPs and Medical Doctors (MDs). A pluralistic, integrated model valuing both systems could lead to more equitable and effective dementia care. Highlights: The majority of people in South Africa engage with Traditional Healing Practitioners (THPs) as part of their healthcare, yet THPs remain largely excluded from dementia research and policy. Barriers to collaboration between THPs and Medical Doctors (MDs) include historical marginalization, mutual distrust, fragmented care pathways, and language differences. Integrating THPs and MDs through structured engagement, bidirectional knowledge exchange, and ethical collaboration could enhance dementia care. Shifting away from the binary opposition of Indigenous Knowledge Systems (IKS) and biomedical approaches toward a more integrated and collaborative model of dementia care could lead to more equitable and effective healthcare. The FUNDISA (Framework for Understanding Neurocognitive Disorders via Indigenous Systems in South Africa) project aims to understand how dementia is conceptualized by THPs and foster collaboration between THPs and MDs to support effective dementia care.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Discrepancies in assessing intellectual disability levels in adults with Down syndrome, Implications for dementia diagnosis

  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Sandkühler, Katja|||0009-0000-7117-2270
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Wlasich, E.
  • Kustermann, J.
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Fernández, Susana|||0000-0002-9777-1156
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • San Juan, Aida
  • Nübling, G.
  • Wagemann, O.
  • Stockbauer, A.
  • Hassenstab, J.
  • Levin, J.
  • Fortea, Juan|||0000-0002-1340-638X
INTRODUCTION: Cut-offs derived from baseline cognitive assessments, stratified by intellectual disability (ID) level, have been proposed to diagnose symptomatic Alzheimer's disease (AD) in Down syndrome (DS). However, discrepancies in ID classification risk misclassification when applying cut-offs across sites. METHODS: This dual-center cohort study included 673 adults with mild to moderate ID at different AD stages. We assessed ID classification discrepancies across sites and the impact on Cambridge Cognitive Examination for Older Adults with Down's Syndrome (CAMCOG-DS) cut-offs for AD dementia diagnosis derived from receiver operating characteristic analysis. RESULTS: Inter-rater agreement for ID level classification was 95% within sites but 60% between sites. While CAMCOG-DS score distributions in the whole cohort were similar across sites, ID classification discrepancies caused higher cut-offs in Barcelona for mild and moderate ID compared to Munich. Applying site-specific cut-offs to another cohort reduced sensitivity and specificity. DISCUSSION: Standardizing ID classification is critical for generalizable cut-offs to accurately diagnose AD dementia based on neuropsychological assessments in DS. Highlights: CAMCOG-DS cut-offs by intellectual disability level classify dementia in Down syndrome. ID classification discrepancies between sites impact CAMCOG-DS diagnostic cut-offs. Applying site-specific cut-offs to other cohorts reduces sensitivity and specificity. Standardized ID classification is essential for generalizable cognitive cut-offs. Use site-specific cut-offs until ID classification is standardized.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cargo of small extracellular vesicles from neuronal origin shows progression of dementia in individuals with Down syndrome

  • Ledreux, A.|||0000-0001-6232-7672
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
INTRODUCTION: Individuals with Down syndrome (DS) are at an ultra-high risk of developing Alzheimer's disease (AD). Diagnosis of AD onset in people with DS can be challenging due to the variable degrees of intellectual disability and cognitive impairment among individuals. METHODS: Plasma samples from individuals with DS diagnosed with AD dementia (n = 33), prodromal AD (n = 31), or cognitively stable (n = 43) were enriched for neuron-derived extracellular vesicles (NDEV) using immunocapture with the L1CAM antibody. We used single-molecule array technology to quantify amyloid-β (Aβ) peptides, Tau, phosphorylated Tau, neurofilament light chain (NfL), and synaptosomal-associated protein 25 (SNAP25) across diagnostic groups. RESULTS: NDEV levels of Aβ40, Aβ42, Tau, pTauT181, pTauT231, NfL, and SNAP25 were significantly higher in people with DS diagnosed with prodromal AD compared to those with no cognitive decline. Middle-aged or older women had higher levels of NDEV biomarkers compared to males. DISCUSSION: NDEV biomarker levels can inform on the onset of AD in individuals with DS. Highlights: Diagnosis of Alzheimer's dementia in individuals with Down syndrome (DS)is challenging. Neuron-derived extracellular vesicles were enriched from plasma of adults with Down syndrome. Alzheimer's disease biomarkers were measured using single molecule array technology. NDEV biomarkers accurately predicted the prodromal stage of dementia in people with DS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Down syndrome in Africa, Challenges, opportunities, and future directions

  • McGlinchey, E.
  • Tewolde, S.
  • He, A.
  • Fortea, Juan|||0000-0002-1340-638X
  • Mbakile-Mahlanza, L.
  • Tefera, A.
  • Epenge, E.
  • Hassenstab, J.
  • Jäck, A.
  • Ranchod, K.
  • El-Jaafary, S.
  • Levin, J.
  • Salama, M.
  • Rubenstein, E.
  • Akinyemi, R.
  • Akinyemi, T.
  • Farombi, T.
  • Lawlor, B.
  • Ikanga, J.
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Stout, S.
  • Balls-Berry, J.
  • Kleinhans, A.V.
  • Maina, R.
  • Merali, Z.
INTRODUCTION: As life expectancy improves for people with Down syndrome (DS) in Africa, the risk of developing DS-associated Alzheimer's disease (DSAD) will rise. There is a pressing need to plan for this emerging challenge, particularly in the context of existing health and social disparities. METHODS: This work emerged from a pan-African collaboration, including discussions at the Brain Ageing and Dementia in Low- and Middle-Income Countries conference held in Nairobi in 2024, where stakeholders identified regional priorities for DS and dementia care. RESULTS: Limited epidemiological, cognitive, biomarker data, delayed diagnoses, and gaps in specialized services may impact access to care. However, innovative solutions, such as mobile biomarker sampling and culturally adapted cognitive assessments, offer promising strategies. DISCUSSION: Integrating global advances in DSAD research with Africa's strengths in community-based care offers opportunities. By prioritizing research, capacity building, and health system integration, this work advocates for the inclusion of DS in Africa's dementia strategies. Highlights: Projected increases in life expectancy for individuals with Down syndrome (DS) in Africa will lead to a substantial rise in DS-associated Alzheimer's disease (DSAD), necessitating urgent planning and response. There is a critical lack of epidemiological, cognitive, and biomarker data on adults with DS in Africa, hindering accurate diagnosis, care planning, and inclusion in global research. Innovative, scalable solutions-such as mobile biomarker sampling and culturally adapted cognitive assessments-offer an opportunity to integrate scientific advances with Africa's strengths in community-based care. Investment in research and capacity building is essential to address current gaps, reduce disparities, and ensure equitable access to emerging diagnostics and treatments for DSAD across the continent.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development of amyloid-negative neuropsychological norms using GAMLSS

  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Estanga, Ainara|||0000-0002-6616-314X
  • Ecay-Torres, Mirian|||0000-0001-7170-6180
  • de Luis, C.L.
  • Rami Gonzalez, Lorena|||0000-0002-7411-1921
  • Tort-Merino, Adrià|||0000-0002-5646-0482
  • Castellví, Magdalena|||0000-0001-8769-9288
  • Pozueta, A.
  • García-Martínez, M.
  • Gómez-Andrés, David|||0000-0001-5654-7791
  • Lage, Carmen|||0000-0003-1703-121X
  • López-Garcia, Sara
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Balasa, Mircea|||0000-0002-1795-4228
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Tainta, Mikel|||0000-0003-0624-1211
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Zhu, Nuole|||0000-0002-0015-9455
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Rodríguez-Rodríguez, Eloy|||0000-0001-7742-677X
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Martinez-Lage, Pablo|||0000-0001-5404-9967
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
INTRODUCTION: Recent research has suggested increased sensitivity of Alzheimer's disease (AD)-negative neuropsychological norms; concurrently, generalized additive models for location, scale, and shape (GAMLSS) have emerged as a promising alternative to traditional norming approaches. Here, we developed amyloid β-negative (Aβ-) next-generation norms (NGN) for a comprehensive neuropsychological battery using GAMLSS. METHODS: We included N = 987 cognitively normal (CN) individuals from a Spanish multicenter study with extensive neuropsychological data and cerebrospinal fluid AD biomarker assessment. NGN were developed using GAMLSS based on the performance of n = 774 Aβ- CN individuals aged 30-90 years. RESULTS: Age-, education-, and sex-adjusted z-scores were obtained for 14 measures covering the main cognitive domains (memory, language, attention/executive, and visuospatial functions). A user-friendly calculator for the z-scores was made available in an open-access ShinyApp to facilitate their application. DISCUSSION: NGN may improve the detection of objective cognitive impairment in clinical and research settings. Highlights: Brain amyloid β (Aβ) is associated with poorer performance in cognitively normal individuals. We provide GAMLSS-based Aβ-negative norms for 14 neuropsychological measures. Age, education, and often sex significantly influence cognitive performance. An online calculator for the demographically adjusted z-scores is freely available.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer's disease in a tertiary memory clinic

  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Ferrer Pérez, Rosa|||0009-0004-9477-699X
  • Zhu, Nuole|||0000-0002-0015-9455
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola-Infante, J.E.
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Alcolea, Daniel|||0000-0002-3819-3245
Background: Knowledge on the effect of analytical variability and storage conditions are essential for the successful implementation of plasma pTau in prospective settings. Aims: To investigate the performance of plasma pTau, measured in consecutive samples with LUMIPULSE, for detecting Alzheimer's disease in a prospective memory clinic setting, along with evaluating its pre-analytical and analytical stability. Methods: We prospectively measured pTau using the LUMIPULSE automated platform in consecutive patient plasma samples collected between May and November 2024 at the Sant Pau Memory Unit (Barcelona). A subset of participants also underwent paired lumbar puncture for CSF AD biomarkers. We compared biomarker concentrations under different short-term storage conditions (4ºC vs -20ºC) and different protocol pipelines, and assessed lot-to-lot variability. In the subset with available CSF biomarkers, logistic regression was used to evaluate the association between plasma pTau217 and the likelihood of a positive (A +) or a negative (A-) CSF amyloid status. Using ROC analysis, in this prospective cohort we evaluated the accuracy of previously established thresholds derived from historical samples. Results: We included 280 participants, divided into two groups: those with (n = 109) and without CSF data (n = 171). Among the subset with CSF, 48% were A +, with a plasma pTau fold-change of 4.5 × compared to A-. We found no differences in plasma pTau concentrations between either short-term storage conditions. The overall coefficients of analytical variation ranged from 1.8% to 3.2%. Plasma pTau concentrations were slightly higher in paired samples of the clinical protocol. Following a two-threshold approach, the need of confirmatory tests (grey zones) after measuring plasma pTau ranged between 45.9% and 18.3% using our previously reported strict or lenient cutoffs (overall accuracy 96.6% and 92.1%, respectively). Conclusions: The robust stability and low lot-to-lot variability of plasma pTau measurement in an automated platform result in high diagnostic performance of this biomarker in the prospective evaluation of patients in a memory clinic setting. These findings support its implementation into clinical routine, offering clinicians an accessible biomarker for AD diagnosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma p-tau217 as a biomarker of Alzheimer's disease pathology in individuals with Down syndrome

  • Huber, H.
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Arslan, Burak
  • Leuzy, Antoine
  • Kittel, Oscar
  • Molfetta, Guglielmo Di
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Lleó, Alberto|||0000-0002-2568-5478
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Blennow, Kaj|||0000-0002-1890-4193
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Fortea, Juan|||0000-0002-1340-638X
  • Ashton, Nicholas J.|||0000-0002-3579-8804
Diagnosing Alzheimer's disease (AD) in adults with Down syndrome (DS), a population with a high genetically determined risk of AD, remains challenging. In this large observational study including n = 2329 samples from the Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and euploid controls from the Sant Pau Initiative on Neurodegeneration (SPIN) with and without symptomatic AD, we investigate if the strong diagnostic performance of plasma p-tau217 observed in sporadic AD extends to the DS population. Plasma p-tau217 discriminated cognitively stable individuals with DS from those with AD dementia with an AUC of 0.96 (95% CI, 0.95-0.97), and from those with prodromal AD with an AUC of 0.90 (95% CI, 0.87-0.92). Amyloid β (Aβ) positive and Aβ negative individuals with DS were distinguished with an AUC of 0.95 (95% CI, 0.92-0.99). In this study, we demonstrate that plasma p-tau217 is highly accurate in detecting amyloid β positivity and predicting clinical progression in individuals with DS, outperforming other plasma biomarkers. These findings support its use as a reliable, noninvasive tool for early AD detection and management in individuals with DS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exploring Plasma Coenzyme Q10 Status in Paediatric Dyslipidaemia

  • Minguez, B.|||0000-0002-7699-3972
  • Paredes-Fuentes, Abraham J.|||0000-0002-7163-2385
  • Oliva, C.
  • Rodriguez-Gonzalez, H.
  • Santos Ocaña, Carlos|||0000-0002-2379-796X
  • Artuch, R.|||0000-0002-3422-9685
  • Santos, Mariela de los
  • Garcia-Volpe, Camila
  • Molera Busoms, Cristina
  • Arias, Angela
  • Yubero, Délia
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Meavilla, Silvia
Coenzyme Q10 (CoQ) is a ubiquitous lipid with different biological functions. In blood, there is a close relationship between CoQ status and cholesterol, which strongly supports the study of both molecules simultaneously. The objective of this study was to evaluate plasma CoQ, lipoprotein concentrations and CoQ/Chol ratio in a cohort of paediatric patients with different types of dyslipidaemias. A total of 60 paediatric patients were recruited (age range: 7 months-18 years), including 52 with different types of hypercholesterolemia, 2 with isolated hypertriglyceridemia and 6 with hypobetalipoproteinemia. Plasma CoQ was analysed by HPLC with electrochemical detection, and lipoprotein and cholesterol concentrations by standard automated methods. The lowest CoQ values were detected in patients with hypobetalipoproteinemia and in two cases of liver cirrhosis. Mean CoQ values were significantly higher in hypercholesterolemic patients compared to controls (average values 1.07 µmol/L and 0.63 µmol/L) while the CoQ/cholesterol ratio did not show differences (170 vs. 163, respectively). Mean CoQ values were significantly lower in the group of patients with hypobetalipoproteinemia compared to controls (mean CoQ values of 0.22 µmol/L vs. 0.63 µmol/L, respectively), while those of CoQ/cholesterol did not show differences. Pearson's correlation test showed a positive correlation between the CoQ and cholesterol values (r = 0.565, p < 0.001) and between the CoQ and the LDL cholesterol values (r = 0.610, p < 0.001). Our results suggest that it is advisable to analyse plasma CoQ and cholesterol concentrations in patients with hypobetalipoproteinemia and hypercholesterolemia associated with liver damage.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Apolipoproteins in Health and Disease

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome, A decade of discovery

  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernández, Susana|||0000-0002-9777-1156
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Estellés, Teresa
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Aranha, Mateus|||0000-0001-9594-292X
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Padilla, Concepción|||0000-0003-4102-6787
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Sánchez-Aced, Érika|||0000-0001-7280-7493
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Muñoz, Laia|||0000-0003-0578-3094
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • Sánchez López, Oriol|||0000-0001-9405-1236
  • Garzón, Diana
  • Ribas, Laia
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Camacho, Valle|||0000-0003-0748-0847
  • Giménez, Sandra|||0000-0001-8031-2319
  • Delaby, Constance|||0000-0002-8606-6814
  • Belbin, Olivia|||0000-0002-6109-6371
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Clarimón, Jordi|||0000-0002-6824-6942
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Videla, Sebastià
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Sanjuan, Aída
  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Franquesa-Mullerat, Maria|||0009-0006-1484-7132
  • Carreras, Mireia
  • Lorente, Oriol
  • Bounasr El Bennadi, Shaima El
  • Elbachiri, Sumia
  • Mota, Cecilia
  • Iulita, M. Florencia|||0000-0002-3360-4498
Down syndrome (DS) is a genetic form of Alzheimer's disease (AD) that offers crucial insights into AD pathogenesis. The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) is a population-based multimodal biomarker cohort studying AD's natural history and clinical trials in DS. DABNI included 1135 participants (mean age 42.82, 46.3% female). At baseline, 673 participants were cognitively stable, 113 had prodromal AD, 239 had AD dementia, and 110 were uncertain due to non-AD conditions. Over 10 years, > 10000 clinical visits were conducted; follow-up showed that progression to symptomatic AD before age 40 was rare, but rates increased after age 50 (> 50% within 5 years). Neuropsychological and biomarker assessments demonstrated excellent diagnostic performance and a predictable sequence of changes, similar to autosomal dominant AD. DABNI participates in AD clinical trials and produced approximately 100 publications. The 10-year DABNI study provided critical insights into DS-associated AD (DSAD) and serves as a key platform for DS clinical trials. Highlights: Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) is a population-based multimodal cohort studying Alzheimer's disease in Down syndrome. Over 10 years, 1135 participants contributed to more than 10000 clinical visits and extensive biomarker studies. DABNI findings have transformed the understanding of Alzheimer's disease in Down syndrome, reinforcing its classification as a genetic form of the disease. The cohort integrates clinical care and research, enhancing early detection and patient management. DABNI supports clinical trials and has produced over 100 publications advancing Down syndrome-related Alzheimer's research.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Circulating short-chain fatty acids and Mediterranean food patterns. A potential role for the prediction of type 2 diabetes risk, The Di@bet.es Study

  • Llauradó, Gemma|||0000-0002-3237-6366
  • Cedó, Lídia|||0000-0003-4354-3411
  • Climent, Elisenda|||0000-0001-6831-8224
  • Badia, Joan
  • Rojo-Martínez, G.|||0000-0003-2179-2134
  • Yanes, Oscar|||0000-0003-3695-7157
  • Vinaixa, Maria
  • Granado-Casas, Minerva|||0000-0003-3447-5728
  • Mauricio, Didac|||0000-0002-2868-0250
  • Fernández-Veledo, Sonia|||0000-0003-2906-3788
  • Vendrell, Joan|||0000-0002-6994-6115
  • Flores-Le Roux, Juana Antonia|||0000-0002-7967-2664
Background: Identifying nutritional patterns associated with developing type 2 diabetes (T2D) can facilitate more effective and personalized dietary interventions. Short-chain fatty acids (SCFAs), key metabolites derived from gut microbiota, are produced through the anaerobic fermentation of dietary fibers. This study aimed to evaluate whether circulating concentrations of SCFAs are associated with specific food consumption patterns and to assess their association with T2D development in at-risk subjects within a prospective cohort (The Di@bet.es Study). Methods: The Di@bet.es study is a prospective, population-based study utilizing random cluster sampling from the Spanish population aged over 18 years (n = 5,072). Among these participants, 4,347 were free of T2D at baseline. Follow-up losses were approximately 45%, resulting in a final re-screened sample of 2,408 subjects. A qualitative food frequency questionnaire evaluated Mediterranean diet (MedDiet) adherence and high-fiber food consumption. The risk of developing T2D was assessed using the FINDRISK. Metabolomics-driven analyses of SCFAs were conducted using gas chromatography-mass spectrometry. Results: Subjects who developed T2D after a median follow-up of seven years had higher baseline circulating concentrations of butyrate and isobutyrate. Circulating concentrations of SCFAs were associated with high-fiber food consumption at baseline. In multivariate analysis, baseline circulating concentrations of butyrate and isobutyrate were independently associated with incident T2D after adjusting for traditional clinical factors. The C-statistics for predicting T2D were 0.847 (95%CI:0.816-0.877) for butyrate and 0.843 (95%CI:0.812-0.875) for isobutyrate in adjusted models, similar to the reference model based on traditional clinical factors (0.840 [95%CI: 0.807-0.873]). Both models improved risk prediction compared to FINDRISK. Dietary patterns did not add predictive value. Sensitivity analysis excluding subjects with prediabetes at baseline confirmed these results. In addition, an association between baseline consumption of high-fiber foods with incident T2D emerged, suggesting a different behaviour between healthy and prediabetic subjects. Conclusions: Baseline circulating concentrations of SCFAs are associated with high-fiber food consumption and independently predict the development of T2D over seven years of follow-up. However, they offer limited improvement in risk prediction compared to traditional risk factors, though they enhance risk prediction as assessed by FINDRISK. Further studies are necessary to evaluate the impact of dietary interventions on SCFA.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Suicidal ideation with and without intention to act, A transdiagnostic network analysis on the interplay between psychopathology, impulsivity, and childhood maltreatment

  • De Prisco, Michele|||0000-0002-2032-1181
  • Roberto Herrero, Natalia|||0000-0002-5391-2711
  • Andreo Jover, Jorge|||0000-0002-6703-8017
  • Ayad-Ahmed, Wala|||0000-0002-0786-0076
  • Bobes-Bascarán, Maria T.|||0000-0002-5279-504X
  • Canal-Rivero, Manuel|||0000-0002-5818-5103
  • Canosa García, Irene
  • Cebrià, Ana Isabel|||0000-0002-2632-8130
  • Crespo-Facorro, Benedicto|||0000-0003-0033-7132
  • Curto-Ramos, Javier
  • Díaz-Marsá, Marina|||0000-0003-1364-3163
  • Torre-Luque, Alejandro de la|||0000-0003-0595-6127
  • Elices, M.|||0000-0002-7034-4242
  • Jiménez-Treviño, Luis|||0000-0002-9551-8587
  • Palao Tarrero, Ángela|||0000-0003-2717-5807
  • Palao, Diego|||0000-0002-3323-6568
  • Pemau, Andrés|||0000-0002-5835-507X
  • Lopez-Pena, Maria Purificacion
  • Ruiz Veguilla, Miguel
  • Sáiz, Pilar A.|||0000-0002-5705-4523
  • Suárez-Soto, Elizabeth|||0000-0001-7599-0078
  • Courtet, Philippe|||0000-0002-6519-8586
  • Vieta, Eduard|||0000-0002-0548-0053
  • Grande, Iria|||0000-0002-0137-0666
  • Pérez Solà, Víctor|||0000-0002-5825-2337
Suicide represents a significant public health concern. Suicide prevention strategies are shifting toward transdiagnostic perspectives examining interrelated risk factors, but their interrelationships remain unclear. This study investigated relationships between psychopathological dimensions, impulsivity, and childhood maltreatment in individuals with suicidal ideation (SI), comparing those with versus without intention to act using network analysis. Data were obtained from the Suicide Prevention and Intervention Study project. Participants were categorized into two groups based on their intention to act according to the Columbia Suicide Severity Rating Scale. Psychological symptoms, impulsivity traits, and childhood maltreatment were assessed. Network analysis was performed, and centrality measures were computed. A total of 1,265 individuals were categorized into the SI without intention to act (n = 345) and SI with intention to act (n = 920) groups. The former showed lower depression and hostility scores, and lower prevalence of major depressive and anxiety disorders. Network analyses revealed that in the SI without intention to act group, obsessive-compulsive symptoms were central, connecting to depression and anxiety, while negatively correlating with non-planning impulsivity. In contrast, the SI with intention to act group showed a more densely interconnected network where emotional abuse served as a bridge between childhood maltreatment and other psychopathological dimensions. This study identifies symptom interaction patterns between individuals with SI without and with intention to act. Understanding these relationships may improve suicide risk assessment and inform personalized interventions, potentially reducing the transition from ideation to action. Trauma-focused approaches addressing emotional abuse may be especially relevant for individuals at high risk.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates

  • Rueda, Ariana|||0000-0001-7588-9279
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Arena, Lourdes Ailen|||0009-0006-1863-3895
  • Mendoza, Julian Ignacio|||0000-0002-1975-3606
  • Aviñó, Ana|||0000-0003-3047-738X
  • Fabrega, Carme|||0000-0003-3816-7634
  • Eritja, Ramon|||0000-0001-5383-9334
  • Paez, David|||0000-0002-5596-6588
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
Precision targeting is a hot topic in cancer nanomedicine, as conventional chemotherapies cause systemic toxicities, creating an urgent need for more selective treatments. Although antibody-drug conjugates (ADCs) are the current gold standard in targeted therapy, their clinical performance remains limited. As an alternative, we previously developed a multivalent protein nanocarrier (T22-GFP-H6) displaying the CXCR4-targeting peptide T22, which offers super-selective tumor accumulation driven by CXCR4 overexpression. This innovative nanovehicle showed favorable biodistribution for targeted delivery of antitumor drugs, including monomethyl auristatin E (MMAE), in a first-generation stochastic nanoconjugate format. However, unlike ADCs, where conjugation strategy is known to influence pharmacokinetics and efficacy, these parameters remain largely unexplored in non-antibody multivalent nanocarriers. Here, we evaluated the impact of precise payload accommodation using two site-specific strategies that attach a single MMAE molecule at distinct structural sites, and we compared them with first-generation nanoconjugates. The conjugation strategy substantially affected the biodistribution and antitumor efficacy, with a solvent-exposed cysteine-conjugation distal to the targeting ligand proving most effective. At equimolar nanocarrier dosing, this construct achieved tumor control similar to the stochastic conjugate in a disseminated hematologic malignancy despite an approximately 4-fold lower MMAE load (drug-to-protein ratio, DPR = 1 vs DPR ≈ 4). Moreover, at equimolar MMAE dosing, it clearly outperformed both the stochastic conjugate and the alternative site-directed design. These findings align with trends in advanced ADCs and provide practical design rules for rational, site-specific conjugation in next-generation protein-based nanomedicines aimed at enabling dose-sparing in oncology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Somatic reversion in CD137 deficiency correlating with Epstein-Barr virus control and clinical improvement

  • Batlle-Masó, Laura|||0000-0002-4209-176X
  • Padrosa Pulido, Joan|||0000-0002-3354-5811
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Perurena-Prieto, Janire
  • Franco-Jarava, Clara|||0000-0002-9788-189X
  • Aguiló-Cucurull, Aina|||0000-0001-5622-778X
  • Martínez Gallo, Mónica|||0000-0002-7340-2161
  • Cea López, Cristina|||0000-0003-0776-6706
  • Rodriguez-Aliberas, Marta
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Casals, Ferran|||0000-0002-8941-0369
  • Redondo, Sara|||0000-0001-8967-7410
  • Torrent, Montserrat|||0000-0003-1917-1056
  • Alsina Manrique, Laia|||0000-0002-3559-0018
  • Colobrán Oriol, Roger|||0000-0002-5964-536X
Epstein-Barr virus (EBV) is an oncogenic virus ubiquitous in human populations. CD8 T cells play a crucial role in establishing a strong anti-EBV immune response. Among the various inborn errors of immunity (IEI) showing a restricted vulnerability to EBV, TNFRSF9 (CD137, 4-1BB) deficiency was described in 2019 in patients with chronic EBV viremia and EBV-associated lymphoproliferative diseases. We here investigated a patient with a history of chronic EBV infection and CD137 deficiency who had previously undergone transplantation from her HLA-identical brother. We found that the brother was also a homozygous carrier of the same TNFRSF9 variant, explaining the patient's inability to control EBV after transplantation. Remarkably, during a period of spontaneous clinical improvement and EBV control, we detected two somatic variants in the patient, which resulted in the emergence of two independent revertant CD8 T cell clones that accounted for up to 20% of CD8 T cells in peripheral blood. Using single cell RNA sequencing we demonstrated that both revertant clones originated post-transplant from donor-derived cells. We report here the first described case of a somatic reversion phenomenon in TNFRSF9 deficiency, correlating with clinical improvement and paving the way for future gene therapy strategies for this IEI.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of the new EASO obesity definition on the detection of atheromatosis in subjects with low-to-moderate cardiovascular risk

  • León-Mengíbar, Josep|||0000-0002-5982-3461
  • Bermúdez-López, Marcelino|||0000-0002-3188-4158
  • Valdivielso, José Manuel|||0000-0003-1343-0184
  • Pamplona, Reinald|||0000-0003-4337-6107
  • Torres, Gerard|||0000-0002-1417-7320
  • Mauricio, Didac|||0000-0002-2868-0250
  • Castro-Boqué, Eva|||0000-0002-1013-0007
  • Fernández, Elvira|||0000-0001-5236-1762
  • Caixàs i Pedragós, Assumpta|||0000-0001-8472-9189
  • Bueno, Marta|||0000-0001-9488-4553
  • Ciudin, Andreea|||0000-0001-5622-0203
  • Hernández García, Marta|||0000-0003-1237-298X
  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Hernández, Cristina|||0000-0002-3109-1721
  • Lecube, Albert|||0000-0001-9684-0183
Traditional body mass index (BMI) does not adequately reflect adipose tissue distribution and associated cardiovascular (CV) risk. To improve risk stratification, the European Association for the Study of Obesity (EASO) proposes to extend the diagnosis of obesity to include individuals with a BMI of 25-30 kg/m², a waist-to-height ratio (WtHR) ≥0.5, and any obesity-related complication. To examine whether this new definition of obesity can better identify the presence of subclinical atheromatosis disease (SAD) in terms of arterial plaque burden compared to the classical BMI-based definition. A cross-sectional including 8,330 participants from the ILERVAS project (ClinicalTrials.gov Identifier: ), aged 45-70 years with low-to-moderate CV risk and no previous CV disease, was included. Obesity was classified using traditional (BMI ≥ 30 kg/m²) and new definitions. Atherosclerosis was assessed through Doppler ultrasound of carotid and femoral arteries. Logistic regression models adjusted for cardiovascular risk factors were used to evaluate associations between obesity definitions and SAD. The new definition increased obesity prevalence from 37.2% to 71.7%. It also revealed higher detection of atheromatous plaques (72.9% vs. 68.6%, p.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

KDEL-mediated modulation of intracellular trafficking in cell-targeted protein drugs

  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Arena, Lourdes Ailen|||0009-0006-1863-3895
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
The biological activity of therapeutic proteins, upon intracellular delivery, is dramatically minimized by lysosomal proteolytic digestion. This is a limitation when developing cell-targeted pharmaceuticals that penetrate target cells via receptor recognition and endosomal engulfment. Since proteins benefit from functional and conformational versatility, editable by genetic engineering, endosomolytic protein domains are often fused to the functional polypeptide to promote their cytosolic delivery, aiming at minimizing proteolysis in mature lysosomes. This straightforward strategy has, however, rendered irregular results, linked to the fusogenic nature of most of the tested domains. Alternatively, proteolysis of protein drugs might be controlled by bypassing the lysosomal route, forcing an unconventional traffic of the uptaken protein material to be secreted from the endoplasmic reticulum (ER). This possibility, used in nature by several plant and microbial proteins, has been evaluated here by functionalizing a protein-only antitumoral drug, based on a cell-targeted diphtheria toxin, with a C-terminal KDEL motif. Thus, if KDEL were able to reprogram the intracellular trafficking, KDEL-tagged cell delivered proteins would be expected to avoid the lysosomal degradation, resulting in enhanced stability and activity. The obtained results validate this hypothesis and point out KDEL as a promising functional agent in cell-targeted protein drugs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biomimetic Protein Materials for Adjuvant-Free Dermal Penetration

  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Escribano-Ferrer, Elvira|||0000-0001-7837-9506
  • Huaca, Vanesa
  • Miranda-Tovar, Eva
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Parladé, Eloi|||0000-0001-5750-550X
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
The effective dermal delivery of functional proteins could substantially improve therapeutic options for common skin disorders, in which current lipid-based or invasive strategies face efficacy and safety limitations. We report a biomimetic protein depot platform based on granular, nontoxic amyloids generated through Zn-mediated coordination of hexahistidine-tagged proteins. Functionalization of these materials with either the cell-penetrating peptide R9 or the tight junction modulator c-CPE, the C-terminal region of the Clostridium perfringens enterotoxin, enabled a systematic evaluation of transdermal penetration in mouse models. Whereas plain and R9-functionalized granules showed restricted permeation, c-CPE-functionalized granules achieved consistent distribution through the dermis into the hypodermal layers. These findings establish self-assembled protein amyloids as a promising and adaptable class of biomaterials for dermal protein delivery. Also, the ability of c-CPE to enhance permeability without auxiliary adjuvants, lipids, or invasive methods highlights the translational potential of this system for clinically applicable, noninvasive management of cutaneous conditions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Associations between air pollution and surrounding greenness with internalizing and externalizing behaviors among schoolchildren

  • Zubizarreta-Arruti, Uxue
  • Bosch, Rosa|||0000-0002-7596-183X
  • Soler Artigas, María|||0000-0002-3213-1107
  • Cabana-Domínguez, Judit|||0000-0002-4732-7284
  • Llonga, Natalia|||0000-0003-4325-6201
  • Carabí-Gassol, Pau
  • Macias-Chimborazo, Valeria
  • Vilar-Ribó, L.|||0000-0001-8758-523X
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Pagerols, Mireia|||0000-0003-0856-6247
  • Prat, Raquel|||0000-0001-8097-6617
  • Rivas, Cristina|||0000-0002-8074-9550
  • Pagespetit, Èlia
  • Puigbó, Júlia
  • Español-Martín, Gemma|||0000-0002-2362-8189
  • Raimbault, B.|||0000-0003-0226-0220
  • Valentín, Antònia|||0000-0002-9275-7101
  • Sunyer Deu, Jordi|||0000-0002-2602-4110
  • Foraster, Maria|||0000-0003-4450-4123
  • Gascon, Mireia|||0000-0003-4537-8472
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Alemany Sierra, Silvia|||0000-0002-7925-6767
Air pollution and greenness are emerging as modifiable risk and protective factors, respectively, in child psychopathology. However, research shows inconsistencies. Here, we examined associations between air pollution and surrounding greenness with internalizing and externalizing behaviors. In addition, the potential modifying role of the genetic susceptibility for these traits and socioeconomic status (SES) was explored. This population-based study included 4485 schoolchildren aged 5-18 years from Spain. Internalizing and externalizing behaviors were assessed using the Child Behavior Checklist (CBCL). Average air pollution (NO, PM, PM, PM, and PM absorbance) and surrounding greenness (NDVI within 100-m, 300-m, and 500-m buffers) school exposure were estimated for 12 months before outcome assessment. Genetic liability was assessed by computing polygenic risk scores (PRS) and SES was calculated using the Hollingshead Four-Factor Index. Associations were analyzed using negative binomial mixed-effects models. Although no associations survived multiple testing, we found that increases of 5.48 μg/m 3 in PM and 2.93 μg/m 3 in PM were associated with a 6% (Mean Ratio (MR) = 1.06; 95% CI: 1.01-1.12) and a 4% (MR = 1.04; 95% CI: 1.00-1.09) increase in internalizing behavior scores. A 0.1 increase in NDVI within a 100-m buffer was associated with a 6% decrease in externalizing behavior (MR = 0.94; 95% CI: 0.89-0.99). Neither differences by sex or age, or moderation effects by PRS or SES, were observed. We found preliminary evidence of detrimental effects of air pollution on internalizing behavior and protective effects of greenness on externalizing behavior, which were not modified by sex, age, SES, or genetic liability. If confirmed, these results reinforce the need for improving air quality, especially around schools, as part of preventive strategies focused on childhood psychopathology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder

  • Strom, Nora I.|||0000-0002-5261-8852
  • Gerring, Zachary F.|||0000-0002-2445-1266
  • Galimberti, Marco|||0000-0001-6052-156X
  • Yu, Dongmei|||0000-0001-7901-4365
  • Halvorsen, Matthew W.|||0000-0002-6707-2418
  • Abdellaoui, Abdel|||0000-0003-1088-6784
  • Rodriguez-Fontenla, Cristina|||0000-0002-9829-6393
  • Sealock, Julia M.|||0000-0002-9346-3498
  • Bigdeli, Tim
  • Coleman, Jonathan R. I.|||0000-0002-6759-0944
  • Mahjani, Behrang|||0000-0001-6087-9537
  • Thorp, Jackson G.|||0000-0002-9461-6417
  • Bey, Katharina|||0000-0001-6392-4997
  • Burton, Christie L.|||0000-0002-8955-6528
  • Luykx, Jurjen J.|||0000-0002-6439-2774
  • Zai, Gwyneth|||0000-0002-0894-6867
  • Alemany Sierra, Silvia|||0000-0002-7925-6767
  • Andre, Christine
  • Askland, Kathleen D.|||0000-0003-1467-8923
  • Bäckman, Julia
  • Banaj, Nerisa|||0000-0002-6317-8549
  • Barlassina, Cristina|||0000-0001-7407-2697
  • Nissen, Judith Becker|||0000-0003-4063-6866
  • Bienvenu, O. Joseph|||0000-0002-8466-102X
  • Black, Donald|||0000-0001-8038-1971
  • Bloch, Michael H.|||0000-0003-0352-4080
  • Børte, Sigrid|||0000-0001-9540-3256
  • Bosch, Rosa|||0000-0002-7596-183X
  • Breen, Michael
  • Brennan, Brian P.|||0000-0001-5468-6552
  • Brentani, Helena|||0000-0001-5192-4682
  • Buxbaum, Joseph D.|||0000-0001-8898-8313
  • Bybjerg-Grauholm, Jonas|||0000-0003-1705-4008
  • Byrne, Enda M.|||0000-0002-9491-7797
  • Cabana-Domínguez, Judit|||0000-0002-4732-7284
  • Camarena, Beatriz
  • Camarena, Adrian|||0000-0001-8512-0607
  • Cappi, Carolina|||0000-0001-6661-3756
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Cavallini, Maria Cristina|||0000-0001-5913-1468
  • Ciullo, Valentina|||0000-0002-4095-7806
  • Cook, Edwin H.|||0000-0002-5848-5114
  • Crosby, Jesse
  • Cullen, Bernadette A.|||0000-0003-1762-092X
  • De Schipper, Elles J.|||0000-0001-9494-451X
  • Delorme, Richard|||0000-0002-5614-3663
  • Djurovic, Srdjan|||0000-0002-8140-8061
  • Elias, Jason A.
  • Estivill, Xavier|||0000-0002-0723-2256
  • Falkenstein, Martha J.|||0000-0001-5074-3409
  • Fundin, Bengt T.|||0000-0002-6037-7331
  • Garner, Lauryn
  • Gironda, Christina
  • Goes, Fernando S.|||0000-0001-6262-8264
  • Grados, Marco A.|||0000-0002-0178-1764
  • Grove, Jakob|||0000-0003-2284-5744
  • Guo, Wei|||0000-0002-4322-3699
  • Haavik, Jan|||0000-0001-7865-2808
  • Hagen, Kristen|||0000-0002-4286-1277
  • Harrington, Kelly|||0000-0001-9668-183X
  • Havdahl, Alexandra|||0000-0002-9268-0423
  • Höffler, Kira D.|||0000-0002-0837-1469
  • Hounie, Ana G.|||0000-0002-5026-2880
  • Hucks, Donald|||0000-0002-2700-5798
  • Hultman, Christina|||0000-0002-0327-2410
  • Janecka, Magdalena|||0000-0001-7406-0776
  • Jenike, Eric
  • Karlsson, Elinor K.|||0000-0002-4343-3776
  • Kelley, Kara
  • Klawohn, Julia|||0000-0002-9436-6948
  • Krasnow, Janice E.|||0000-0003-0316-6279
  • Krebs, Kristi|||0000-0003-0494-2751
  • Lange, Christoph|||0000-0002-9691-4741
  • Lanzagorta, Nuria|||0000-0001-6769-6813
  • Levey, Daniel|||0000-0001-8431-9569
  • Lindblad-Toh, Kerstin|||0000-0001-8338-0253
  • Macciardi, Fabio|||0000-0003-0537-4266
  • Maher, Brion|||0000-0001-9809-0064
  • Mathes, Brittany
  • McArthur, Evonne|||0000-0003-4566-4321
  • McGregor, Nathaniel|||0000-0001-7195-4993
  • McLaughlin, Nicole C.|||0000-0002-4016-2747
  • Meier, Sandra|||0000-0002-3287-5894
  • Miguel, Euripedes C.|||0000-0002-9393-3103
  • Mulhern, Maureen|||0000-0001-8642-4741
  • Nestadt, Paul S.
  • Nurmi, Erika L.|||0000-0003-4893-8957
  • O'Connell, Kevin S.|||0000-0002-6865-8795
  • Osiecki, Lisa|||0000-0002-9408-8722
  • Ousdal, Olga Therese|||0000-0002-0728-3141
  • Palviainen, Teemu|||0000-0002-7847-8384
  • Pedersen, Nancy L.|||0000-0001-8057-3543
  • Piras, Fabrizio|||0000-0003-3566-5494
  • Piras, Federica|||0000-0002-9546-7038
  • Potluri, Sriramya|||0000-0003-3877-0038
  • Rabionet, Raquel|||0000-0001-5006-8140
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Rauch, Scott|||0000-0001-7699-6754
  • Reichenberg, Abraham|||0000-0003-2729-8575
  • Riddle, Mark A.|||0000-0001-8764-2134
  • Ripke, Stephan|||0000-0003-3622-835X
  • Rosário, Maria C.|||0000-0002-8577-3306
  • Sampaio, Aline S.|||0000-0001-5568-6167
  • Schiele, Miriam A.|||0000-0003-2613-6515
  • Skogholt, Anne Heidi|||0000-0001-7466-0405
  • Sloofman, Laura G Sloofman G.|||0000-0001-7628-4378
  • Smit, Jan
  • Soler Artigas, María|||0000-0002-3213-1107
  • Thomas, Laurent|||0000-0003-0548-2486
  • Tifft, Eric|||0000-0002-7480-0276
  • Vallada, Homero|||0000-0001-5123-8295
  • van Kirk, Nathanial|||0000-0002-1975-4238
  • Veenstra-VanderWeele, Jeremy|||0000-0002-6349-1076
  • Vulink, Nienke N.|||0000-0001-8991-9627
  • Walker, Christopher P.|||0000-0002-6069-0184
  • Wang, Ying
  • Wendland, Jens|||0000-0001-5106-5013
  • Winsvold, Bendik Slagsvold|||0000-0003-4171-8919
  • Yao, Yin|||0000-0001-7487-4294
  • Zhou, Hang|||0000-0002-7694-6391
  • Agrawal, Arpana|||0000-0002-0313-793X
  • Alonso, Pino|||0000-0002-5779-9111
  • Berberich, Götz|||0000-0001-8300-9294
  • Bucholz, Kathleen K.|||0000-0003-3794-0736
  • Bulik, Cynthia M.|||0000-0001-7772-3264
  • Cath, Danielle|||0000-0001-9539-4118
  • Denys, Damiaan|||0000-0002-3191-3844
  • Eapen, Valsamma|||0000-0001-6296-8306
  • Edenberg, Howard J.|||0000-0003-0344-9690
  • Falkai, Peter|||0000-0003-2873-8667
  • Fernandez, Thomas V.|||0000-0003-0830-022X
  • Fyer, Abby J.|||0000-0002-0944-2505
  • Geller, Dan A.|||0000-0001-8692-4156
  • Grabe, Hans J.|||0000-0003-3684-4208
  • Greenberg, Benjamin D.|||0000-0002-5648-0002
  • Hanna, Gregory L.|||0000-0002-0742-6990
  • Hickie, Ian B.|||0000-0001-8832-9895
  • Hougaard, David M.|||0000-0001-5928-3517
  • Kathmann, Norbert|||0000-0002-1348-7060
  • Kennedy, James L.|||0000-0002-8733-3806
  • Lai, Dongbing|||0000-0001-7803-580X
  • Landén, Mikael|||0000-0002-4496-6451
  • Le Hellard, Stéphanie|||0000-0002-8085-051X
  • Leboyer, Marion|||0000-0001-5473-3697
  • Lochner, Christine|||0000-0002-4766-3704
  • McCracken, James T.|||0000-0003-0370-0777
  • Medland, Sarah Elizabeth|||0000-0003-1382-380X
  • Mortensen, Preben Bo|||0000-0002-5230-9865
  • Neale, Benjamin M.|||0000-0003-1513-6077
  • Nicolini, Humberto|||0000-0003-2494-0067
  • Nordentoft, Merete|||0000-0003-4895-7023
  • Pato, Michele
  • Pato, Carlos|||0000-0002-5858-266X
  • Pauls, David L.|||0000-0002-8107-345X
  • Piacentini, John|||0000-0003-4195-7194
  • Pittenger, Christopher|||0000-0003-2117-9321
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Rasmussen, Steven A.|||0000-0002-8327-0692
  • Richter, Margaret A.|||0000-0001-5450-2936
  • Rosenberg, David R.|||0000-0002-0005-4151
  • Ruhrmann, Stephan|||0000-0002-6022-2364
  • Samuels, Jack F.|||0000-0002-6715-7905
  • Sandin, Sven|||0000-0001-6994-4884
  • Sandor, Paul|||0000-0003-2397-0758
  • Spalletta, Gianfranco|||0000-0002-7432-4249
  • Stein, Dan J.|||0000-0001-7218-7810
  • Stewart, S. Evelyn|||0000-0002-0994-6383
  • Storch, Eric A.|||0000-0002-7631-3703
  • Stranger, Barbara E.|||0000-0001-9021-7331
  • Turiel, Maurizio|||0000-0002-8793-2112
  • Werge, Thomas|||0000-0003-1829-0766
  • Andreassen, Ole A.|||0000-0002-4461-3568
  • Børglum, Anders D.|||0000-0001-8627-7219
  • Walitza, Susanne|||0000-0002-8161-8683
  • Hveem, Kristian|||0000-0001-8157-9744
  • Hansen, Bjarne K.|||0000-0001-5659-1119
  • Rück, Christian P.|||0000-0002-8742-0168
  • Martin, Nicholas G.|||0000-0003-4069-8020
  • Milani, Lili|||0000-0002-5323-3102
  • Mors, Ole|||0000-0002-5660-0393
  • Reichborn-Kjennerud, Ted|||0000-0003-4653-0034
  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Kvale, Gerd|||0000-0001-5449-2344
  • Mataix-Cols, David|||0000-0002-4545-0924
  • Domschke, Katharina|||0000-0002-2550-9132
  • Grünblatt, Edna|||0000-0001-8505-7265
  • Wagner, Michael
  • Zwart, John-Anker|||0000-0001-5721-0154
  • Breen, Gerome|||0000-0003-2053-1792
  • Nestadt, Gerald|||0000-0001-9461-5249
  • Kaprio, Jaakko|||0000-0002-3716-2455
  • Arnold, Paul D.|||0000-0003-2496-4624
  • Grice, Dorothy E.|||0000-0002-8833-2549
  • Knowles, James A.|||0000-0002-3307-5741
  • Ask, Helga|||0000-0003-0149-5319
  • Verweij, Karin|||0000-0001-9868-7821
  • Davis, Lea K.|||0000-0001-5143-2282
  • Smit, Dirk J.|||0000-0001-8301-8860
  • Crowley, James J.|||0000-0001-9051-1557
  • Scharf, Jeremiah M.|||0000-0002-4742-5896
  • Stein, Murray B.|||0000-0001-9564-2871
  • Gelernter, Joel|||0000-0002-4067-1859
  • Mathews, Carol A.|||0000-0003-2208-7058
  • Derks, Eske M.|||0000-0002-6292-6883
  • Mattheisen, Manuel|||0000-0002-8442-493X
Obsessive-compulsive disorder (OCD) affects ~1% of children and adults and is partly caused by genetic factors. We conducted a genome-wide association study (GWAS) meta-analysis combining 53,660 OCD cases and 2,044,417 controls and identified 30 independent genome-wide significant loci. Gene-based approaches identified 249 potential effector genes for OCD, with 25 of these classified as the most likely causal candidates, including WDR6, DALRD3 and CTNND1 and multiple genes in the major histocompatibility complex (MHC) region. We estimated that ~11,500 genetic variants explained 90% of OCD genetic heritability. OCD genetic risk was associated with excitatory neurons in the hippocampus and the cortex, along with D and D type dopamine receptor-containing medium spiny neurons. OCD genetic risk was shared with 65 of 112 additional phenotypes, including all the psychiatric disorders we examined. In particular, OCD shared genetic risk with anxiety, depression, anorexia nervosa and Tourette syndrome and was negatively associated with inflammatory bowel diseases, educational attainment and body mass index.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characterization of Infarct Size and Remodeling Using CMR and PET in Mice Models of Reperfused and Non-Reperfused Myocardial Infarction

  • Gavara Doñate, Jose|||0000-0002-3483-7066
  • Molina-Garcia, Tamara
  • Ezzeddin, Mustafa
  • Diaz, Ana
  • Perez-Solé, Nerea|||0000-0003-3527-0337
  • Ortega, Maria
  • Marcos Garcés, Víctor|||0000-0001-5565-5547
  • de Dios, Elena
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Ruiz-Sauri, Amparo
  • Rios-Navarro, Cesar|||0000-0002-6405-6279
  • Bodi, Vicente|||0000-0001-6425-5828
Background/Objectives : Unlike post-mortem histopathology, cardiovascular magnetic resonance (CMR) and positron emission tomography (PET) enable longitudinal assessment of structural, functional, and metabolic alterations in preclinical myocardial infarction models. This study aims to describe the temporal evolution of infarct size and systolic function by CMR and glucose consumption via PET, explore their differences in non-reperfused and reperfusion infarction models, and assess their capacity to predict histology-derived infarct size and systolic function at chronic phase CMR. Methods : Two murine models of myocardial infarction were generated using permanent (non-reperfused, n = 8) or transient (reperfused, n = 9) coronary occlusion. CMR and fluorine-18 2-fluoro-2-deoxyglucose PET imaging were performed at baseline and at 1, 7, and 21 days post-infarction to quantify infarct size, systolic function, and myocardial glucose metabolism. Infarct size was also assessed using Masson's trichrome staining. Results : At 24 h post-infarction, CMR-derived infarction together with significant reduction in systolic function and glucose metabolism were already noted in both models. At 21-day CMR, however, reperfused mice showed lower infarct size and more preserved systolic function compared to their non-reperfused counterparts, while no differences in glucose metabolism were reported. Infarct size and systolic function at 1-day CMR and the number of segments with reduced glucose consumption at 1-day PET independently predicted histology-derived infarct size and long-term systolic function. Conclusions : Combined PET/CMR imaging enables non-invasive, sequential evaluation of infarct size, systolic function, and glucose metabolism in experimental myocardial infarction. This multimodality approach is well suited for assessing the efficacy of emerging therapies in preclinical research.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Apolipoprotein E and Alzheimer's disease pathology in a diverse autopsy study

  • Suemoto, C.K.|||0000-0002-5942-4778
  • Paradela, Regina
  • Leite, Renata E. P.
  • Paes, Vitor R.
  • Pasqualucci, Carlos A.
  • Ferriolli, Eduardo
  • Zatz, Mayana|||0000-0003-3970-8025
  • do Nascimento Santos, Gabriel
  • de Alexandria, Marvin Afonso Longo Salvador
  • Pereira, Ana C.
  • Fortea, Juan|||0000-0002-1340-638X
  • Naslavsky, Michel
  • Grinberg, Lea T.
Apolipoprotein E allele 4 (APOE ε4) is the main genetic risk factor for late-onset Alzheimer's disease (AD), but most evidence comes from White populations in high-income countries. We investigated APOE and AD pathology in an ethnically diverse Brazilian autopsy cohort. This cross-sectional study used Biobank for Aging Studies (BAS) data. AD pathology was evaluated with Braak, Consortium to Establish a Registry for Alzheimer's Disease, and Thal criteria. APOE genotypes were obtained from blood or brain tissue. Regression models were adjusted for age, sex, race, and education; interaction with race was tested. Among 1391 participants (mean age 75.1 ± 12.4 years, 50% women, 64% White), APOE ε4showed a dose response with greater AD pathological burden and higher odds of AD diagnosis, while APOE ε2/X was protective. APOE ε4/ε4 did not show full penetrance across age groups. Associations were similar in White and Black individuals. APOE ε4was strongly associated with AD pathology, with consistent associations across racial groups. {'list': {'@list-type': 'bullet', '@id': 'alz70927-list-0001', 'list-item': [{'p': 'APOE ε4 increased AD neuropathological burden in Brazilians.'}, {'p': 'APOE ε2/εX was protective against AD pathology.'}, {'p': 'APOE ε4/ε4did not show full penetrance across age groups.'}, {'p': 'Associations between APOE and AD pathology were similar by race.'}, {'p': 'Large multiethnic autopsy study expands evidence beyond high-income country studies.'}]}}.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeting psychological pain after a suicide attempt, scoping review and intervention protocol

  • Comendador Vázquez, Laura|||0000-0002-5221-4794
  • Palao, Diego|||0000-0002-3323-6568
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
  • Andreo Jover, Jorge|||0000-0002-6703-8017
  • Baca-García, Enrique|||0000-0002-6963-6555
  • Barrigón, María Luisa|||0000-0002-2497-6353
  • Bobes-Bascarán, Maria T.|||0000-0002-5279-504X
  • Botí, M.|||0000-0003-2963-6929
  • Díaz-Marsá, Marina|||0000-0003-1364-3163
  • Elices, M.|||0000-0002-7034-4242
  • Gaona Casas, Omar Ariel|||0009-0008-5297-7485
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Grande, Iria|||0000-0002-0137-0666
  • Jiménez-Treviño, Luis|||0000-0002-9551-8587
  • Palao Tarrero, Ángela|||0000-0003-2717-5807
  • Pedrola-Pons, Anna|||0009-0007-1641-5541
  • Roberto Herrero, Natalia|||0000-0002-5391-2711
  • Sáiz, Pilar A.|||0000-0002-5705-4523
  • Suárez-Soto, Elizabeth|||0000-0001-7599-0078
  • Torre-Luque, Alejandro de la|||0000-0003-0595-6127
  • Alacreu-Crespo, Adrián|||0000-0002-0633-2810
  • Cebrià, Ana Isabel|||0000-0002-2632-8130
  • Pérez Solà, Víctor|||0000-0002-5825-2337
Background/Objectives: Psychological pain-also termed psychache or mental pain-has been suggested to constitute a relevant factor in the emergence of suicidal behaviour. Despite conceptual advances, empirical research on interventions specifically designed to alleviate psychological pain in individuals who have attempted suicide remains scarce. The present scoping review maps existing psychological and pharmacological interventions targeting psychological pain, identifies their core components, delineates gaps for future research, and proposes a therapeutic intervention protocol. Methods: Literature was searched through PubMed, PsycInfo, and ClinicalTrials.gov (until October 2025) using combinations of the terms suicide, psychache, psychological pain, intervention, treatment, therapy, pharmacological treatment, and psychotherapy. Both randomised controlled trials, non-randomised controlled trials, and literature reviews were included. Results: Evidence indicates that few interventions explicitly target psychological pain. Most suicide-specific therapies indirectly address components of psychological pain-such as unbearable affect, loss of meaning, and social disconnection. Narrative-based, emotion regulation, and acceptance-based therapies appear promising. Emerging pharmacological approaches may relieve psychological pain; however, further evidence is required. Conclusions: Integrating psychological pain as a therapeutic focus-through narrative, tolerance-building, and relational strategies-may enhance post-attempt interventions. Future trials should systematically measure psychological pain and test its role as a mediator of suicidal outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Iron Deficiency Is Associated With Impaired Myocardial Reperfusion in ST-Segment-Elevation Myocardial Infarction, Influence of the Definition Used

  • Barrabés, José A.|||0000-0001-7062-6277
  • Inserte, Javier|||0000-0003-2283-3591
  • Castellote, Laura
  • Buera Surribas, Irene|||0000-0001-6110-2367
  • Milà Pascual, Laia|||0009-0007-4932-657X
  • Sambola, Antonia
  • Uribarri, Aitor|||0000-0002-6911-7480
  • Vidal Burdeus, María|||0000-0002-9823-5021
  • Aluja, David|||0000-0002-0448-9419
  • Delgado-Tomás, Sara
  • Tobías-Castillo, Pablo E.|||0000-0003-0304-6197
  • Calvo-Barceló, Maria
  • Guala, Andrea|||0000-0002-5006-8164
  • Rodríguez Palomares, José F.|||0000-0002-7229-9780
  • García del Blanco, Bruno|||0000-0002-4527-1600
  • Beneitez Pastor, David|||0000-0002-6541-6600
  • Ferreira-Gonzalez, Ignacio|||0000-0002-1208-5561
The role of iron deficiency (ID) in ST-segment-elevation myocardial infarction (STEMI) remains unclear. This study aimed to assess whether ID is associated with impaired myocardial reperfusion in STEMI and whether this association is affected by ID definition. We included 942 consecutive patients with STEMI successfully treated with primary percutaneous coronary intervention. ID was defined either as recommended by international guidelines or, alternatively, as ferritin <100 ng/mL, transferrin saturation <20%, or serum iron ≤13 μmol/L. In 595 patients, serum soluble transferrin receptor levels were measured. Impaired myocardial reperfusion was defined as lack of ST-segment resolution ≥50% 60 to 90 minutes after percutaneous coronary intervention. Results: ID prevalence varied across these definitions. Impaired reperfusion was present in 12.7% of patients without ID and 41.0% of those with ID defined by transferrin saturation <20% (P<0.001). This association was less pronounced for serum iron ≤13 μmol/L, weaker for guideline criteria, and absent for high (≥1.59 mg/L) soluble transferrin receptor levels or low ferritin. Transferrin saturation <20%, but not ferritin-based criteria, was associated with poorer clinical course and left ventricular function and higher in-hospital mortality and remained an independent predictor of impaired reperfusion after adjusting for baseline predictors and anemia. Conclusions: ID defined by transferrin saturation <20% is strongly related to impaired ST resolution and predicts a worse in-hospital outcome in patients with STEMI treated with primary percutaneous coronary intervention. The association of other ID criteria with myocardial reperfusion or with the clinical course is weaker or absent. The potential preventive or therapeutic strategies targeting ID in STEMI warrant further investigation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Transcriptional reprogramming triggered by neonatal UV radiation or Lkb1 loss prevents BRAF V600E -induced growth arrest in melanocytes

  • McGrail, Kimberley|||0000-0001-7227-7306
  • Granado-Martínez, Paula|||0000-0002-7765-8914
  • Orsenigo, Roberto
  • Caratù, Ginevra|||0000-0003-1085-8062
  • Nieto, Paula
  • Heyn, Holger|||0000-0002-3276-1889
  • Ferrer, Berta|||0000-0002-1255-4647
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Muñoz Couselo, Eva|||0000-0001-7556-7608
  • García-Patos Briones, Vicente|||0000-0003-1654-6035
  • Recio Conde, Juan Ángel|||0000-0002-7320-3832
The mechanisms behind UVB-initiated, neonatal-specific melanoma linked to BRAF V600E are not well understood, particularly regarding its role in growth arrest. We found that, beyond mutations, neonatal UV irradiation or Lkb1 loss promotes a cell-autonomous transcriptional reprogramming that prevents BRAF V600E -induced growth arrest, leading to melanoma development. Using UVB-dependent and independent mouse models, genomic analyses, clinical data, and single-cell transcriptomics, we identified a transcriptional program that bypasses growth arrest, promoting melanoma. In humans, many of these genes are linked to poor survival and are upregulated in melanoma progression and other RAS pathway-driven tumors. Reconstitution experiments showed these genes cooperate with BRAF V600E in melanocyte transformation, dedifferentiation, and drug resistance. Depleting gene products like UPP1 highlights their potential as therapeutic targets. Our findings reveal that BRAF V600E -mutated melanomas can develop independently of nevus progression and identify novel targets for treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease

  • Janelidze, Shorena
  • Therriault, Joseph
  • Brum, Wagner S.
  • Pichet Binette, Alexa|||0000-0001-5218-3337
  • Stomrud, Erik
  • Palmqvist, Sebastian|||0000-0002-9267-1930
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Rahmouni, Nesrine
  • Gispert, Juan Domingo|||0000-0002-6155-0642
  • Blennow, Kaj|||0000-0002-1890-4193
  • Doré, Vincent
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Villeneuve, Sylvia
  • Johnson, Sterling C.
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Petersen, Ronald C.
  • Schindler, Suzanne E.
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Ossenkoppele, Rik
  • Hansson, Oskar|||0000-0001-8467-7286
  • Salvadó, Gemma
  • Bali, Divya
  • Orduña Dolado, Anna
  • Mattsson-Carlgren, Niklas
  • Coomans, Emma M.
  • Benzinger, Tammie L. S.
  • Feizpour, Azadeh
  • Rowe, Christopher C.
  • Jack Jr, Clifford R.|||0000-0001-7916-622X
Importance: Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. Objective: To assess the utility of plasma phosphorylated tau 217 (p-tau217) for classifying Aβ status in cognitively unimpaired individuals, both as a stand-alone test and in a 2-step approach where positive plasma results were confirmed using a second modality (Aβ positron emission tomography [PET] or cerebrospinal fluid [CSF]). Design, Setting, and Participants: This cross-sectional cohort study used data collected between June 2009 and March 2024. We included 2916 cognitively unimpaired participants from 12 international independent observational cohorts in the US, Europe, Australia, and Canada with available plasma p-tau217 levels and CSF or PET Aβ biomarkers. Performance comparisons between mass spectrometry and immunoassay-based p-tau217 measurements were also performed (n = 964). Exposures: Plasma p-tau217 levels measured by immunoassay. Main Outcome and Measures: Aβ status, determined by CSF or Aβ PET biomarkers. Results: Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ϵ4 allele. As a stand-alone test, plasma p-tau217 achieved a positive predictive value (PPV) of 79% (95% CI, 74-84) and an overall accuracy of 81% (95% CI, 80-82). In a 2-step workflow, the PPV and accuracy significantly increased to 91% (95% CI, 86-95). While this approach required screening of 677 individuals with plasma p-tau217 to identify 100 Aβ-positive individuals, compared to 536 participants when using PET alone, it reduced the need for PET testing to 124. Immunoassays demonstrated comparable PPVs to mass spectrometry (80% [95% CI, 74-86] vs 85% [95% CI, 81-90]; P =.12) but significantly lower overall accuracy (82% [95% CI, 79-84]% vs 88 [95% CI, 86-90]; P <.001) and true Aβ-positive detection rate (49% [95% CI, 43-55] vs 69% [95% CI, 64-75]; P <.001). Conclusions and Relevance: The findings highlight the potential of plasma p-tau217 as a stand-alone test - or when used in a sequential 2-step approach alongside PET or CSF testing - as a cost-effective, scalable, and minimally burdensome strategy for identifying preclinical AD. Tailored screening workflows that incorporate p-tau217 can improve efficiency in participant selection for preclinical AD trials and, in the future, help guide access to disease-modifying treatments..
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Precision targeting of CXCR4+ leukemia cells by a humanized MMAE-nanoconjugate in an AML mouse model

  • Garcia León, Annabel|||0000-0003-3007-9306
  • Mendoza, Julian Ignacio|||0000-0002-1975-3606
  • Rueda, Ariana|||0000-0001-7588-9279
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Sierra, Jorge|||0000-0002-7966-0356
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
Acute myeloid leukemia (AML) presents major clinical challenges due to chemoresistance and high relapse rates, primarily driven by therapy-resistant leukemic stem cells (LSCs) within the bone marrow. To address this issue, we developed T22-HSNBT-H6-MMAE, a novel humanized nanoconjugate designed to target CXCR4 cells while delivering the cytotoxic payload monomethyl auristatin E (MMAE). CXCR4 signaling pathway plays a critical role in LSC survival by preserving stem-like properties and activating protective mechanisms that promote treatment resistance. Moreover, CXCR4 is overexpressed in approximately 50 % of AML patients and is associated with poor prognosis and high relapse rates. We evaluated the therapeutic potential of T22-HSNBT-H6-MMAE using in vitro assays with AML cell lines and primary patient samples, as well as in vivo studies in a disseminated AML mouse model. Our results demonstrated that T22-HSNBT-H6-MMAE exerts a CXCR4-dependent cytotoxic effect through mitotic catastrophe and apoptosis induction in CXCR4 AML cell lines. In vivo evaluation in a disseminated CXCR4 AML mouse model showed potent antineoplastic activity, with complete suppression of leukemic dissemination and significantly prolonged survival, all without systemic toxicity. Notably, the nanoconjugate remained effective even in models with extensive bone marrow involvement and exhibited activity against diverse patient-derived CXCR4 AML blasts, while sparing healthy donor bone marrow and peripheral blood mononuclear cells (PBMCs) from significant toxicity. Collectively, these findings highlight T22-HSNBT-H6-MMAE as a promising therapeutic candidate for a broad range of AML patients, offering selective antineoplastic activity against CXCR4 leukemic cells.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Nanotoxin induces in situ pyroptosis to sensitize αPD1 to ablate metastases in microsattellite stable colorectal cancer

  • Carrasco-Díaz, Luis Miguel|||0000-0003-0567-2802
  • Otero-Mateo, Marc
  • Álamo, Patricia|||0000-0003-0510-5701
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Virgili Manrique, Anna Cristina|||0000-0001-9733-6034
  • Paez, David|||0000-0002-5596-6588
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Mangues, Ramon|||0000-0003-2661-9525
Nanomedicine has not generated anticancer immunotherapies because of insufficient targeted specificity, lack of immunity, and associated toxicity. We developed a T22-DITOX-H6 (TDX) nanotoxin to selectively release the diphtheria toxin in the cancer cells in immunosuppressed CXCR4-overexpressing (CXCR4 +) colorectal (CRC) models, inducing pyroptosis and anticancer effect. Microsatellite stable (MSS) CRC patients do not respond to current immunotherapy. Since pyroptosis is highly immunogenic, we treated with TDX immunocompetent CXCR4 + CT26 MSS metastatic CRC models to selectively deliver the toxin to induce in situ pyroptosis mediated by the activation of NLRP3, Caspase-1 GSDMD and IL-1β. In contrast to immunosuppressed, in situ pyroptosis by TDX in immunocompetent models trigger CD8 + T cell recruitment, activation and killing of cancer cells in tissues, mimicking the pyroptosis that the host induces to kill diphtheria-infected cells. The combination of TDX and αPD1 further increases CD8 + recruitment and perforin secretion, achieving a tissue-specific antimetastatic activity in mesentery, peritoneum, and lung, and especially in liver metastases, without systemic toxicity. This is the first time that a novel nanomedicine achieves local T cell activation and antimetastatic effect mediated by pyroptosis and immunogenic cell death, whereas the combination with αPD1 enhances T cell activation, reaching a synergistic response in MSS CRC models.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

High-frequency oscillations >250 Hz in people with Down syndrome and associated Alzheimer's disease dementia

  • Lisgaras, Christos Panagiotis
  • Giménez, Sandra|||0000-0001-8031-2319
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Blessing, Esther
  • Fortea, Juan|||0000-0002-1340-638X
  • Osorio, Ricardo S.
INTRODUCTION: Alzheimer's disease (AD) dementia has near full penetrance in adults with Down syndrome (DS) and is strongly linked to late-onset myoclonic epilepsy in Down syndrome (LOMEDS). However, promising biomarkers of epileptogenicity, such as high-frequency oscillations (HFOs >250 Hz), have not been studied. This study is the first to use wideband polysomnography in DS to investigate if HFOs occurred and preceded AD dementia and LOMEDS. METHODS: Wideband (0.1 to 500 Hz, 2048 Hz) polysomnography was performed using the international 10-20 system. HFOs were automatically detected during slow-wave sleep, followed by manual review. RESULTS: Fourteen individuals with DS and five age-matched euploid controls were studied, with all DS cases showing HFOs. HFOs emerged before AD dementia and LOMEDS and showed hemispheric lateralization in asymptomatic but not symptomatic AD dementia cases. A trend toward increasing HFO rates with age in DS warrants further confirmation. DISCUSSION: HFOs are promising biomarkers that may predict symptomatic AD dementia in adults with DS. Highlights: Wideband polysomnography reveals a new electrical abnormality in DS. HFOs precede AD dementia in DS. The occurrence of HFOs in DS is independent of an epilepsy diagnosis. HFOs showed hemispheric lateralization in asymptomatic DS cases. A trend of increased HFO rate with advancing age warrants further investigation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A randomized study of 2 risk assessment models for individualized breast cancer risk estimation

  • López-Fernández, Adrià|||0000-0002-2844-5998
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Pérez, Eduard
  • Darder, Esther
  • Vallmajó, Anna
  • Cruellas, Mara|||0000-0002-6953-9675
  • Roqué, Ariadna|||0000-0003-0492-7463
  • Cartró, Mireia
  • Carrasco, Estela|||0000-0003-1964-7675
  • Rezqallah, Alejandra
  • Jimenez-Macedo, Ana Raquel
  • Torres Esquius, Sara|||0000-0001-7540-7284
  • Espinosa-Bravo, Martín|||0000-0002-4293-3875
  • Teule, Alex|||0000-0003-0028-7200
  • Munté, Elisabet|||0000-0001-8396-8284
  • Tuset, Noemi|||0000-0001-8432-7059
  • Diez, Orland|||0000-0001-7339-0570
  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Llort, Gemma|||0000-0001-9987-7862
  • Carver, Tim|||0000-0003-1508-3091
  • Ficorella, Lorenzo|||0000-0002-0577-1571
  • Mavaddat, Nasim|||0000-0003-0307-055X
  • Mercadé Carceller, Anna|||0000-0002-4714-3565
  • Antoniou, Antonis C.
  • Brunet, Joan|||0000-0003-1945-3512
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Duran-Lozano, Laura
  • Pardo, Mònica
  • Alfonso, Rosa
  • Bareas, Adriana
  • Torres, Maite|||0000-0002-2497-3478
  • López, Consol
Background Estimating breast cancer risk involves quantifying genetic and non-genetic factors. This supports health interventions and risk communication to ensure adherence to screening recommendations. This study evaluated the change in risk estimation when incorporating breast density and polygenic risk score (PRS) into the baseline cancer risk assessment and compared the efficacy of 2 risk-assessment delivery models. Methods This 2-step study included 663 healthy women with a family history of breast cancer in which no pathogenic variants were identified. First, breast density and PRS were added to the baseline risk assessment for all participants. A randomized intervention study compared 2 delivery models (in-person vs pre-recorded video) for risk assessment in women at moderate or average risk. All tests were 2-sided. Results Breast density and PRS reclassified the risk group into 33% of the participants, with only 5% reclassified as high-risk. After disclosure of their estimated multifactorial risk, 65% of women aligned their risk perception with their estimated risk, compared to 47% at baseline (P <. 05). No statistically significant differences were found in the primary endpoint cancer worry, mean = 10.2 (SD = 3.1) vs 10.1 (2.7), between delivery models. In-person delivery had slightly better psychological outcomes (excluding the primary outcome) and higher satisfaction, though few participants in the video group sought in-person clarification. Conclusions Incorporating breast density and PRS into risk assessments led to substantial reclassification, with 1 in 5 women facing de-escalated surveillance. Personalized assessments improve objective perceptions alignment. A model using a pre-recorded video-based model matches in-person delivery for moderate and average-risk women and is scalable for population-level implementation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical Impact and Prognostic Value of Alzheimer Disease Biomarkers in the Very Old

  • Ceriello, Chiara
  • Torres Bonafonte, Olga H.|||0000-0002-0305-8211
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Vera-Campuzano, Elena
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Álvarez-Sánchez, Esther|||0009-0002-8760-2153
  • Lorente, Oriol
  • Carreras, Mireia
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Belbin, Olivia|||0000-0002-6109-6371
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
Background and Objectives: Alzheimer disease (AD) is increasingly viewed as a clinical-biological continuum, but the utility of biomarkers in individuals aged ≥80 years, the so-called “very old,” remains uncertain, because of concerns about its clinical usefulness. This study aimed to determine the clinical impact and prognostic value of AD biomarkers in very old individuals. Methods: We performed a retrospective longitudinal cohort study within the Sant Pau Initiative on Neurodegeneration (SPIN, Barcelona, Spain), a memory clinic–based research cohort. Patients were referred from primary care physicians or community neurologists for evaluation within a public universal health care catchment area. We included SPIN participants evaluated between October 2013 and May 2024 who were aged ≥80 years and had mild cognitive impairment (MCI) at the baseline visit. Participants underwent standardized clinical and neuropsychological assessments and had CSF and plasma biomarker measurements available. AD biology was defined by the CSF phosphorylated tau at threonine 181/amyloid-β 42 ratio. Plasma phosphorylated tau at threonine 217 (p-Tau217) was evaluated for (1) diagnostic accuracy for AD biology and (2) prognostic associations with longitudinal cognitive change (Mini-Mental State Examination [MMSE]) and progression to dementia. Analyses used linear mixed-effects models for MMSE trajectories and Cox regression for dementia conversion. Results: A total of 167 participants were included (mean age 82.3 years, 59% women) with a mean follow-up of 35.8 months; the ones with AD biology (n = 116, 69%) had worse baseline cognitive performance, particularly in memory, compared with those without (Cohen d = 0.34, p = 0.03). Plasma p-Tau217 showed excellent diagnostic accuracy for detecting AD biology (0.93, 95% CI 0.88–0.98; cutoff 0.19 pg/mL; sensitivity 94.5%; specificity 84%). Over time, participants with AD biology declined faster on the MMSE than those without (−0.47 vs −0.18 points per year; p < 0.01). Cox models showed an increased risk of progression to a dementia stage among individuals with higher plasma p-Tau217 concentrations (hazard ratio 1.49, 95% CI 1.05–2.13, p = 0.026). Discussion: In very old individuals with MCI, AD biology (CSF) and plasma p-Tau217 identify individuals at higher risk of faster cognitive decline and progression to dementia. Limitations of this study include the single-center design and the modest sample size.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sex Hormone-Binding Globulin Prevents Carbon Tetrachloride-Induced Liver Fibrosis Development

  • Alvarez-Guaita, Anna
  • Brianso-Llort, Laura|||0000-0002-5650-8503
  • Cabrera-Serra, Julia
  • Fuertes-Rioja, Lidia
  • Ramos-Pérez, Lorena
  • Salcedo, Maria-Teresa|||0000-0002-4822-5060
  • Hernández, Cristina|||0000-0002-3109-1721
  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Martínez Selva, David|||0000-0002-0333-5629
Circulating sex hormone-binding globulin (SHBG) concentrations are lower in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), reflecting its potential role in metabolic liver dysfunction. Our prior studies demonstrated that SHBG can attenuate MASLD by limiting hepatic lipid deposition, partly through suppression of lipogenic pathways, in both cellular and animal models. In the present work, we have examined whether SHBG could protect against development of liver fibrosis. For this purpose, in vitro and in vivo studies were performed. In vitro, we used co-cultures of human hepatocellular carcinoma cell line (HepG2) and human hepatic stellate cell line (LX-2) cells transfected using an SHBG expression vector vs. vehicle and treated with transforming growth factor beta 1 (TGF-β1). For in vivo studies we used wild-type and human SHBG transgenic mice developing liver fibrosis induced by carbon tetrachloride (CCl). Our results clearly showed that SHBG overexpression reduced the TGF-β1-induced expression in collagen in LX-2 cells. Moreover, SHBG overexpression reduced the CCl induced liver fibrosis in both male and female mice. Histological examination revealed that SHBG transgenic mice had reduced NAS score and decreased collagen accumulation, assessed by Sirious Red staining. In addition, human SHBG transgenic mice treated with CCl exhibited lower collagen 1A1 (Col1A1) protein levels when compared with wild-type CCl treated mice. Mechanistically, SHBG attenuated fibrosis primarily through modulation of the TGF-β1/matrix metalloproteinases (MMPs)/tissue inhibitor metalloproteinases 1 (TIMP1) axis, characterized by reduced TGF-β1 levels, increased metalloprotease activity, and decreased TIMP1 levels compared with wild-type CCl treated mice. Notably, female SHBG transgenic mice exhibited greater protection against fibrosis than males, indicating a sex-dependent effect likely mediated by differences in sex steroid signaling. Taken together, we demonstrate for the first time that SHBG protects against liver fibrosis by promoting collagen degradation via the TGF-β1/MMPs/TIMP1 pathway. Further research is needed to elucidate the role of sex steroids in the regulation of MMPs and the observed sexual dimorphism.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Lipids and lipoproteins in the interstitial tissue fluid regulate the formation of dysfunctional tissue-resident macrophages, Implications for atherogenic, tumorigenic, and obesogenic processes

  • Lee-Rueckert, Miriam
  • Jauhiainen, Matti|||0000-0002-3836-3785
  • Kovanen, Petri T.
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
An inflammatory and lipid-enriched tissue microenvironment is a common characteristic of the extracellular niches of affected tissues in atherosclerosis, cancer, and obesity. These respective interstitial environments appear to be induced by infiltration of plasma lipids and early local recruitment of monocyte-derived macrophages. In the tissue niches, the macrophages display remarkable phenotypic and functional plasticity and exert multifaceted roles in tissue homeostasis. Multiple local signaling events contribute to the phenotypic polarization of the tissue-resident macrophages into M1-like, M2-like, and multiple mixed subpopulations. This study aims to review and compare the roles of lipids and lipoproteins in shaping the inflammatory and lipid-enriched microenvironments of atherosclerotic arterial intima, malignant tumors, and obese adipose tissue, so generating dysfunctional macrophages. Circulating lipoprotein-bound lipids and albumin-bound fatty acids can cross the vascular endothelial barrier and infiltrate the interstitial fluids, resulting in variable levels of plasma-derived lipids, notably low-density lipoproteins (LDL), high-density lipoproteins (HDL), and locally generated small lipid-poor HDL species (preβ-HDL). Whilst LDL particles mainly supply liver-derived cholesterol to the cells of peripheral tissues, HDL particles can promote the reverse transfer of cellular cholesterol into the circulation and ultimately via the liver to the gut for its fecal excretion. Thus, the LDL/HDL ratio in the interstitial fluids can either promote or prevent cholesterol accumulation in the tissue-resident macrophages. Various types of peripheral cells modify interstitial LDL and HDL particles by oxidation, proteolysis, lipolysis, aggregation, or fusion, rendering them dysfunctional. By engulfing excessive amounts of extracellular lipids and modified LDL particles in such lipid-rich microenvironments, macrophages can become dysfunctional, a typical example being the atherosclerotic arterial intima. Similarly, tissue microenvironments characteristic of several malignant tumors and the obese adipose tissue are rich in triglyceride (TG)-rich lipoproteins and free fatty acids, inducing accumulation of TG and glycerophospholipids in the intracellular lipid droplets of macrophages. The lipid-loaded macrophages are currently considered novel markers for diagnosis and selective therapeutic targets not only in the arterial intima but also in malignant tumors and obese adipose tissue. Together, the available data identify potential roles of lipids and lipoproteins present in the interstitial fluids of the atherosclerotic arterial intima, malignant tumors, and obese adipose tissue in the generation of distinct lipid-loaded macrophage subpopulations and suggest their contributory roles in the development and progression of atherosclerosis, cancer, and obesity, the three major health concerns worldwide.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Circulating tumor DNA in patients with cancer, insights from clinical laboratory

  • Illana Cámara, Francisco José|||0009-0001-9717-5688
  • Muñoz-Bravo, José Luis|||0000-0001-6253-8330
  • González-Fernández, Carolina
  • Trapé, Jaume
  • Diaz-Lagares, Angel|||0000-0002-9114-9227
  • Fernández-Galán, Esther
  • Valiña Amado, Laura
  • Garcia-Martín, Carme
  • Miró-Cañís, Sílvia
  • Martínez-Peinado, Antonio
  • Filella, Xavier
  • González, Alvaro
  • Barco Sánchez, Antonio
Blood-based circulating tumor DNA (ctDNA) analysis has emerged as a highly relevant non-invasive method for molecular profiling of solid tumors, offering valuable information about the genetic landscape of cancer. Somatic mutation analysis of ctDNA is now used clinically to guide targeted therapies for advanced cancers. Recent advancements have also revealed its potential in early detection, prognosis, minimal residual disease assessment, and prediction/monitoring of therapeutic response. In recent years, significant progress has been made with the development of various PCR and NGS-based methods designed for assessing gene variants in ctDNA of patients with cancer. However, despite the transformative possibilities that ctDNA analysis presents, challenges persist. Standardization of preanalytical and analytical protocols, assay sensitivity, and the interpretation of results remain critical hurdles that need to be addressed for the widespread clinical implementation of ctDNA testing. In addition to somatic mutations, emerging studies on DNA methylation (epigenomics) and fragment size patterns (fragmentomics) in several types of biological fluids are yielding promising results as non-invasive biomarkers for effective cancer management. This review addresses the clinical applications of somatic gene variants in ctDNA, emphasizes their potential as cancer biomarkers, and highlights essential factors for successful implementation in clinical laboratories and cancer management.
ABACUS. Repositorio de Producción Científica
Publicación Artículo científico (JournalArticle)

Physical fitness and cardiac function in childhood cancer survivors

  • Valenzuela, Pedro L.
  • Morales, Javier S.
  • Santana Sosa, Elena
  • Herrero Velasco, Blanca
  • Baño Rodrigo, Antonio
  • Santa Cruz Ramos, Eva
  • Santos Lozano, Alejandro
  • Lucía Mulas, Alejandro
  • Fiuza Luces, María del Carmen
Childhood cancer treatment has long-term health sequelae but there is more controversy for physical fitness. We compared fitness and echocardiographic variables in childhood cancer survivors (CCSs) and controls. A secondary aim was to determine the potential role of previous enrollment in inpatient exercise, and of current physical activity (PA) levels. CCSs showed impairments in some physical fitness and cardiac parameters ≥ 4 yrs posttreatment, which seemed independent of previous inpatient exercise background but not of MVPA/VPA levels after treatment.
ABACUS. Repositorio de Producción Científica
Publicación Artículo científico (JournalArticle)

Even at 100+: Acute Exercise Modulates Inflammatory Pathways in Centenarians

  • Plaza Florido, Abel
  • Brea Alejo, Lidia
  • Pérez Prieto, Inmaculada
  • Carrera Bastos, Pedro
  • Rosado Muñoz, María
  • Pagola Aldazabal, Itziar
  • Barranco Gil, David
  • Santos Lozano, Alejandro
  • Rodríguez Romo, Gabriel
  • Lucía Mulas, Alejandro
  • et al.
Centenarians exhibit remarkable disease resilience despite chronic low-grade inflammation. We investigated the inflammation-related proteome response to acute exercise in seven centenarians (100–104 years). Exercise downregulated 52 proteins (e.g., TNF, IL10, IL1RN, CCL family members) involved in immune cell trafficking, apoptosis, and cytokine regulation. Even at the extreme end of the lifespan, humans retain molecular responsiveness to exercise, with modulation of inflammation-related pathways.
ABACUS. Repositorio de Producción Científica
Publicación Artículo científico (JournalArticle)

Physical exercise and breast cancer-related lymphedema: an umbrella review, systematic review and meta-analysis

  • García Chico, Celia
  • López Ortiz, Susana
  • Pinto Fraga, José
  • Ceci, Claudia
  • Valenzuela, Pedro L.
  • Peñín Grandes, Saúl
  • Maroto Izquierdo, Sergio
  • Graziani, Grazia
  • Fiuza Luces, María del Carmen
  • Lucía Mulas, Alejandro
  • et al.
The present study aimed to summarize the current evidence on the impact of exercise in patients at risk or with breast cancer-related lymphedema (BCRL) through an umbrella review of existing meta-analysis and a systematic review and meta-analysis of randomized controlled trials (RCTs). Strong evidence supports the beneficial effects of exercise on upper- and lower-body strength and upper-limb disability in patients at risk or with BCRL.
ABACUS. Repositorio de Producción Científica
Publicación Artículo científico (JournalArticle)

Exercise pills for cardiometabolic health cannot mimic the exercise milieu

  • Plaza Florido, Abel
  • Lindholm, Malene E.
  • Carrera Bastos, Pedro
  • Santos Lozano, Alejandro
  • Valenzuela, Pedro L.
  • Fiuza Luces, María del Carmen
  • Radom Aizik, Shlomit
  • Lucía Mulas, Alejandro
Physical exercise can play an important role both in primary and secondary cardiovascular disease prevention by virtue of its multisystem effects. These beneficial adaptations at the whole-body level include improvements in mitochondrial health, vascular function, and autonomic balance, together with attenuation of inflammation and the release of ‘exerkines’ with pleiotropic effects. Thus, several research groups have attempted to develop so-called ‘exercise pills’ or ‘exercise mimetics’: that is, substances that are theoretically capable of reproducing some of the cardiometabolic benefits associated with regular exercise. In this review we summarize pharmacological and phytochemical agents which, when used alone or in combination with exercise, may improve cardiometabolic health. We also discuss the current gaps and future steps needed to translate these findings into therapeutic applications.
Repisalud
Publicación Artículo científico (JournalArticle)

HIV/HCV prevalence and the retention paradox in marginalized populations in Madrid (2019-2023): A large-scale cross-sectional study.

  • Valencia, Jorge
  • Ryan, Pablo
  • Codina Márquez, Helena
  • Cuevas, Guillermo
  • Manzano, Samuel
  • Estévez, Samuel
  • Martinez, Isidoro
  • Sepulveda-Crespo, Daniel
  • Resino, Salvador
Objectives: Marginalized urban populations experience a high burden of HIV and HCV. We assessed the prevalence and risk factors for both infections and characterized the care cascades in a cohort of vulnerable individuals in Madrid, Spain. Methods: We conducted a cross-sectional study (2019-2023) of 4582 individuals via mobile units in high-risk hotspots, offering integrated rapid HIV/HCV testing with point-of-care HCV-RNA confirmation. Multivariable logistic regression identified independent HIV risk factors. Results: HIV prevalence was 6.3% (95% CI: 5.6-7.0). Among people with HIV (PWH), 17.0% of known cases were not receiving antiretroviral therapy; PrEP uptake was zero among HIV-negative individuals. A history of injecting drug use was the primary HIV risk factor (adjusted odds ratio[aOR] 6.6; 95% CI: 4.6-9.5), followed by age >50 years, Spanish origin, and alcohol/benzodiazepine misuse (all P < 0.05). Active HCV prevalence was 5.5% (95% CI: 4.9-6.2); 15.7% in PWH vs 4.8% in people without HIV (P < 0.001). Among confirmed cases, HCV linkage (≥95.2%) and treatment (≥88.6%) were high; however, 16.8% of all antibody-positive individuals (23.2% among PWH) missed confirmatory RNA testing. Conclusions: HIV and HCV remain prevalent, characterized by discontinuities in retention rather than diagnosis. Integrated, low-threshold strategies combining harm reduction with social support are required to address this syndemic.
Repisalud
Publicación Artículo científico (JournalArticle)

Adolescent exposure to benzophenone ultraviolet filters: cross-sectional associations with obesity, cardiometabolic biomarkers, and asthma/allergy in six European biomonitoring studies.

  • Peinado, Francisco M
  • Pérez-Cantero, Ainhoa
  • Olivas-Martínez, Alicia
  • Espín-Moreno, Lydia
  • de Haro, Tomás
  • Boada, Luis D
  • Rodríguez-Carrillo, Andrea
  • Govarts, Eva
  • Pedraza-Díaz, Susana
  • Esteban-Lopez, Marta
  • Blaha, Ludek
  • Blahova, Lucie
  • Janasik, Beata
  • Wasowicz, Wojciech
  • Lignell, Sanna
  • Rambaud, Loïc
  • Riou, Margaux
  • Fillol, Clémence
  • Denys, Sébastien
  • Murawski, Aline
  • Brantsæter, Anne Lise
  • Sakhi, Amrit Kaur
  • Iszatt, Nina
  • Schoeters, Greet
  • Kolossa-Gehring, Marike
  • Fernández, Mariana F
  • Mustieles, Vicente
Background: Exposure to benzophenone-1 (BP-1) and benzophenone-3 (BP-3), widely used as UV filters in personal care products, has been associated with adverse health effects. However, epidemiological evidence is limited and inconclusive, particularly in vulnerable populations such as teenagers. Objective: To examine the relation between BP-1 and BP-3 concentrations and obesity, cardiometabolic biomarkers, and asthma/allergy outcomes in European teenagers, including possible sex-specific associations. Methods: A multi-country cross-sectional study was conducted using pooled data from six aligned studies from the Human Biomonitoring for Europe Initiative (HBM4EU). Sociodemographic data, cardiometabolic biomarkers, and asthma/allergy outcomes were collected through questionnaires. Anthropometric data and BMI z-scores were calculated (n = 1339). Plasma/serum cardiometabolic biomarkers and asthma/allergy outcomes were available for a subsample (n = 173-594). Urinary BP-1 and BP-3 concentrations were adjusted for creatinine dilution using the traditional standardization (trad.) and the covariate-adjusted creatinine standardization (CAS) method. Generalized additive models, linear, logistic, and multinomial mixed models were applied, and sex-interaction terms were tested. Results: Each natural log-unit increase in urinary BP-3 (CAS) concentrations was associated with higher odds of obesity in the whole population (OR: 1.20; 95%CI: 1.04-1.38). Sex-specific associations were also found with BP-1 (CAS) and BP-3 (CAS) concentrations, which were associated with higher odds of obesity in male teenagers (OR: 1.25; 95% CI: 1.01-1.55; OR: 1.34; 95%CI: 1.09-1.65, respectively). Linear mixed models showed consistent findings toward higher BMI z-scores. A negative association was found between BP-1 (CAS) concentration and serum adiponectin levels in females (% change per loge-unit increase: -3.73, 95%CI: -7.32, -0.10). BP-3 (CAS) concentrations were also associated with higher odds of non-food allergies in males (OR: 1.27; 95%CI: 1.00-1.63). Traditional creatinine adjustment showed similar or slightly attenuated estimates compared to the CAS method. Conclusions: BP-1 and BP-3 exposure was cross-sectionally associated with higher odds of obesity in European male teenagers, highlighting the need to update regulations and keep exposure levels as low as practically achievable. Longitudinal studies are needed to confirm these findings.
Repisalud
Publicación Artículo científico (JournalArticle)

Persistent Low Anti-HIV Neutralizing Antibody Titers in HIV/HCV Coinfection Despite HCV Cure: A 5-Year Longitudinal Analysis.

  • Sepulveda-Crespo, Daniel
  • Sánchez-Merino, Víctor
  • Amigot-Sánchez, Rafael
  • Rubio-Pérez, Almudena
  • Díez, Cristina
  • Hontañón, Víctor
  • Berenguer, Juan
  • González-García, Juan
  • García, Felipe
  • Martinez, Isidoro
  • Yuste, Eloísa
  • Resino, Salvador
Background: Anti-HIV neutralizing antibodies (anti-HIV-nAbs) play a critical role in the immune defense against HIV by preventing viral entry and limiting replication. This study longitudinally evaluated the titers and variability of anti-HIV-nAbs in individuals coinfected with HIV and HCV. Samples were collected at three time points: before starting HCV treatment, one year after completion, and five years post-treatment. Methods: A retrospective analysis was conducted on 71 HIV/HCV-coinfected patients who achieved a sustained virologic response following antiviral therapy for HCV. A control group of 41 HIV-monoinfected individuals was also included. Anti-HIV-nAb titers were evaluated by HIV neutralization assays using a panel of six recombinant HIV viruses representing multiple genetic subtypes. Generalized Linear Mixed Models and Generalized Linear Models were used for statistical analysis. p-values were adjusted using the Benjamini-Hochberg procedure (q-value). Results: HIV-neutralizing antibody responses in HIV/HCV-coinfected individuals remained stable over five years following HCV therapy without significant changes (q-value > 0.05). The mean neutralization scores remained stable, with baseline scores of 6.1 (95% CI: 5.4-6.7), 6.2 (95% CI: 5.5-6.8) at one year post-HCV therapy, and 6.0 (95% CI: 5.3-6.7) at five years post-HCV therapy. HIV/HCV-coinfected individuals consistently showed lower neutralization scores compared to the control group throughout the follow-up (q-value < 0.05). Regression analyses adjusted for age, gender, nadir CD4+, and baseline CD4+ counts confirmed that the observed differences between HIV-monoinfected and HIV/HCV-coinfected individuals persisted (q-value < 0.05) at both the baseline and after HCV therapy completion. Conclusions: Successful HCV eradication in HIV/HCV-coinfected individuals did not normalize anti-HIV-nAb titers, which remained consistently lower than those in HIV-monoinfected controls over five years.
Repisalud
Publicación Artículo científico (JournalArticle)

Dengue nanosensors: a roadmap for clinical viability.

  • Codina Márquez, Helena
  • Quero-Delgado, Marta
  • Gómez, Rafael
  • Resino, Salvador
  • Martinez, Isidoro
  • Sepulveda-Crespo, Daniel
Dengue nanosensors promise much but have failed in clinical application. This paradox stems from a focus on record sensitivity over real-world robustness. We propose a paradigm shift from materials discovery to product engineering, providing a translational roadmap to guide viable diagnostics from the lab bench to the patient.
Repisalud
Publicación Artículo científico (JournalArticle)

Trends of non-lethal intentional self-harm and suicide in Spain 2018–2023: a nationwide registry-based study

  • Lopez-Cuadrado, Teresa
  • Mortier, Philippe
  • Alonso, Jordi
  • Martínez-Alés, Gonzalo
Background: Monitoring suicide and non-lethal intentional self-harm (NLISH) is critical for prevention efforts. We analysed trends in NLISH and suicide in Spain (2018–2023), including related demographic and clinical factors. Methods: Nationwide population-based study including all NLISH hospitalisations (from health registries) and suicides (from national mortality data) in Spain between 2018 and 2023. We first examined the sociodemographic characteristics and method used for both outcomes, and the clinical characteristics of NLISH hospitalisations. Then, we evaluated annual and monthly trends in NLISH and suicide rates overall and by sex and age group using Joinpoint regression. Findings: Between 2018 and 2023, we identified 73,692 NLISH hospitalisations and 23,496 suicides in Spain, averaging 12,282 and 3916 annually, respectively. NLISH hospitalisations were more common among women (n = 44,304; 60·1%), and suicides among men (n = 17,471; 74·4%). Youth aged 10–24 accounted for 17,915 (24·3%) NLISH hospitalisations but only 1125 (4·8%) suicides; conversely, individuals aged ≥65 represented 7327 (31·2%) suicides but only 9410 (12·8%) NLISH hospitalisations. The leading methods were drug poisoning for NLISH (n = 50,643; 68·7%) and hanging for suicide (n = 10,810; 46·0%). From 2018 to 2023, NLISH rates rose annually by 8·0% (95% CI: 1·5, 15·9), especially among young women shortly after the 2020 initial pandemic outbreak. Suicide rates rose 2·6% annually (95% CI: 0·6, 4·8), especially among young women and middle-aged men. Interpretation: Non-lethal self-harm is rising in Spain, especially among young women. Suicide shows smaller but significant increases. Urgent, age- and gender-sensitive strategies are needed to address all suicidal behaviour and ensure timely mental health care.
Repisalud
Publicación Artículo científico (JournalArticle)

Determining and characterizing circulating nucleosomes in advanced cancer with electrochemical biosensors assisted by magnetic supports and proteomic technologies.

  • Tejerina-Miranda, Sandra
  • Carral-Ibarra, Elisa
  • Gamella, Maria
  • Montero-Calle, Ana Maria
  • Pedrero, María
  • Pingarrón, José M
  • Barderas Manchado, Rodrigo
  • Campuzano, Susana
Measuring and monitoring plasma nucleosomes (small fragments of chromosomes released into the blood during cell death), and their proteomic profiles is a promising approach for improved early detection, diagnosis, and prognosis of cancer diseases as well as for disease and therapy follow-up, contributing to more personalized and effective cancer care. Early detection is imperative in colorectal cancer (CRC), as it has been proven to significantly improve patient outcomes. Indeed, in CRC, blood circulating nucleosome levels and their histone alterations have been correlated with tumor stage and the presence of metastasis. Moreover, they constitute promising markers for CRC monitoring and prognosis in a minimally invasive way. The current technologies used for their detection suffer from notable drawbacks such as non-selective identification and quantification of unknown cancer-relevant proteomic trademarks, expensive procedures, and variable results related to staff experience. Taking advantage of the sensitive, fast, cost-effective, and reliable methodologies that electroanalytical technologies offer for the determination of multilevel biomarkers in liquid biopsies, we report in this paper the first electrochemical immunoplatform for the isolation and determination of circulating nucleosomes in plasma using an anti-H3.1 histone variant, integrated with proteomics insights to confirm nucleosomes isolation and identify associated proteins with potential as CRC biomarkers. The developed bioplatform was used to analyze 0.5 μg of nuclear extracts from CRC cells with different metastatic potential as well as 1/5 diluted plasma samples, demonstrating the suitability to effectively discriminate CRC patients in advanced stages from healthy individuals through liquid biopsy.
Repisalud
Publicación Artículo de revisión (ReviewArticle)

Diagnostic performance of dried blood spot hepatitis C virus core antigen testing for hepatitis C screening: A systematic review and meta-analysis.

  • Treviño-Nakoura, Ana
  • Sepulveda-Crespo, Daniel
  • Bellon, José M
  • Codina, Helena
  • Amigot-Sánchez, Rafael
  • Quero-Delgado, Marta
  • Ryan, Pablo
  • Martinez, Isidoro
  • Resino, Salvador
Dried blood spot (DBS) sampling is increasingly used for hepatitis C virus (HCV) screening. HCVcAg testing offers a faster and more streamlined approach to diagnosing HCV infection. We conducted a systematic review and meta-analysis to assess the diagnostic performance of the Abbott ARCHITECT HCV Ag assay for screening active HCV infection using DBS samples. Eight studies (n = 1229) were selected among all published studies available up to October 4, 2024, in different databases with a search strategy registered (PROSPERO: CRD42022363975). The gold standard method was the HCV PCR test. Data were analyzed using the MIDAS module in STATA with a random effects model. Combined diagnostic accuracy measures were as follows: sensitivity 85%, specificity 100%, positive likelihood ratio (PLR) 233.1, negative likelihood ratio (NLR) 0.15, and summary receiver operating characteristic (SROC) 0.99. Likelihood ratios and Fagan's nomogram suggested that the HCVcAg assay with DBS samples can confirm or rule out active HCV infection with over 92% accuracy in high-prevalence settings (≥5%). However, in low-prevalence settings (≤1%), a confirmatory test must be required for positive results. The ability of the test to identify people without HCV infection was high regardless of HCV prevalence, with an error rate of less than 3%. This meta-analysis is subject to limitations, particularly due to the number of included studies and significant heterogeneity among them. HCV screening using the Abbott ARCHITECT HCV Ag assay with DBS samples showed excellent diagnostic performance, but its external validity may be limited when HCV prevalence is low (≤1%).
Repisalud
Publicación Artículo científico (JournalArticle)

Prevalence and risk factors of active hepatitis C infection among at-risk migrant populations in Madrid, Spain, 2019 to 2023.

  • Ryan, Pablo
  • Valencia, Jorge
  • Pérez-García, Felipe
  • Quero-Delgado, Marta
  • Cuevas, Guillermo
  • Manzano, Samuel
  • Estévez, Samuel
  • Martinez, Isidoro
  • Sepulveda-Crespo, Daniel
  • Resino, Salvador
Background: Hepatitis C virus (HCV) microelimination among at-risk migrants supports global elimination goals.AIMTo evaluate risk factors, prevalence and trends of active HCV infection among at-risk migrants screened for HCV in Madrid from 2019-23. Methods: At-risk migrants (born outside Spain, living in country < 10 years regardless of legal status), were screened for HCV via mobile units with rapid antibody testing, and confirmed by RNA testing. Recruitment of this convenience sample focused on migrant centres, shelters, harm reduction centres and social service sites. Primary outcome was active HCV prevalence. Risk factors analysed included origin, alcohol use, no stable income, drug use and sexual behaviour. Data were analysed using general linear models with negative binomial distribution and p values adjusted for multiple comparisons (q values). Results: TSAmong 2,288 migrants, 6.5% (149/2,288) had anti-HCV antibodies, 47.0% (70/149) of whom tested positive for HCV-RNA; 81.4% (57/70) began antiviral therapy. Overall prevalence of active HCV infection was 3.1% (70/2,288). Injection drug use (non-active vs never used (aIRR: 7.3; 95% CI: 2.7-12.7) and active (aIRR: 14.7; 95% CI: 6.7-32.1)), European origin (vs non-European; aIRR: 5.8; 95% CI:  2.7-12.7) and alcohol misuse (vs no misuse; aIRR: 1.8; 95% CI: 1.1-2.9) were main risk factors. Prevalence showed no significant change during 2019-23 in the overall population and across risk groups. Conclusion: At-risk migrants screened in Madrid had a high prevalence of active HCV infection. This is higher than reported estimates for the general Spanish population and supports the need to enhance targeted HCV prevention, screening and treatment strategies among migrant populations.